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Abstract 
mTOR (mammalian target of rapamycin) is a serine/threonine protein kinase which belongs to 
the family of phosphoinositide 3-kinase related kinases (PIKK), which also includes ATR, 
ATM, DNA-PK, SMG1 and TRRAP. mTOR contains several conserved protein-protein 
interaction modules at the N-terminus and a protein kinase domain at the C-terminus. The 
regulatory interactions of mTOR are mainly mediated by HEAT (Huntingtin, Elongation 
factor 3, protein phosphatase 2A, and TOR1) repeats and FAT (FRAP, ATM and TRRAP) 
domains. In contrast to other PIKK family members, mTOR possesses a unique FRB 
(FKBP12/Rapamycin Binding) domain which mediates the interaction with the 
FKBP12/rapamycin inhibitory complex. 
mTOR is a key component of two distinct multi-protein complexes in mammalian cells, 
termed mTOR complex 1 (TORC1)  and mTOR complex 2 mTORC2). A diverse range of 
extracellular and intracellular signals stimulate both mTOR complexes to regulate cell 
growth, survival and proliferation. Dysregulation of mTOR signalling has been implicated in 
various human pathologies, including cancer, inflammation, neurodegenerative and metabolic 
disorders. Therefore, mTOR is an attractive target for drug discovery. In cancer research, 
mTOR inhibitors have shown a potent anti-proliferative activity in pre-clinical studies and 
several of these are currently being evaluated in clinical trials.   
There is only one mTOR gene in higher vertebrates, which is known to encode two splicing 
isoforms: mTORα and mTORβ. In contrast to the full length mTORα protein, mTORβ lacks 
most of its protein-protein interaction modules, HEAT and FAT, but retains domains 
responsible for FKBP12/rapamycin binding, protein kinase activity and regulation. 
Importantly, mTOR was shown to shorten considerably the G1 phase of the cell cycle,  to 
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stimulate cell proliferation and to possess oncogenic potential in cell-based and xenograft 
studies.   
Like other PIKK family members, there is increasing evidence of the presence of mTOR 
splicing isoforms. The main aim of this study was to identify new mTOR splicing isoforms 
and to determine their molecular characterization. In addition we aim to explore the ability of 
these isoforms to phosphorylate known mTOR targets such as 4E-BP1. Furthermore, we aim 
to study the role of the new isoforms in the mTOR–mediated cellular processes, such as cell 
proliferation, and the contribution of the identified isoforms in the oncogenic characteristics 
of cells. 
In this study, we have employed bioinformatics, biochemical, cell and molecular techniques 
to identify and characterize two novel mTOR splicing isoforms, denoted mTORδ and 
mTOR. When compared to mTORα, the mTORδ splice variant contains only the N-terminal 
HEAT repeats and a unique C-terminal region, while the mTORγ isoform possesses a 12 
amino acid deletion in the kinase domain. The existence of the mTORδ isoform was 
confirmed at mRNA and protein levels by identifying corresponding EST clones and 
detecting the splice variant with specific anti–mTORδ antibodies. Furthermore, we have 
found several EST clones corresponding to the mTORγ splicing variant. In contrast to 
mTORα, the stably expressed mTORδ and mTOR lack the kinase activity in vitro. It was 
also found that stable overexpression of mTORδ and mTORγ splice variants in HEK293 cells 
inhibits cell proliferation and colony formation in soft agar. These findings suggest that 
identified novel isoforms have the potential to regulate the mTOR signalling pathway in a 
dominant–negative manner. 
  
5 
 
Acknowledgments 
I would like to express my sincere gratitude to my supervisor Professor Ivan Gout 
whose passion for science is truly inspiring, for offering me this PhD position, for the 
continuous support of my study, as well as for all his help and guidance during the 
production of my PhD thesis. His guidance helped me in all the time of research and 
writing of this thesis. I would also like to thank my committee members, Professor 
Elizabeth Shephard and Professor John Christodoulou for their advice on both 
research as well as on my career.  
My sincere thanks also goes to Dr. Alexander Zhyvoloup for enlightening me the first 
glance of research. 
My friends and colleagues made the time during the research unforgettable. Special 
thanks to Ahmed, Pascale, Lena, Yugo, Kamil and Mahmoud for all their help, 
humour and support. Also, thanks to all the girls and guys I met around the department 
and shared a joke with from time to time. You all made life more enjoyable. I would 
also like to thank all of my friends who supported me and encouraged me to strive 
towards my goal. 
Last but not the least a special thanks to my family for spurring me on to complete this 
thesis and for all their support during my studies and in particular my mother who 
spent sleepless nights praying for me and was always my support in the moments 
where I needed support.  
  
6 
 
Table of contents 
Declaration ................................................................................................................................. 2 
Abstract ...................................................................................................................................... 3 
Acknowledgments ...................................................................................................................... 5 
List of Figure ............................................................................................................................ 12 
Abbreviations ........................................................................................................................... 17 
Chapter 1: General Introduction ........................................................................................ 24 
1.1 mTOR, an overview ................................................................................................. 24 
1.1.1 The mTOR Structure ............................................................................................ 25 
1.1.2 mTOR Complexes in mammalian cells ............................................................... 28 
1.1.2.1 mTORC1 ..................................................................................................... 30 
1.1.2.2 mTORC2 ..................................................................................................... 31 
1.1.2.3 Regulation of mTOR ................................................................................... 32 
1.1.2.3.1 mTORC1 regulation ............................................................................... 32 
1.1.2.3.2 mTORC2 Regulation .............................................................................. 35 
1.2 Role of mTOR in cellular functions ......................................................................... 35 
1.2.1 mTOR signalling in the regulation of protein synthesis ...................................... 38 
1.2.2 Implication of mTOR signalling in the regulation of cell survival ...................... 39 
1.2.3 Role of mTOR signalling in mitochondrial biogenesis ........................................ 42 
1.2.4 Regulation of ribosomal biogenesis via the mTOR signalling pathway .............. 42 
1.2.5 Role of mTOR signalling in autophagy ............................................................... 43 
1.2.6 mTOR signalling and lipid biosynthesis .............................................................. 43 
7 
 
1.2.7 Other roles of mTOR in regulating cellular processes ......................................... 46 
1.3 FKBP12 – Rapamycin Complex .............................................................................. 46 
1.3.1 Overview of Rapamycin ....................................................................................... 46 
1.3.2 Overview of FKBP12 ........................................................................................... 47 
1.4 Initial evidence for the existence of mTOR splicing isoforms ................................. 48 
1.5 Aim of the study ....................................................................................................... 50 
1.6 Methods of isolating mTOR ..................................................................................... 50 
Chapter 2: Methodology .................................................................................................... 54 
2.1 Materials ................................................................................................................... 54 
2.1.1 Common laboratory reagents ............................................................................... 54 
2.1.2 Molecular cloning materials ................................................................................. 54 
2.1.3 Proteins ................................................................................................................. 55 
2.1.4 Antibodies ............................................................................................................ 56 
2.1.5 Mammalian cell lines ........................................................................................... 56 
2.1.6 Bacteria ................................................................................................................. 57 
2.2 Methods .................................................................................................................... 57 
2.2.1 Molecular methods ............................................................................................... 57 
2.2.1.1 Primers design ............................................................................................. 57 
2.2.1.2 DNA digestion ............................................................................................ 58 
2.2.1.3 DNA ligation ............................................................................................... 58 
2.2.1.4 Polymerase chain reaction .......................................................................... 58 
2.2.1.5 Electrophoresis and DNA purification ........................................................ 59 
8 
 
2.2.1.6 DNA sequencing ......................................................................................... 59 
2.2.1.7 Transformation and plasmid amplification ................................................. 60 
2.2.1.7.1 Plasmid DNA Purification ...................................................................... 60 
2.2.2 Mammalian cell culture ........................................................................................ 61 
2.2.2.1 Maintenance of cell lines ............................................................................ 61 
2.2.2.2 Cell counting ............................................................................................... 62 
2.2.2.3 Serum and nutrient starvation and stimulation ........................................... 62 
2.2.2.4 DNA transfection ........................................................................................ 62 
2.2.2.5 Generation of stable cell lines ..................................................................... 63 
2.2.2.6 Cryopreservation ......................................................................................... 64 
2.2.2.7 Cell line defrosting ...................................................................................... 64 
2.2.3 Protein isolation methods ..................................................................................... 65 
2.2.3.1 Mammalian cell lysis for protein analysis .................................................. 65 
2.2.3.2 Measuring protein concentration ................................................................ 65 
2.2.3.3 Immunoprecipitation ................................................................................... 65 
2.2.3.4 Affinity Purification .................................................................................... 66 
2.2.3.5 SDS-PAGE ................................................................................................. 67 
2.2.3.5.1 Protein sample preparation ..................................................................... 68 
2.2.3.5.2 Preparation of SDS-PAGE ..................................................................... 68 
2.2.3.6 Protein Visualisation ................................................................................... 69 
2.2.3.6.1 Coomassie Staining ................................................................................ 69 
2.2.3.6.2 Silver Staining ........................................................................................ 70 
9 
 
2.2.3.6.3 Western Blotting ..................................................................................... 70 
2.2.3.6.3.1 Proteins transfer to membrane ......................................................... 70 
2.2.3.6.3.2 Immunoblotting ............................................................................... 71 
2.2.3.6.3.3 Developing Immunoblots ................................................................ 71 
2.2.3.6.3.4 Stripping and re-probing .................................................................. 72 
2.2.3.7 Bacteria Cell Lysis and Purification GST-fusion Proteins ......................... 72 
2.2.4 Bioinformatics methods ....................................................................................... 73 
2.2.5 Functional analysis ............................................................................................... 74 
2.2.5.1 In Vitro Kinase Assay ................................................................................. 74 
2.2.5.2 MTT proliferation assay ............................................................................. 75 
2.2.5.3 Colony Forming Assay ............................................................................... 75 
2.2.6 Statistical analysis ................................................................................................ 76 
Chapter 3: Chapter Three: Identification of novel mTOR isoforms .................................. 78 
3.1 Evidence of the existence of a novel mTOR isoforms ............................................. 78 
3.2 Different approaches to identify novel isoforms ...................................................... 81 
3.2.1 Protein analysis .................................................................................................... 81 
3.2.1.1 Results of the protein purification approach ............................................... 82 
3.2.1.1.1 GST-FKBP12 Purification ..................................................................... 82 
3.2.1.1.2 Preparation of the affinity Matrix ........................................................... 83 
3.2.1.1.3 The affinity matrix sensitivity (optimisation) ......................................... 84 
3.2.1.1.3.1 The effect of rapamycin concentration ............................................ 85 
3.2.1.1.3.2 The effect of buffer .......................................................................... 86 
10 
 
3.2.1.1.3.3 The effect of beads on protein binding ............................................ 86 
3.2.1.1.3.4 The effect of GST-FKBP12 ............................................................. 88 
3.2.1.1.3.5 Different purification isolates of the protein ................................... 88 
3.2.1.1.3.6 The effect of different GST-FKBP12 concentrations ...................... 90 
3.2.1.1 Patterns of mTOR immuno–reactive bands from different tissues and cell 
lines 91 
3.2.1.2 Summary of protein analysis approach ....................................................... 98 
3.2.2 Bioinformatics and molecular approaches ........................................................... 99 
Chapter 4: Molecular characterisation and functional analysis of mTORδ ..................... 104 
4.1 Molecular characteristics of the mTORδ isoform .................................................. 104 
4.1.1 Introduction ........................................................................................................ 104 
4.1.2 Generation of Flag–tagged mTOR and mTOR S2215Y plasmids .................. 108 
4.1.3 Generation of the pcDNA3–Flag–mTORδ plasmid .......................................... 113 
4.1.4 DNA sequence analysis of the generated plasmids ............................................ 115 
4.1.5 Generation of stable cell lines expressing mTORδ ............................................ 118 
4.2 Functional Analysis ................................................................................................ 122 
4.2.1 mTORδ kinase activity ....................................................................................... 123 
4.2.2 MTT assay – cell proliferation assay ................................................................. 124 
4.2.3 Colony formation assay ...................................................................................... 127 
4.2.4 Discussion and conclusions ................................................................................ 130 
Chapter 5: Molecular characterisation and functional analysis of mTOR ..................... 135 
5.1 Molecular characteristics of the mTORγ isoform .................................................. 135 
11 
 
5.1.1 Introduction ........................................................................................................ 135 
5.1.2 Generation of a Flag-tagged mTOR plasmid ................................................... 138 
5.1.3 DNA sequence analysis of the constructed pcDNA3 – Flag – mTOR plasmid 145 
5.1.4 Generation of HEK 293T cells stably expressing the mTOR isoform ............. 146 
5.2 Functional Analysis ................................................................................................ 149 
5.2.1 mTOR kinase assay ............................................................................................ 150 
5.2.2 MTT assay – cell proliferation assay ................................................................. 152 
5.2.3 Colony formation assay ...................................................................................... 155 
5.2.4 Discussion and conclusions ................................................................................ 158 
Chapter 6: Discussion ...................................................................................................... 161 
6.1 mTOR protein ........................................................................................................ 161 
6.2 Discussion .............................................................................................................. 165 
6.3 Conclusion .............................................................................................................. 169 
6.4 Future directions for mTORδ and mTORγ ............................................................ 170 
6.4.1 The effect of the mTORδ and the mTORγ on the cell cycle and cell size ......... 170 
6.4.2 Cellular localization of the mTORδ and the mTORγ ......................................... 171 
6.4.3 The effect of the mTORδ and the mTORγ on the progression of tumour in a 
xenograft model in nude mice ........................................................................................ 171 
6.4.4 Binding partners of the mTORδ and the mTORγ .............................................. 172 
Appendices ............................................................................................................................. 174 
References .............................................................................................................................. 176 
 
12 
 
 
List of Figure 
Figure 1.1: Diseases linked to dysregulated mTOR signalling and the corresponding affected 
organs (Dazert and Hall 2011) ......................................................................................... 26 
Figure 1.2: Schematic diagram of mTOR domains with phosphorylation sites noted (Harris 
and Lawrence, Jr. 2003) ................................................................................................... 28 
Figure 1.3: Schematic diagram of mTOR complexes. a) mTOR complex 1 and its targets. b) 
mTOR complex 2 and its targets ...................................................................................... 29 
Figure 1.4: Regulation of mTORC1 by hormones, growth factors and nutrients. Processes that 
up regulate signaling are shown in black; those that down regulate signaling are shown in 
red. .................................................................................................................................... 34 
Figure 1.5: Schematic diagram of downstream targets of mTORC1 and its role in cellular 
functions. .......................................................................................................................... 37 
Figure 1.6: Regulation of cap-dependent translation initiation by mTORC1 via 4E-BP. ....... 39 
Figure 1.7: Role of mTORC2 in cellular survival. The mTORC2 promotes cellular survival by 
activating Akt and via SGK1 phosphorylation (Laplante and Sabatini 2012). ................ 41 
Figure 1.8: Regulation of lipid synthesis by mTOR. ............................................................... 45 
Figure 1.9: Modular representation of mTOR isoforms .......................................................... 50 
Figure 3.1: Northern blotting of human tissues indicates the presence of several potential 
mTOR splicing forms ....................................................................................................... 79 
13 
 
Figure 3.2: Western blot of Gel filtration analysis of mTOR splicing forms in MCF7 cells 
indicates the presence of several potential mTOR splicing forms ................................... 79 
Figure 3.3: Western blotting examples of commercially available antibodies targeting mTOR 
(280 kDa). ......................................................................................................................... 80 
Figure 3.4: Coomassie stain of affinity purification of GST-FKBP12. ................................... 83 
Figure 3.5: Schematic diagram of the affinity matrix mTOR and identify a new mTOR 
splicing isoform. ............................................................................................................... 84 
Figure 3.6: Affinity purification of mTORα and mTORβ from HEK 293 cells over-expressing 
mTORα and mTORβ. ....................................................................................................... 85 
Figure 3.7: Western blotting to study the effect of buffer on GST-FKBP12 binding efficiency 
to Glutathione Sepharose beads. ...................................................................................... 86 
Figure 3.8: Western blotting to study the effect of Beads on FKBP12 binding efficiency. .... 87 
Figure 3.9: Western blotting to study the effect of bead volume and protein concentration on 
the amount of mTOR purified using the affinity matrix. ................................................. 88 
Figure 3.10: Western blotting to study the effect of GST-FKBP12 concentration on the 
binding efficiency of mTOR to affinity matrix. ............................................................... 90 
Figure 3.11: Western blotting of affinity purified mTOR from Rats’ Heart. ........................... 92 
Figure 3.12: Western blotting of affinity purified mTOR from Starved and starved stimulated 
HEK 293. .......................................................................................................................... 93 
14 
 
Figure 3.13: Western blotting of affinity purified mTOR from HEK 293 using the modified 
procedure, after the 3D structure has been revealed (15 min incubation with rapamycin).
 .......................................................................................................................................... 94 
Figure 3.14: Commercially available antibodies against different mTOR epitope. ................. 97 
Figure 3.15: Western blotting of affinity purified mTOR against different antibodies. .......... 99 
Figure 3.16: Schematic domain organization of mTOR splicing forms ................................ 101 
Figure 3.17: Western blotting analysis testing the expression of mTORδ in different cell lines.
 ........................................................................................................................................ 102 
Figure 4.1: Schematic representation of the domain organisation of the mTORδ splice 
isoform. .......................................................................................................................... 107 
Figure 4.2: Schematic representation of the domain organisation of the mTORβ mutant..... 107 
Figure 4.3: Plan for the generation of the pcDNA3–Flag–mTORα and pcDNA3–Flag–mTOR 
S2215Y isoforms. ........................................................................................................... 109 
Figure 4.4: Agarose gel image of the DNA fragments used for the construction of pcDNA3–
Flag–mTORα and pcDNA3–Flag–mTOR S2215Y. ...................................................... 110 
Figure 4.5: Agarose gel image of colonies selected for digestion and sequencing analysis. . 111 
Figure 4.6: Agarose gel image of the results of the digestion analysis of the pcDNA3–Flag–
mTORα and pcDNA3–Flag–mTOR S2215Y plasmids for the first selection which 
showed negative results. ................................................................................................. 112 
15 
 
Figure 4.7: Agarose gel image of the results of the digestion analysis of the pcDNA3–Flag–
mTORα and pcDNA3–Flag–mTOR S2215Y plasmids for the second selection which 
demonstrated positive results. ........................................................................................ 113 
Figure 4.8: Plan to generate pcDNA3–Flag–mTORδ. ........................................................... 114 
Figure 4.9: Agarose gel image of the DNA fragments used for the construction of pcDNA3–
Flag–mTORδ. ................................................................................................................. 115 
Figure 4.10: Sequencing analysis of pcDNA3–Flag–mTOR S2215Y. .................................. 116 
Figure 4.11: mTORδ COOH-terminal sequence highlighted in red. ..................................... 117 
Figure 4.12: Nucleotide sequence alignment of the mTORδ fragment. ................................ 118 
Figure 4.13: Western blot confirming the expression of Flag–mTORδ, Flag–mTORα and 
Flag–mTOR S2215Y in transfected HEK 293 cells. ..................................................... 120 
Figure 4.14: Parental HEK 293 cells demonstrate a higher proliferation potential than HEK 
293 cells over–expressing the mTORδ isoform. ............................................................ 126 
Figure 4.15: The mTORδ protein stably enhances either cell cycle arrest or cell death. ....... 129 
Figure 5.1: A schematic representation of the domain organisation of the mTOR splicing 
isoform. .......................................................................................................................... 137 
Figure 5.2: A schematic diagram demonstrating the location of the 12–amino acid deletion in 
mTORβ. .......................................................................................................................... 138 
Figure 5.3: The plan for the construction of the pcDNA3–Flag–mTORγ isoform. ............... 140 
16 
 
Figure 5.4: Agarose gel image of the DNA fragments used for the construction of pcDNA3–
Flag–mTORγ. ................................................................................................................. 141 
Figure 5.5: Agarose gel image of the pcDNA3–Flag–mTOR colonies selected for digestion 
analysis. .......................................................................................................................... 142 
Figure 5.6: Agarose gel image of the results of the digestion analysis of the constructed 
pcDNA3–Flag–mTOR plasmid showing the absence of the insert band (negative result).
 ........................................................................................................................................ 143 
Figure 5.7: Agarose gel image of the resultant of the digestion analysis of the constructed 
pcDNA3–Flag–mTOR plasmid confirming the presence of the insert band. .............. 144 
Figure 5.8: Sequencing analysis of pcDNA3–Flag–mTOR. ................................................ 146 
Figure 5.9: Western blot confirming the high expression of Flag–mTORγ in parallel with the 
other mTOR isoforms in HEK 293 cell lines. ................................................................ 148 
Figure 5.10: In vitro kinase assay for mTOR. ...................................................................... 152 
Figure 5.11: mTORγ negatively regulates cellular proliferation. .......................................... 154 
Figure 5.12: mTORγ down–regulates the anchorage-independent growth of HEK 293 in soft 
agar. ................................................................................................................................ 157 
  
17 
 
Abbreviations 
3D   Three-dimensional 
4E-BP  Eukaryotic initiation factor 4E binding protein 
A549   Human lung carcinoma  
AB  Antibody 
Akt/PKB Protein Kinase B 
AMPK  AMP-activated protein kinase 
APS   Ammonium persulphate 
ATCC  American Type Culture Collection 
ATG13 Autophagy-related 13 
ATG13 Autophagy-related protein 13 
ATP  Adenosine Triphosphate 
BAD  Pro-apoptotic protein 
BLAST Basic Local Alignment Search Tool 
Cdc42  Cell division control protein 42 
CO2  Carbon dioxide  
Cos7   Monkey kidney fibroblast-like 
CREMt Polyvinylidene difluoride 
18 
 
cryo-EM  Cryo-electron microscopy 
DMEM  Dulbecco’s Modified Eagle’s medium 
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic Acid 
DNA-PK DNA-dependent protein kinase 
DTT  Dithiothreitol 
E.Coli  Escherichia coli 
ECL   Chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
eEF2K  Elongation factor 2 kinase 
eIF4E  Eukaryotic translation initiation factor 4E 
FAT  FRAP, ATM, and TRRAP 
FATC  FRAP-ATM-TRRAP-C-terminal domain 
FATN  FRAP-ATM-TRRAP-N-terminal domain 
FBS   Foetal bovine serum 
FIP200 FAK family kinase-interacting protein 200kDa  
FKPB12 FK506-binding protein of 12 kDa 
FOXO1 Forkhead box protein O1 
19 
 
FOXO3 Forkhead box protein O3 
FRAP  FKBP12-rapamcyin associated protein 
FRB   FKBP12 Rapamycin Binding domain 
FTS   Farnesylthiosalicylic acid  
GSK  Glycogen synthase kinase 3 
HEAT  Huntingtin, elongation factor 3, protein phosphatase 2A, and TOR1 
HEK 293  Human Embryonic Kidney 293 Cells  
HELA  Human cervical epithelial carcinoma cell line 
HepG2  Hepatocellular carcinoma 
HRP   Horseradish peroxidase-linked 
IPMK   Identified inositol polyphosphate multikinase 
IPTG   Isopropyl- 1 -thio-â -D-galactopyranoside 
LB   Luria Broth 
MAPK  Mitogen-activated protein kinase 
MAPKAP1 Mitogen–activated protein kinase-associated protein1 
MCF7  Human breast adenocarcinoma cell line 
MDM2 Mouse double minute 2 homolog 
mLST8/GβL Mammalian LST8/G-protein β-subunit like protein 
20 
 
mRNA  Messenger Ribonucleic Acid 
mSin1  Mammalian stress activated protein kinase – interacting protein 
mTOR Mammalian Target of Rapamycin and recently known as Mechanistic Target 
of Rapamycin   
mTORC1 mTOR Complex 1 
mTORC2 mTOR complex 2 
MW  Molecular Weight 
NITE   National institute of technology and evaluation 
PCR   Polymerase chain reaction 
PDB  Protein Data Bank 
PGC1α Peroxisome proliferator–activated receptor gamma coactivator 1-alpha 
PI3K   Phosphatidylinositol-3-kinase  
PIKK  Phosphatidyl inositol 3’ kinase-related kinases 
PKC   Protein kinase C 
PP2A  Protein Phosphatase 2 
PPAR-γ  Peroxisome proliferator-activated receptor-γ 
PPARγ Peroxisome proliferator–activated receptor gamm 
PRAS40 Proline-rich AKT substrate 40 kDa 
21 
 
protor   Protein observed with Rictor 
PVDF  Polyvinylidene difluoride 
Rac1  Ras-related C3 botulinum toxin substrate 1   
RAFT  Rapamycin and FKBP12 target 
Rag  Recombination Activation protein 
RAPT  Rapamycin target 
raptor   Regulatory associated protein of mTOR 
RD   Regulatory domain 
Rheb   Ras homolog enriched in brain 
RhoA  Ras homolog gene family, member A 
rictor   Rapamycin insensitive companion of mTOR 
RPM  Revolutions per minute 
rRNA   Ribosomal RNA  
S6K  S6 Kinase 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
SEP   Sirolimus effector protein  
SGK1  Serum/glucocorticoid regulated kinase 1 
SOC   Super Optimal broth with Catabolite repression 
22 
 
SREBP1  Sterol regulatory element–binding protein 1 
SREBP-1 Sterol regulatory element binding protein-1 
STAT3 Signal transducer and activator of transcription 3 
STAT3 Signal transducer and activator of transcription 3 
TBST  Tris-Buffered Saline and Tween 20 
TEMED  Tetramethylethylenediamine 
TIF-IA  Transcription initiation factor IA 
Tm   Temperatures 
tRNA  Transfer RNA 
UCL   University College London 
ULK1  Unc51-like kinase 1 
ULK1  Unc-51-like kinase 1  
UV  Ultra-violet 
YY1  Yin Yang 1 
  
23 
 
 
 
 
Chapter 1 
General Introduction 
 
Chapter one  Zeyad Alharbi 
 
24 
 
 
Chapter 1: General Introduction  
 
1.1 mTOR, an overview 
The mammalian Target of Rapamycin (mTOR), but now officially mechanistic TOR, 
also known as FRAP, RAFT, or RAPT, is an evolutionarily conserved, 280 kDa 
serine/threonine protein kinase. mTOR belongs to the phosphatidyl–inositol 3–
kinase–related kinase (PIKKs) protein family. The mTOR protein plays a critical role 
in regulating cellular processes, such as cellular growth, proliferation, cytoskeletal 
organization, survival, protein transcription and protein synthesis (Corradetti and 
Guan 2006; Hay and Sonenberg 2004) 
The mTOR protein lies in the centre of intersecting signalling pathways. Due to its 
position, mTOR plays a critical role in regulating these pathways, therefore mTOR 
regulates key cellular processes. Dysregulation of the mTOR pathway has been 
implicated in many diseases, such as tumorigenesis, metastasis (Graff and Zimmer 
2003), metabolic diseases including diabetes (Schaeffer and Abrass 2010), cardiac 
hypertrophy (Young and Nickerson-Nutter 2005), sepsis (Kimball et al. 2003; Lang 
and Frost 2007) and after traumatic brain injury (Chen et al. 2007 (Adapted from 
Dazert and Hall, 2011) (Figure 1.1).  
Growth factors, nutrients and hormones activate mTOR and magnify its activity. In 
different forms of cancer, this activity is dysregulated (Choo et al. 2006; Hardie 
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2008; Inoki et al. 2003; Laplante and Sabatini 2009). Amplified mTOR activity will 
in turn accelerate protein synthesis and stimulate multiple proteins promoting tumour 
progression. Amplified mTOR-mediated processes may increase cell growth, 
proliferation, cellular metabolism and energy utilization. In addition, mTOR may 
increase tumour angiogenesis through the production of pro-angiogenic factors and 
also by directly driving vascular cell proliferation (Fingar and Blenis 2004). mTOR 
is known as a vital regulator of gene expression at the level of transcription and 
translation, and consequently is an excellent intracellular target for anti-cancer 
therapy. 
The aim of this study is to elucidate the regulation of mTOR signalling in health and 
cancer, by identifying different splicing isoforms of mTOR and defining their roles 
in mTOR mediated cellular processes. In this study, I focus on providing evidence 
for the existence of a new mTOR splicing isoform, identifying its domain structure 
and expression pattern in cell lines and tissues, as well as elucidating its contribution 
to cellular processes in health and disease.  
1.1.1 The mTOR Structure 
The mTOR protein consists of 2,549 amino acids, composing multiple highly 
conserved domains. Similar to other PIKK family members, mTOR contains a 
protein kinase domain at the COOH-terminus and a long stretch of protein-protein 
interaction modules within its NH2-terminus.  
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Figure 1.1: Diseases linked to dysregulated mTOR signalling and the corresponding 
affected organs (Adapted from Dazert and Hall, 2011) 
 
The NH2-terminal includes a chain of HEAT (Huntingtin, elongation factor 3, 
protein phosphatase 2A, and TOR1) repeats, which form a helical structure. These 
HEAT repeats enable protein–protein interactions. Therefore, it is important for 
mediating mTOR interaction with other proteins in the mTOR complexes (Perry and 
Kleckner 2003). The crystal structure of other proteins which contain HEAT repeats, 
such as human DNA-dependent protein kinase (DNA-PK), show that the large 
number of alpha-helical HEAT repeats are vital for protein-protein interactions  
(Sibanda et al. 2010). 
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The HEAT repeats are followed by a moderately conserved FAT (FRAP, ATM, and 
TRRAP) domain. There is also a short FATC at the COOH-terminal. The FAT and 
FATC domains are found in all PIKK family members. It has been proposed that 
these two domains interact with each other, thus concealing the kinase domain until 
mTOR is activated by phosphorylation in response to diverse extracellular stimuli 
and cellular metabolites. In addition, deletion of 20 amino acids (amino acids 2,430–
2,450)  just upstream of the FATC domain, resulted in an increase in mTOR kinase 
activity, thus magnifying the stimulation toward downstream targets in vitro and in 
vivo (Sekulic et al. 2000). Between the FAT and FATC domains there are three 
domains: a) FKBP12 Rapamycin Binding (FRB) domain, which is the target of the 
inhibitory rapamycin–FKBP12 complex; b)  adjacent  to the FRB domain lies a 
highly conserved serine-threonine kinase domain; c)  Regulatory domain (RD) is 
located downstream of the kinase domain (Figure 1.2).   
Several activating mutations have been recently identified in mTOR, but their 
detailed analysis indicated that none of them possesses an oncogenic potential 
(Brown et al. 1995; Kim et al. 2002; Peterson et al. 1999; Vilella-Bach et al. 1999).  
The crystal structure of mTOR has not yet been determined, but molecular modelling 
suggests that most of the protein consists mainly of helical structures (Perry & 
Kleckner 2003). 
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Figure 1.2: Schematic diagram of mTOR domains with phosphorylation sites noted 
(Adapted from Harris and Lawrence, Jr. 2003). 
 
The mTOR protein primarily localized in the cytosol. However it has also been 
associated with the membranes of several organelles such as the Golgi, endoplasmic 
reticulum, mitochondria and nucleus (Desai et al. 2002; Drenan et al. 2004; Liu and 
Zheng 2007; Sabatini et al. 1999; Tirado et al. 2003; Withers et al. 1997).  
1.1.2 mTOR Complexes in mammalian cells 
mTOR has been shown to localize in the cytoplasm in two multiprotein complexes, 
mTOR Complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Guertin and 
Sabatini 2005a) (Figure 1.3). 
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Figure 1.3: Schematic diagram of mTOR complexes. a) mTOR complex 1 and its targets. b) mTOR complex 2 and its targets 
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1.1.2.1 mTORC1 
The multi-protein mTORC1 is composed of mTOR, regulatory associated protein of 
mTOR (raptor), mammalian LST8/G-protein β-subunit like protein (mLST8/GβL), 
Proline-rich AKT substrate 40 kDa (PRAS40), and the newly identified inositol 
polyphosphate multikinase (IPMK) (Hara et al. 2002; Kim et al. 2002; Kim et al. 
2003; Kim et al. 2011; Vander et al. 2007). 
Indeed, some proteins in mTORC1 are known to be essential for mTOR to perform 
mTORC1 activities (Hara et al. 2002; Kim et al. 2002; Sancak et al. 2007). Raptor 
(150 kDa) has been reported to play critical roles in mediating mTORC1 assembly 
and consequently mTORC1 function. In addition, it helps to recruit mTORC1 
substrates, as well as regulate its activity and subcellular localization. Raptor 
interacts with mTOR via a strong NH2-terminal interaction and a weaker COOH-
terminal interaction (Hara et al. 2002; Kim et al. 2002; Sancak et al. 2008). 
The function of mLST8 (36 kDa) in mTORC1 is ambiguous, since lack of this 
protein does not show any effect on mTORC1 activity in vivo (Guertin et al. 2006). 
PRAS40 (40 kDa) has been recognised as a negative regulator of mTORC1. It was 
identified as a raptor-interacting protein. Later in this text we will discuss that, in 
vitro, Akt phosphorylate PRAS40, which prevents it from inhibiting mTORC1 in 
cells (Sancak et al. 2007; Vander et al. 2007; Wang et al. 2007). 
IPMK is an inositol phosphate multiple kinase, which catalyses the formation of 
higher phosphorylated inositols, InsP5 and InsP6. IPMK stabilizes mTOR-raptor 
interaction through the NH2-terminal sequence of IPMK. The IPMK NH2-terminal 
sequence is a specific binding site of mTOR. Depletion of IMPK resulted in reduced 
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mTORC1 activity and reduced mTORC1 response to stimulation by amino acids. 
IMPK regulates amino acid signaling to mTOR, independently of its catalytic 
function. (Kim et al. 2011). 
The three-dimensional (3D) structure of human mTORC1 has been determined by 
cryo-electron microscopy (cryo-EM). The cryo-EM revealed the shape of mTORC1, 
however, it was not possible to define the inter-molecular and inter-subunit 
boundaries at the available resolution (Yip et al. 2010). 
1.1.2.2 mTORC2 
mTORC2 like mTORC1 contains mTOR and mLST8/GβL, but instead of raptor, 
PRAS40, and IPMK, it contains rapamycin insensitive companion of mTOR (rictor), 
mammalian stress activated protein kinase – interacting protein (mSin1), and the 
protein observed with Rictor (protor) (Frias et al. 2006; Jacinto et al. 2004; Pearce et 
al. 2007; Sarbassov et al. 2004; Yang et al. 2006). 
 mLST8 is a component of both mTORC1 and mTORC2. Although mLST8 is not 
required for mTORC1, it is required for mTORC2 function. Moreover, lack of 
mLST8 can disrupt the assembly of mTORC2 and its functions (Guertin et al. 2006).  
Rictor (200 kDa), also known as mAVO3, is rapamycin insensitive companion of 
mTOR, and it is critical for mTORC2 activity. It might also help in protein-protein 
interactions (Sarbassov et al. 2004).  
mSin1 (70 kDa), also known as mitogen-activated protein kinase-associated protein1 
(MAPKAP1), is critical for the assembly of mTORC2 and consequently for 
phosphorylation of its target, Akt/PKB (Frias et al. 2006). 
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Protor (42 kDa) increase the mTORC2–mediated activation of SGK1 (Pearce et al. 
2007; Pearce et al. 2011). 
1.1.2.3 Regulation of mTOR 
1.1.2.3.1 mTORC1 regulation  
The regulation of mTORC1 activity appears to be complex and is likely to be 
dependent on the organization of the various subunits in the mTORC1 (Yip et al. 
2010a). 
The activity of mTORC1 is stimulated by the integration of many signals, including 
growth factors, insulin, nutrients and energy availability (Figure 1.4). In addition 
mTORC1 could be regulated by cellular stresses such as hypoxia, osmotic stress, 
reactive oxygen species and viral infection (Avruch et al. 2005; Corradetti & Guan 
2006; Fang et al. 2001; Hay & Sonenberg 2004; Kim et al. 2002). 
Ras homolog enriched in brain (Rheb) binds near the mTOR kinase domain, and 
plays a critical role in stimulating mTORC1 activity (Long et al. 2005a; Long et al. 
2005). Insulin activates Rheb through Phosphatidylinositol-3-kinase (PI3K) pathway, 
whereas, growth factors activate Rheb through mitogen-activated protein kinase 
(MAPK) signaling pathway and accelerate insulin signaling activity. Growth factors, 
insulin, and amino acids can keep Rheb in its active form, and therefore stimulate 
mTORC1 activity (Guertin and Sabatini 2007; Shaw and Cantley 2006).  
In contrast, PRAS40 inhibits Rheb–dependent mTORC1 activation in a dose-
dependent manner in vitro (Sancak et al. 2007; Vander et al. 2007). Akt/PKB is a 
serine/threonine protein kinase, activated by growth factors. Akt has two main roles 
in mTORC1 activation. First, Akt inhibit TSC1/2, which prevents Rheb from 
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activating mTORC1. Secondly, it phosphorylates PRAS40, hence preventing its 
function as a Rheb inhibitor (Sancak et al. 2007; Vander et al. 2007). 
Another method for mTORC1 activation, independent of Rheb, is via amino acids 
and Rag. Lack of amino acids from the medium resulted in inhibition of mTORC1 
activity. Amino acids activate Rag on the lysosomal surface. This activation allows it 
to recruit and bind to mTORC1, where Rheb–GTP is also situated, leading to 
activation of mTORC1 (Sancak et al. 2008; Sancak et al. 2010). The underlying 
mechanism of this process is still not clearly understood. 
The activity of mTORC1 is inhibited by low nutrient levels, growth factor 
deprivation, energy stress, caffeine, rapamycin, farnesylthiosalicylic acid (FTS), and 
curcumin (Beevers et al. 2006; Kim et al. 2002; McMahon et al. 2005).  
The kinase domain in mTOR is relatively similar to the one in PI3K. mTOR activity 
can be inhibited in vitro with high concentrations of PI3K inhibitors, LY92900 and 
Wortmannin (Brunn et al. 1996a; Hay & Sonenberg 2004). There are many known 
compounds which compete with ATP binding to mTOR kinase domain, suppressing 
its activity. These compounds are known as ATP competitive mTOR inhibitors and 
include PP242, Torin1, WYE-354, AP23573 and Ku-0063794. In contrast to 
Rapamycin, they inhibit both mTORC1 and mTORC2 activity. These inhibitors have 
a significant selectivity over PI3K (Feldman et al. 2009; Garcia-Martinez et al. 2009; 
Mita and Tolcher 2007; Thoreen et al. 2009; Yu et al. 2009).  
Although relatively short exposure to FKBP12-rapamycin did not affect the 
structural integrity of mTORC1, extended incubation (more than 20 minutes) 
resulted in disassembly of mTORC1 (Yip et al. 2010a) 
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Figure 1.4: Regulation of mTORC1 by hormones, growth factors and nutrients. Processes that up 
regulate signaling are shown in black; those that down regulate signalling are shown in red. 
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1.1.2.3.2 mTORC2 Regulation  
Compared to mTORC1, there is limited information about mTORC2 regulation. 
mTORC2 has been shown to be growth factor sensitive but nutrient insensitive 
(Jacinto et al. 2004; Loewith et al. 2002; Sarbassov et al. 2004). After growth factor 
stimulation, mTORC2 is activated in numerous cell lines and tissues. The underlying 
mechanism of this activation is still unknown (Frias et al. 2006; Sarbassov et al. 
2004; Sarbassov et al. 2005; Yang et al. 2006). 
Rapamycin is known to inhibit mTORC1 activity. In contrast, mTORC2 was 
identified as a rapamycin-insensitive mTOR complex. Subsequent studies have 
shown that prolonged exposure to rapamycin treatment can disrupt mTORC2 
assembly, consequently inhibiting its activity. In addition, prolonged exposure 
promotes rapamycin binding to free mTOR molecules, thus inhibiting the formation 
of new mTORC2 (Sarbassov et al. 2005; Sarbassov et al. 2006).  
Some proteins in the mTORC2, such as mLST8, are required to maintain the rictor-
mTOR, but not the raptor-mTOR, lack of mLST8 can disrupt the assembly of 
mTORC2, thus affecting mTORC2 function (Guertin et al. 2006).  
1.2 Role of mTOR in cellular functions 
The mTOR pathway has been shown to control multiple cellular processes, including 
cell growth, cell cycle progression, nutrient plasticity, cellular survival, metabolism 
and translation initiation. Translation initiation is the most studied function of mTOR 
and is the rate-limiting step in protein synthesis (Gingras et al. 2004) (Figure 1.5). 
mTORC1 has been shown to interact, direct or indirect, with many targets include 
S6K, 4E-BP, ATG13, ULK1, TIF-IA, Lipin-1, SREBP1, PPARγ, PGC1α, and 
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STAT3. These targets are responsible for regulation of many cellular processes, 
including protein and lipid synthesis, mitochondrial and ribosomal biogenesis and 
autophagy. 
The mTORC2 plays a critical role in cell survival, metabolism, and proliferation. The 
mTORC2 phosphorylates and activates its downstream effectors Akt/PKB, 
serum/glucocorticoid regulated kinase 1 (SGK1), and protein kinase C (PKC). Akt 
plays a critical role in multiple cellular processes including glucose metabolism, 
apoptosis, cell proliferation, transcription and cell migration (Frias et al. 2006; 
Guertin and Sabatini 2005; Guertin & Sabatini 2007; Hresko and Mueckler 2005; 
Lee et al. 2005; Sarbassov et al. 2005; Yang et al. 2006). 
mTORC2 functions as an important regulator of the cytoskeleton, via its organisation 
and stimulation of F-actin stress fibres, by enhancing the phosphorylation of protein 
kinase C α (PKCα) and paxillin, and also by the addition of GTP to RhoA, Rac1 and 
Cdc42 (Sarbassov et al. 2004). 
Despite all the differences between lower and higher eukaryotic organisms, budding 
yeast and Drosophila can still be considered as models when studying the 
mammalian TOR. TOR is a highly conserved protein kinase, with high sequence 
identity and functional similarity between yeast, Drosophila and mammals. Also 
cellular processes in lower and higher eukaryotes are more likely to be conserved. 
TOR in budding yeast and Drosophila participates in a variety of cellular processes 
(Crespo and Hall 2002; Rohde et al. 2001) and some of these roles have not yet been 
proven in mammals. The implication of mTOR in many diseases suggests that it has 
unidentified targets and roles in mammalian cells. 
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Figure 1.5: Schematic diagram of downstream targets of mTORC1 and its role in cellular functions. 
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1.2.1 mTOR signalling in the regulation of protein synthesis 
mTORC1 controls cell growth by phosphorylating the key regulators of protein 
synthesis, including S6 Kinase 1 (S6K1) and the eukaryotic translation initiation 
factor 4E binding protein 1 (4E-BP1). S6K1 and 4E-BP1 are the two best 
characterized targets of mTORC1 (Hay & Sonenberg 2004; Ma and Blenis 2009; 
Richter and Sonenberg 2005). 
4E-BP1 binds tightly to the eukaryotic translation initiation factor 4E (eIF4E), 
preventing it from performing its translation initiation roles. eIF4E binds to 5'-capped 
mRNAs and recruits them to the ribosomal initiation complex for translation (Pause 
et al. 1994). To initiate translation, eIF4E needs to be released from 4E-BP1. The 
mTORC1 phosphorylates two sites in 4E-BP1 in vitro (Brunn et al. 1997; Burnett et 
al. 1998; Gingras et al. 2001). This phosphorylation initiates subsequent 
phosphorylation of Thr-70 followed by Ser-65 (Gingras et al. 2001; Heesom and 
Denton 1999; Mothe-Satney et al. 2000). Moreover, mTORC1 has been shown to 
phosphorylate at least four residues of 4E-BP1 in a hierarchical manner (Gingras et 
al. 1999; Huang and Houghton 2001; Mothe-Satney et al. 2000) (Figure 1.6).  
S6K has been known to regulate cell growth (Shima et al. 1998). mTORC1 
phosphorylates S6K1 on the hydrophobic-motif residue Thr-389 (Pullen and Thomas 
1997; Saitoh et al. 2002), followed by subsequent phosphorylation by PDK1 (Pullen 
et al. 1998;Pullen & Thomas 1997). Activation of S6K1 augments cell growth by 
stimulating the initiation of protein synthesis, through phosphorylation of Ribosomal 
protein S6 and other components which participate in protein synthesis (Peterson and 
Schreiber 1998). S6K1 participates in a positive feedback loop with mTORC1 by 
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phosphorylating mTOR at two sites, stimulating mTOR activity (Chiang and 
Abraham 2005; Holz and Blenis 2005).  
 
 
Figure 1.6: Regulation of cap-dependent translation initiation by mTORC1 via 4E-BP. 
Unphosphorylated 4E-binding proteins bind tightly to eIF4E, preventing it from 
interacting with eIF4G and thus inhibiting translation. The mTORC1 phosphorylates 
4E-BPs in a hierarchical manner, releasing the 4E-BP from eIF4E. This results in the 
recruitment of eIF4G to the 5’ cap and allows translation initiation to proceed 
(Adapted from Ma & Blenis 2009). 
 
1.2.2 Implication of mTOR signalling in the regulation of cell survival 
In normal cells, there is a balance between survival and apoptotic signals. If these 
signals are dysregulated, cells might either recover or enter the programme of cell 
death. PI3K signalling pathway plays a critical role in mediating pro-survival 
processes. Pro-survival signalling pathways are often dysregulated in cancer cells. 
Suppression of these survival signals promotes apoptotic processes. Therefore 
survival signals are known to be excellent targets for anti-cancer therapy (Foster 
2004).  
The mTOR plays a critical role in cell survival in the following ways. Firstly, 
mTORC2 promotes Akt activity. Akt then phosphorylates and inactivates several 
pro-apoptotic factors, promoting cellular growth and survival. These factors include  
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GSK3b, BAD, forkhead family transcription factors and MDM2 (Vivanco and 
Sawyers 2002). Akt phosphorylates the forkhead box proteins FOXO1 and FOXO3, 
preventing their translocation to the nucleus. FOXO1 and FOXO3 are transcription 
factors that promote gene expression of proteins responsible for apoptosis (Guertin et 
al. 2006) (Figure 1.7). 
Secondly, mTOR, via Akt, mediates the stabilization of cell surface amino acid 
transporters, protecting cells from apoptosis (Edinger and Thompson 2002). 
Thirdly, mTORC1 phosphorylates and activates S6K1 which generates a negative 
feedback loop to suppress PI3K activity, resulting in reduced survival signals. 
Fourthly, mTOR, via S6K1, has been shown to inhibit the pro-apoptotic protein 
BAD (Harada et al. 2001). 
mTORC1 phosphorylates 4E-BP1 and S6K1, promoting mRNA translation, 
ribosome biogenesis, and down–regulate autophagy. This allows mTOR to regulate 
cell growth, proliferation and survival (Hara et al. 2002; Kim et al. 2002; Kim et al. 
2003; Ruggero and Pandolfi 2003). 
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Figure 1.7: Role of mTORC2 in cellular survival. The mTORC2 promotes cellular 
survival by activating Akt and via SGK1 phosphorylation (Adapted from Laplante and 
Sabatini 2012). 
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1.2.3 Role of mTOR signalling in mitochondrial biogenesis 
In mammalian cells, mTOR activity positively correlates with mitochondrial activity 
(Schieke et al. 2006). mTORC1 inhibition by rapamycin has been shown to down-
regulate the rate of oxygen consumption and mitochondrial oxidative capacity 
(Cunningham et al. 2007). The mTOR appears to regulate peroxisome-proliferator-
activated receptor coactivator (PGC1α). In addition to the role of PGC1α in 
regulating the expression of many mitochondrial genes, PGC1α also acts as 
transcriptional coactivator for Yin Yang 1 (YY1) in an mTOR–dependent manner. 
YY1 belongs to the zinc-finger GLI–Kruppel class of transcription factors. 
Knockdown of YY1 resulted in a significant decrease in mitochondrial gene 
expression (Cunningham et al. 2007; Dunlop and Tee 2009; Schieke and Finkel 
2006). 
1.2.4 Regulation of ribosomal biogenesis via the mTOR signalling pathway 
The rate of protein synthesis can be regulated by increasing the translation efficiency 
of existing ribosomes and by the production of new ribosomes. mTOR is a key 
regulator of both processes, either directly or indirectly, via several components. 
These include eIF4B, eIF4G, and eIF4E (Hay & Sonenberg 2004). In addition, 
mTORC1 phosphorylates 4E-BP preventing its activity, as a translational repressor 
(Brunn et al. 1997; Burnett et al. 1998; Gingras et al. 2001).  
 Moreover, S6K and its targets, the ribosomal protein S6 and elongation factor-2 
kinase (eEF2K), also contribute to ribosome biogenesis. mTOR, via S6K, regulates 
ribosome biogenesis by controlling the expression of ribosomal protein mRNAs and 
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the transcription of ribosomal RNA (rRNA) and tRNA, a major limiting step in 
ribosome biogenesis (Crespo & Hall 2002; Rohde et al. 2001). 
Transcription machinery for ribosomal RNA synthesis is regulated by RNA 
polymerase I (Pol I). This process is mediated by the transcription factor TIF-IA. 
TIF-IA is also known as regulatory factor that regulate the formation of the 
transcription initiation complex. mTOR activates TIF-IA, consequently mTOR 
regulate transcription of ribosomal RNA (Mayer et al. 2004). 
1.2.5 Role of mTOR signalling in autophagy 
mTOR inhibits autophagy, a catabolic process involving the degradation of cellular 
components to constituent amino acids. Conversely, in the case of cellular stress, 
mTOR is inhibited and autophagy is activated (Crespo & Hall 2002; Rohde et al. 
2001). In mammalian cells, autophagy–related 13 (ATG13), Unc-51–like kinase 1 
(ULK1), FAK family kinase–interacting protein 200kDa (FIP200), and ATG101 
forms a complex, which regulates autophagy (Ganley et al. 2009; Hosokawa et al. 
2009; Jung et al. 2010). mTORC1 phosphorylates ATG13 and ULK1, inhibiting the 
complex ability to initiate autophagy (Hosokawa et al. 2009a; Hosokawa et al. 2009). 
The mTOR-mediated autophagy inhibition allows cells to survive in extreme 
conditions. Although mTOR has been known as a key regulator of autophagy, the 
underlying regulatory mechanisms are not clearly understood (Blommaart et al. 
1995; Shigemitsu et al. 1999). 
1.2.6 mTOR signalling and lipid biosynthesis 
The mTOR has been known to regulate cell growth and proliferation via its role in 
protein synthesis. However, there is growing evidence showing that mTOR controls 
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cell growth and proliferation by lipid synthesis, a process which is required for cell 
membrane synthesis and storage of lipid as a source of energy. 
The mTORC1 controls lipid synthesis by regulating the transcription factor sterol 
regulatory element binding protein-1 (SREBP-1). SREBP-1 regulates the expression 
of genes required for cholesterol, fatty acid, triglyceride and phospholipid synthesis 
(Horton et al. 2002). The mechanism of SREBP-1 regulation by mTOR is still not 
well understood.   
Activated Akt positively regulates the expression of genes involved in lipid synthesis 
and nuclear accumulation of SREBP-1 (Manning and Cantley 2007). Inhibition of 
mTOR by rapamycin, inhibits the Akt mediated SREBP-1 activation and the 
expression of genes responsible for lipid synthesis. In mammalian cells, SREBP-1 
depletion inhibits cell growth (Porstmann et al. 2008).   
mTORC1 also controls adipogenesis by regulating the expression and activation of 
peroxisome proliferator-activated receptor-γ (PPAR-γ). PPAR-γ is a nuclear receptor 
which regulates the expression of genes involved in fatty acid uptake, synthesis, 
esterification, and storage in the newly formed adipocytes.  
Lipin1, a phosphatidic acid phosphatase, plays an essential role in adipogenesis. 
Lipin-1 promotes triglyceride synthesis and acts as coactivator for PPAR-γ. Lipin1 is 
phosphorylated in response to insulin and nutrients in a rapamycin-sensitive manner 
(Koh et al. 2008; Laplante and Sabatini 2009). A diagram illustrating the regulation 
of lipid synthesis by mTORC1 is shown in Figure 1.8 
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Figure 1.8: Regulation of lipid synthesis by mTOR. 
The mTORC1 mediates the cleavage of the transcription factor SREPBP-1, resulting 
in its translocation to the nucleus. SREPBP-1 induces the expression of several genes 
that are required by lipogenesis. The mTORC1 also activates PPARγ via several 
mechanisms, which enhance the expression of lipogenic genes (Adapted from 
Laplante and Sabatini 2012). 
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1.2.7 Other roles of mTOR in regulating cellular processes 
mTOR also regulates gene expression by playing a role in the subcellular localization 
of transcription factors (Beck and Hall 1999). mTOR has been shown to directly 
phosphorylate the signal transducer and activator of transcription 3 (STAT3) 
transcription factor (Yokogami et al. 2000), and S6K1 phosphorylates CREMt, 
another transcription factor (de Groot et al. 1994). Microarray RNA analysis has 
shown that mTOR affects the expression of genes responsible for many metabolic 
and biosynthetic pathways (Peng et al. 2002). 
mTOR may also regulate post-transcriptional processes by modulating the activity of 
some proteins directly involved in post-transcriptional processes of mRNA 
biogenesis (Wilson and Cerione 2000).  
In yeast, protein phosphatases are important downstream targets of TOR. 
Phosphatase activity in yeast helps the transcriptional and translational processes 
required for ribosome biogenesis (Crespo & Hall 2002). These phosphatase activities 
have not yet been identified in mammals.  
1.3 FKBP12 – Rapamycin Complex 
1.3.1 Overview of Rapamycin 
Rapamycin was identified as an antifungal agent from extracts of the soil bacterium, 
Streptomyces hygroscopicus. The bacterium was found on Easter Island in the 1970s 
(Sehgal 2003). Subsequent studies on rapamycin revealed impressive tumour- and 
immuno-suppressive activities (Sehgal et al. 1975; Sehgal 2003; Vezina et al. 1975). 
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Rapamycin is an mTOR inhibitor that can be administered either orally or 
intravenously. It enters the tumour cell, where it forms a complex with FK506-
binding protein of 12 kDa (FKPB12). This complex binds the FRB domain of 
mTOR, suppressing its activity (Chen et al. 1995; Sabatini et al. 1994; Sarbassov et 
al. 2006). The inhibition of mTOR activity suppresses mTOR mediated protein 
synthesis, eventually resulting in anticancer effects (Dancey 2005). It suppresses 
tumour cell growth and proliferation and angiogenesis. mTOR inhibition as an anti 
cancer therapy has been investigated in number of tumour types including renal 
cancer, breast cancer, lung cancer, colorectal Islet cells cancer. In addition to other 
mTOR inhibitors, Rapamycin has been helpful in studying mTORC1 activities. 
Rapamycin as a drug specifically inhibits mTOR, resulting in reduced cell growth, 
cell cycle progression and proliferation. Rapamycin was proven to be efficient as 
antifungal, immunosuppressant and anticancer. However, resistance to rapamycin 
has been reported (Brunn et al. 1996b; Gingras et al. 2001b; Schmelzle and Hall 
2000).   
1.3.2 Overview of FKBP12 
FKBP12 is a peptidyl-prolyl isomerase, abundantly found in many eukaryotes and 
ubiquitously, that may function as a protein–folding chaperone for proteins 
containing proline residues (Schreiber 1991). Rapamycin inhibits the isomerase 
activity of FKBP12 (Heitman et al. 1991;  Koltin et al. 1991; Wiederrecht et al. 
1991). Although, mTOR is able to bind to rapamycin-FKBP12 complex, it is unable 
to bind to either rapamycin or FKBP12 separately (Chen et al. 2007; Gingras et al. 
2001; Schmelzle & Hall 2000; Stan et al. 1994). The crystal structure of FKBP12-
rapamycin in complex with the FRB domain of mTOR did not reveal how this 
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interaction prevents phosphorylation of direct mTORC1 substrates and the 
mechanism of mTOR inhibition by rapamycin remains unclear (Choi et al. 1996). 
Previous biochemical studies indicated that binding of FKBP12-rapamycin to 
mTORC1 may result in a conformational change and cause the dissociation of 
mTOR complex1 proteins (Kim et al. 2002). 
Recent studies of mTORC1 by cryo-EM reveals that relatively short exposure to 
FKBP12-rapamycin does not affect the structural integrity of mTORC1, while 
extended incubations resulted in disassembly of mTORC1. No intact mTORC1 
particles could be detected after one hour incubation (Yip et al. 2010).  
It was proposed that FKBP12-rapamycin binds to mTORC1 and this binding blocks 
access to the active site for mTOR substrates, S6K1 and 4E-BP1 (Yip et al. 2010a). 
It has been shown that within cells, rapamycin does not completely inhibit 4E-BP1 
phosphorylation (Choo et al. 2008; Feldman et al. 2009; Thoreen and Sabatini 2009) 
or mTORC1 stability (Kim et al. 2002) suggesting that cells contain buffering 
mechanisms that counter the effects of rapamycin on mTORC1 and that these are lost 
when mTORC1 is purified (Yip et al. 2010a). 
1.4 Initial evidence for the existence of mTOR splicing isoforms 
Since mTOR has been identified and studied based on rapamycin sensitivity, it is 
possible that mTOR is participating in non-rapamycin related processes, which have 
not yet been identified. In addition, TOR in budding and fission yeast shows some 
signaling activity in a rapamycin insensitive manner. It is unknown whether mTOR 
can also signal in a completely rapamycin–insensitive manner in humans (Fingar et 
al. 2002; Fingar & Blenis 2004). 
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Like other PIKK family members, there is an increasing evidence of the presence of 
mTOR splicing isoforms. Data from our laboratory suggests the existence of several 
potential splicing isoforms of mTOR. Northern blotting of human tissues as well as 
western blotting of gel filtration fraction analysis of mTOR from MCF7 cell lysates, 
indicate the presence of several potential mTOR splicing forms. Our laboratory has 
also provided evidence for the existence of the mTOR splicing isoform, mTORβ, 
which lacks most of HEAT and FAT domains (Panasyuk et al. 2009) (Figure 1.9). In 
vivo, mTORβ could form complexes with Raptor and Rictor. In vitro, mTORβ has 
been shown to phosphorylate the same substrates, as originally reported for the full 
length mTOR (mTORα). The mTORβ has also been shown to accelerate cell cycle 
progression and to stimulate cell proliferation. Moreover, mTORβ overexpression in 
cells was shown to have oncogenic potentials, when tested in vitro (colony formation 
assay) and in vivo (tumour formation in nude mice) (Panasyuk et al. 2009).  
There are numerous commercially available mTOR specific antibodies which 
recognise different regions in mTOR. When tested in western blotting, they 
recognise the full length mTOR (280kDa) and a number of immunoreactive bands 
with lower molecular weight in total cell lysates from different cell lines and tissues. 
These bands may represent the product of mTOR degradation, non-specific binding 
or potential splicing isoforms of mTOR. 
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Figure 1.9: Modular representation of mTOR isoforms 
 
1.5 Aim of the study  
In the course of identification and characterization of mTOR in our laboratory, 
preliminary experimental evidence was obtained in support for the existence on 
novel mTOR splicing isoforms. Therefore, the initial aim of this study is to search 
for novel mTOR splicing isoforms by applying bioinformatics, biochemical and 
molecular biology approaches. The identification of additional mTOR splice variants 
will inspire us to investigate their ability to form regulatory signalling complexes 
mTORC1 and mTORC2, and to phosphorylate known downstream substrates. 
Furthermore, our efforts will be focused on studying the role of the novel isoforms in 
the mTOR–mediated cellular processes, such as cell proliferation, cell survival and 
oncogenic transformation. 
1.6 Methods of isolating mTOR 
In order to find novel mTOR splicing isoforms, we looked at how previous 
researchers had identified mTOR. TOR was discovered as a target of FKBP12-
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rapamycin complex, which was known to arrest cell cycle progression. Mammalian 
TOR was first identified and reported in 1994, and given different names: FKBP12-
rapamcyin associated protein (FRAP), rapamycin and FKBP12 target (RAFT), 
rapamycin target (RAPT), or sirolimus effector protein (SEP) (Brown et al. 1994; 
Chen et al. 1994; Chiu et al. 1994; Sabatini et al. 1994; Sabers et al. 1995). 
Brown et al. isolated mTOR, designated FRAP, using a fusion protein of 
Glutathione-S transferase with the FKBP12, in complex with rapamycin, to identify 
the binding partner from MG-63 cells (Brown et al. 1994).  
Sabatini et al. isolated mTOR, designated RAFT, using cross-linking and affinity 
purification procedures for proteins interacting with FKBP12 in the presence of 
rapamycin. They identified two proteins, RAFT1 245 kDa and RAFT2 35 kDa 
(Sabatini et al. 1994). RAFT1 was described as TOR, while RAFT2 has never been 
mentioned again. 
Chen et al. isolated mTOR from Molt 4 cells, BJAB cells and from normal human T 
cells, using the GST-FKBP12:Rapamycin affinity matrix method. The identified 
protein was designated SEP and when tested in complex with FKBP12-rapamycin, 
exhibited immunosuppressive activity (Chen et al. 1994). 
Chiu et al. isolated mTOR, designated RAPT, using a two-hybrid system to screen a 
mouse cDNA library. The isolated mammalian clones, which interact with FKBP12 
in the presence of rapamycin, were further expressed in yeast for protein-protein 
interaction studies (Chiu et al.1994). 
Sabers et.al. isolated mTOR as a protein target of FKBP12-rapamycin complex in 
mammalian cells. Their strategies depending on affinity purification technique, by 
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incubating the tissue extract with GST-FKBP12 in the presence of rapamycin (Sabers 
et al. 1995). 
In our laboratory, a novel mTORβ isoform was originally identified in cell lines and 
tissues by immunoblot analysis with in-house developed anti-mTOR mABs (Figure 
1.9). Subsequently, molecular cloning of a cDNA corresponding to mTORβ was 
carried out using a panel of specific primers and the polymerase chain reaction 
(PCR) approach (Panasyuk et al. 2009).  
 
 
  
 
 
CHAPTER 2 
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Chapter 2: Methodology  
 
2.1 Materials 
2.1.1 Common laboratory reagents 
All the general purpose chemicals were purchased from Sigma-Aldrich, 
Thermo Fisher Scientific UK limited, BDH Analar, and Melford Laboratories Ltd. 
UK unless otherwise stated. General cell culture reagents were purchased from 
PAA Laboratories GmbH. Pre-stained protein molecular weight markers, DNA 
Markers, and restriction enzymes were obtained from Fermentas. All solution and 
buffers summarized in Appendix A 
2.1.2 Molecular cloning materials  
To purify a good amount of GST-FKBP12 to be used to prepare the affinity matrix, 
pGEX-FKBP12 plasmid was generated within the lab.  
To carry out experiments for mTOR functional analysis, I employed in these studies 
wild type and activated forms of mTOR. A single amino acid mutation in mTOR, 
S2215Y resulted in nutrient-independent activation of mTORC1 (Sato et al. 2010). 
Cells expressing Flag–mTORα and S2215Y were used as positive controls. In the 
other hand, cells transfected with a vector and cells transfected with an empty vector 
will be used as negative controls. 
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The pcDNA3 Flag-mTOR, pcDNA3 Flag-mTOR, pcDNA3 Flag-mTOR wild type 
and pcDNA3 Flag-mTOR S2215Y mutants were generated. Generated expression 
vectors have been confirmed by restriction analysis and sequencing. Theses 
expression vectors were used for generation of stable cell lines. 
The pME18SFL3 mTOR plasmid was obtained courtesy from the National institute 
of technology and evolution (NITE). All other plasmids were obtained from 
Invitrogen. 
2.1.3 Proteins  
GST-FKBP12 was purified from bacteria using recombinant GST fusion protein, 
which was over-expressed in E.Coli Rosetta cells. The bacteria containing the vector 
was induced by IPTG, lysed, sonicated, centrifuged, and GST-FKBP12 protein was 
purified using Glutathione-Sepharose, and dialysed by desalting column.  
Affinity matrix was prepared by coupling GST-FKBP12 in complex with Rapamycin 
to Glutathione Sepharose beads, and tested using lysates of cells over-expressing 
mTORα (280kDa) and mTORβ (80kDa). GST-FKBP12 purification was repeated 4 
different times to test different reaction conditions, which could affect the affinity of 
mTOR to bind to the affinity matrix. These conditions and factors include 
Rapamycin, GST-FKBP12, buffers, and beads. 
His-tagged S6K1 were purified from Sf9 insect cells and provided by Alexander 
Zhyvoloup. 4EBP1 and Akt Were purified within the laboratory by previous PhD 
student in our Laboratory. 
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2.1.4 Antibodies 
The monoclonal anti-Flag antibody was purchased from Sigma-Aldrich. Horseradish 
peroxidase-linked (HRP) secondary antibodies, anti-rabbit and anti-mouse, were 
purchased from Promega. Monoclonal antibodies against actin, myc and polyclonal 
Anti-F11 mTOR antibody were generated in the lab by previous students for other 
purposes. Anti Phospho-Akt (#4051) and anti Phospho-4E-BP1 (#2855) were 
obtained from Cell Signalling. Anti-S6K1 (phosphpoT389) (ab2571) were acquired 
from Abcam. Anti-Phospho-mTOR (Ser2448) (09-213) and polyclonal antibodies 
towards the C-terminal peptides of anti-mTOR (07-231) antibodies were obtained 
from Millipore. The antibody targeting the N-terminal N-19 (sc-1549) of mTOR 
was purchased from Satnta cruz. The mTOR sequence was sent to our 
collaborators in Ukraine to generate anti-mTOR C-terminal antibody. The 
Polyclonal antibodies targeting the mTOR were produced by immunizing a mouse 
with a synthetic peptide corresponding to residues 28 – 59 of human mTOR. 
Antibodies are purified by protein A and peptide affinity chromatography (further 
details about anti–mTOR discussed in chapter four). 
2.1.5 Mammalian cell lines 
HEK 293 (human kidney embryonic cells), MCF-7 (breast adenocarcinoma), Cos7 
(monkey kidney fibroblast-like), HepG2 (hepatocellular carcinoma), A549 (human 
lung carcinoma), MCF7 (human breast adenocarcinoma cell line) and HELA (human 
cervical epithelial carcinoma) cell lines were obtained from the American Type 
Culture Collection (ATCC). All other cell lines were kindly provided by Dr. Mina 
(Institute of structural and molecular biology, University College London). The rat 
heart tissue was extracted in the lab.  
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2.1.6 Bacteria 
Escherichia coli XL-10 Blue competent cells, Genotype: supE44 hsdR17 recA1 
endA1 gyrA46 thi relA1 lac-F [proABiacI9 lacZÄM 15 Tn1 0(tetr)]. These cells were 
used in the amplification of plasmid DNA. 
Escherichia coli BL21(DE3) pLysS cells. Genotype: F- ompT hsdSB (rB - mB -) gal 
dsm (DE3) pLysS (CamR). The DE3 designation means the strains contain the Ȝ 
DE3 lysogen that carries the gene for T7 RNA polymerase under control of the 
lacUV5 promoter. Isopropyl- 1 -thio-â -D-galactopyranoside (IPTG) is required to 
induce expression of the T7 RNA polymerase. These cells were used in the 
expression of GST fusions. 
2.2 Methods 
2.2.1 Molecular methods 
2.2.1.1 Primers design  
Primers were designed using the known DNA sequence of the template. Primers 
were checked for the absence of potential DNA secondary structure formation and 
annealing of primers to itself or within primer pairs, potential self-
complementarity and GC content of the primers to insure similar melting 
temperatures of the primers. Annealing temperatures (Tm) for each primer were 
calculated using Equation 2-1:  
Tm(°C)=2(A+T) + 4(G+C) Equation 2-1 
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All primers were ordered from MWG-Biotech. To check primers were correctly 
designed and also whether DNA had been correctly inserted into a vector, 10-50 
ng/μL DNA samples in 30 μL H2O were sent off for sequencing analysis as 
discussed is section (2.2.1.6). 
2.2.1.2 DNA digestion  
All restriction endonucleases were purchased from Fermentas and digests were 
carried out in the manufacturer’s recommended digestion buffer. As per the 
manufacturer’s recommendations, five units of restriction enzyme were used to 
digest 1μg of DNA in a total volume of 20μL.  The reaction mixtures were 
incubated at 37°C for 1hr.  
2.2.1.3 DNA ligation  
A rapid DNA ligation kit from Fermentas was used to ligate DNA fragments to 
linearised vector. In order to reduce the risk of self-ligation of the plasmids, at 
least a 1:3 molar ratio of vector: insert was utilised in the ligation reactions. The 
reactions were conducted at room temperature using 1μL of T4 DNA Ligase and 
5μL of Rapid Ligation Buffer in a total reaction volume of 20μL. The reaction 
mixture was used for transformation.    
2.2.1.4 Polymerase chain reaction  
The polymerase chain reaction (PCR) was used to amplify specific DNA 
sequences from DNA templates, using specific DNA primer oligonucleotides. 
PCR was performed using 2 ng DNA template in a 20 μL total volume containing 
0.2 mM dNTPs, 2 μM of each primer, and 0.5 U DNA polymerase (Thermo 
Scientific) in 1x reaction buffer as supplied. The reaction was carried out for 30 
cycles, consisting of a denaturing stage (98°C for 30s), a primer annealing stage 
Chapter two  Zeyad Alharbi 
 
59 
 
(56-59° for 30s), and finally a polymerase extension stage (72°C for 1 minutes). 
After completion of the cycling amplification, a final extension stage (72°C for 3 
minutes) was applied. Reactions were carried out in a thermal cycler (Labnet 
Multigene II). 
2.2.1.5 Electrophoresis and DNA purification  
DNA fragments were visualised by separation on an agarose based gel. 0.6 to 1 % 
w/v agarose gels were used throughout this thesis for DNA purification and 
analysis. The required weight of agarose was added to TAE buffer (40 mM Tris-
Acetate, 1 mM EDTA, pH 7.0) and heated in order to dissolve the agarose. After 
cooling the solution to approximately 50°C, Gel-Red dye supplied by Biotium 
was added in a 10,000x dilution. The liquid agarose solution was then poured into 
a mould containing a well-forming comb and left at room temperature so that it 
could solidify. DNA samples were prepared and mixed with 6X DNA loading 
buffer supplied by Fermentas, and then they were loaded into the wells in the gel. 
The samples were then electrophoresed at 80V in TAE buffer to achieve 
separation. Standard molecular weight markers (1kb Gene Ruler from Fermentas) 
were used to ascertain the sizes of the various fragments. The DNA was observed 
by exposing the gel to long-wave UV light. Purification of the requisite DNA 
fragments from the gel was performed by excising the bands of interest and using 
DNA Gel Extraction kit (QIAGEN) to obtain the DNA. 
2.2.1.6 DNA sequencing  
Minimum of three grams of plasmid DNA was air dried and sent for sequencing 
by MWG Biotech, GATC Biotech or by Wolfson Institute for Biomedical 
Research, UCL. 
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2.2.1.7 Transformation and plasmid amplification  
The XL-10 E.Coli competent cells, initially stored at -70°C were thawed on 
ice and 50 µl cell suspensions were mixed with 1 µl ligation mixture or 50 ng of 
plasmid DNA. After 20 minutes incubation on ice, the cells were induced to take 
up the DNA by heat-shock at 42°C for 45 seconds, followed by immediate 
cooling on ice for 2 minutes and allowed to recover in 1 ml of warm SOC (Super 
Optimal broth with Catabolite repression) medium or 1 ml of LB medium for 45-
60 minutes at 37°C in shaking incubator (220 rpm). The bacterial cells were 
then briefly centrifuged (3000 rpm for 5 minutes) and the pellet resuspended in 
100µl of LB medium. Bacterial suspension was spread onto pre-warmed LB agar 
plates containing the appropriate selective antibiotic and incubated overnight at 
37°C. 
2.2.1.7.1 Plasmid DNA Purification 
Plasmid DNA was purified using QIAGEN mini- or midi- Plasmid Purification kit 
(QIAGEN) according to the manufacturer‘s instructions. The QIAGEN plasmid 
purification protocol is based on alkaline lysis of the bacterial cells, followed by 
binding of plasmid DNA to anion-exchange resin under appropriate low salt and pH 
conditions. Bacterial pellet from overnight shaker-culture of XL-10 E. coli was re-
suspended in the provided P1 buffer. The suspension was subsequently lysed by P2 
buffer and neutralised with buffers N3 respectively. Cellular debris was removed by 
centrifugation and the supernatant containing the circular plasmid DNA was 
collected. The supernatant was applied to a QIAGEN spin column. Further 
centrifugation through the column results in the plasmid DNA binding to the column. 
The plasmid DNA was then washed by centrifugation with PB and PE buffers and 
eluted using TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) or ddH2O. 
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The plasmid DNA can be desalted and concentrated by isopropanol precipitation. To 
precipitate the DNA, an equal volume of 100% isopropanol was added to the DNA 
solution and immediately centrifuged at 13000 rpm for 30 minutes. The DNA pellet 
was washed with 70% ethanol, air-dried for 5-10 min and dissolved in an 
appropriate volume of ddH2O or TE buffer. The quality and purity of plasmid DNA 
was checked by DNA agarose gel alongside a comparative DNA ladder (1 kb 
GeneRuler, Fermentas). The plasmid DNA concentration was determined by nano-
drop analysis. 
2.2.2 Mammalian cell culture 
2.2.2.1 Maintenance of cell lines  
HEK 293 cells were maintained in a high glucose Dulbecco’s Modified Eagle’s 
medium (DMEM, from PAA). Media were supplemented with 10% v/v foetal bovine 
serum (FBS, from Hyclone) and 1% penicillin/streptomycin v/v antibiotics. Cells 
were grown in 37̊C humidified incubators at 10% CO2. At about 60-80% confluency, 
cells were passaged. The media was aspirated and the cells were washed once with 
Dulbecco’s phosphate buffered saline (PBS from PAA). The 1X trypsin-EDTA 
(supplied by PAA) was then added to detach cells from the plates. The cells were 
then incubated at 37̊C for 1-2 minutes in order to fully detach the cells. The cellular 
suspension was pipetted up and down continuously to break up any clumps of cells. 
A fresh media was then added to neutralise the trypsin. The volume of cellular 
suspension required to achieve a desired confluency was then added with a fresh 
medium into new plates. All culturing procedures were carried out in a sterile 
laminar flow hood. All media and reagents used had been previously pre-warmed to 
37̊C. 
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2.2.2.2 Cell counting  
To count cells, DMEM was removed from plated cells, which were then washed 
with 1X PBS and trypsin as described for maintenance of cell lines (2.2.2.1). Un-
detached cells were mixed with DMEM and spun at 1000 RPM for 5 minutes. The 
cell pellet was re-suspended in fresh PBS, a 2 µL aliquot of which was added to a 
vial containing 10 ml CASYTON Buffer solution (Innovatis). The cells were 
thoroughly mixed with the buffer and then analysed using the CASY Model TT 
cell counter (Innovatis), which relies on electronic pulse area analysis for 
measurements. The CASY machine enables the measurement of total and viable 
cell numbers, cell size, percentage viability and cell aggregation factors. 
2.2.2.3 Serum and nutrient starvation and stimulation 
HEK 293 cells were serum starved at about 70% confluency using Dulbecco's 
modified Eagle's medium (DMEM) High Glucose containing L-glutamine and 
penicillin/streptomycin for 36 hours. The complete DMEM medium was aspirated 
and was replaced with serum-free DMEM medium. The cells were then incubated 
at 37°C overnight in this medium. Serum stimulation is carried out by the addition 
of 10% fetal bovine serum for 1 hour followed by harvesting the cells. For 
nutrient starvation, next morning, the serum-free media was removed and the PBS 
was added into the plates. The cells were then incubated at 37°C for 1 hour to 
achieve nutrient starvation. At this point, the cells were used for analysis.   
2.2.2.4 DNA transfection 
When a 10cm plate had reached 80% confluency it was split (1/3) into three new 
10cm plates with 8mL of fresh DMEM complete medium. 24hrs later, the media 
was aspirated and 10mL of new DMEM complete medium was added to each 
plate. 10μg of plasmid DNA was then mixed with 200μL of sterile 150mM NaCl. 
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The DNA and NaCl were mixed very well by pipette action. 35μL of Exgen500 
transfection reagent supplied by Fermentas was then added and the solution was 
immediately mixed by pipette action for 10 seconds. The tubes were then 
incubated at room temperature for 10 minutes before being added drop wise to the 
previously prepared plates of HEK 293 cells with refreshed medium. The 
transfected cells were then placed in an incubator at 37̊C for 48 hours before being 
used for experiments or frozen at -80̊C.  
2.2.2.5 Generation of stable cell lines 
Mammalian expression victors encoding FLAG-mTOR for different isoform have 
been generated. These constructs contain the neomycin resistance gene which 
allows selection of transfected cells with Geneticin (G-418). Before Geneticin 
treatment HEK 293 cell were tested for the Geneticin resistance and the optimum 
concentration for selection were obtained. HEK 293 cells were transfected with 
each vector, and transient transfected cells showed good level of expression of 
these mTOR isoforms. 48 hours after transfection, cells were split 1/20 into 
complete medium containing 1200 µg/ml of G-418. Selective medium was changed 
every 2-3 days and cell survival was monitored over the period of two weeks to 
identify colonies that had integrated a gene construct. Selected colonies were 
mixed and screened for protein expression. Those cell clones that tested positive 
for expression were frozen in DMEM medium containing 50% FBS and 10% 
dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. 
To maintain HEK 293 stable cell lines, the vial of cells was removed from the 
liquid nitrogen and thawed quickly at 37°C. Immediately before the cells were 
completely thawed, the outside of the vial was decontaminated with 70% ethanol, 
and the contents transferred to a 10 cm plate containing 10 ml of complete medium 
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without antibiotic [DMEM (high glucose), 10% FBS, 2 mM L-glutamine]. The 
plate was incubated at 37°C for 2-4 hours to allow the cells to attach to the 
bottom of the plate. The cells were maintained in a complete medium [DMEM 
(high glucose), 10% FBS and 1% Penicillin-Streptomycin] containing the 
selective antibiotic G-418 at a final concentration of 200 ug/ml. 
2.2.2.6 Cryopreservation  
Healthy cells of a low passage number (passage 2-5) were grown to about 80% 
confluency in DMEM, supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37˚C, 10% CO2. After media was removed, the cells 
were washed with PBS and treated with Trypsin-EDTA as described for the 
maintenance of cell lines (2.2.2.1). Cells were resuspended in fresh DMEM and 
spun for 5 minutes at 1000 RPM. The medium was removed and cells were re-
suspended in 90% FBS, 10% Dimethyl Sulphoxide (DMSO). The cell suspension 
was placed in freezing vials and stored at -80˚C overnight in a box containing 
isopropanol, which allows the vials containing the cells to slowly come to 
temperature, preventing cell death. Cells were then placed in liquid nitrogen 
storage tanks for future use. 
2.2.2.7 Cell line defrosting  
To maintain cell lines, the vial containing cells was thawed quickly in a 37˚C 
water bath. The outside of the vial was decontaminated with 70% ethanol just 
before cells were completely thawed, and the contents were transferred to DMEM 
supplemented with 10% v/v FBS and 1% penicillin/streptomycin v/v antibiotics. 
The cells were spun at 1000 RPM for 5 minutes and the pellet of cells were re-
suspended in fresh media and transferred to a new plate, which also contained 
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fresh media. The cells were incubated in a humidified, 37˚C, 10% CO2 incubator 
and checked daily until they reached 70-90% confluence. 
2.2.3 Protein isolation methods 
2.2.3.1 Mammalian cell lysis for protein analysis 
Cells were washed twice with ice-cold PBS and extracted with lysis buffer (0.3% 
v/v CHAPS , 50 mM Tris-HCl pH 6.8, 100 mM NaCl, 2 mM EDTA, 50 mM NaF, 
25 mM 2-glycerophosphate, EDTA-free protease inhibitor cocktail (Roche), final 
pH 7.5). Cells were scraped from the dishes and transferred to micro-centrifuge 
tubes. Tubes were incubated on ice for 30 minutes prior to centrifugation at 14000 
rpm at 4ºC for 30 minutes to remove insoluble material. Supernatants were 
transferred into fresh tubes and the total protein concentrations of cellular extracts 
were determined by Bradford protein assay. 
2.2.3.2 Measuring protein concentration  
The total protein concentration in cell lysates was determined using the 
Coomassie (Bradford) protein reagent (Pierce). The reagent was diluted 1:1 with 
ddH2O to give the working solution. Samples were made up by adding 1 μl of 
each lysate sample to 1 ml of reagent solution and standards were prepared by 
diluting appropriate amounts of 2 mg/ml Bovine Serum Albumin (BSA) to give a 
range from 0.5-8 μg/ml. All absorbance measurements were taken on an 
Eppendorf BioPhotometer at 595 nm using plastic 1ml cuvettes. 
2.2.3.3 Immunoprecipitation 
Immunoprecipitation of particular proteins was achieved by using antibodies that 
were specific for the protein of interest. Antibody was added to Protein A 
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sepharose beads followed by the total cell lysate in a microcentrifuge tube. The 
sample tubes were then placed on a rotating wheel for 2hrs at 4°C. Following 
incubation on the wheel, the tubes were washed 3x prior to loading on a SDS-
PAGE gel.    
2.2.3.4 Affinity Purification  
GST-FKBP12 was purified from bacteria using recombinant GST fusion protein, 
which was over-expressed in E.Coli Rosetta cells. The bacteria containing the 
vector was induced by IPTG, lysed, sonicated, centrifuged, and GST-FKBP12 
protein was purified using Glutathione-Sepharose, and dialysed by desalting 
column.  
The GST fusion proteins were then batch-purified from the supernatant by binding 
to Glutathione–Sepharose beads (Amersham Pharmacia Biotech) for 3 hours at 
4°C. Beads were washed in ice cold lysis buffer (2 times). GST fusion proteins 
were eluted by competition with 20mM glutathione in 100 mM Tris-HCl pH 8.0, 
150 mM NaCl (elution buffer). Elution was repeated three times,  eluted fractions 
were subjected to dialysis against dialysis buffer 1 (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 1mM DTT) overnight 4°C, and then against dialysis buffer 2 (buffer 1 
containing 50 % glycerol) for three hours at 4°C to remove free glutathione and to 
concentrate the protein. Dialysis into 50 % glycerol allows long term storage at -
20°C while avoiding damage to the protein caused by repetitive freeze-thaw 
cycles. The quality of the purified proteins was analysed by SDS-PAGE 
Affinity matrix was prepared by coupling GST-FKBP12 in complex with 
Rapamycin to Glutathione Sepharose, and tested using lysates of cells over-
expressing mTORα, (280kDa), and mTORβ, (80kDa). GST-FKBP12 purification 
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was repeated 4 different times to test different reaction conditions, which could 
affect the affinity of mTOR to bind to the affinity matrix. These conditions and 
factors include Rapamycin, GST-FKBP12, buffers, and beads. 
2.2.3.5 SDS-PAGE 
Cellular proteins were separated based on their molecular weight (MW). This was 
done using either the discontinuous SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) system as described by Laemmli (Laemmli, 1970), or the mini-
PROTEAN® TGXTM (Tris-Glycine eXtended) precast gels (BIO-RAD 
laboratories, Inc.).  
When proteins are mixed and boiled with Laemmli sample buffer, the SDS 
detergent present in the buffer binds to the proteins. This results in the 
linearization of the protein as well as the formation of a uniform negative charge 
across the length of the protein. Consequently, the proteins samples separation 
based solely upon their size. During electrophoresis, movement of the larger 
proteins is physically retarded by the matrix, whilst smaller proteins meet with 
less opposition and move further more quickly. 
The home made system gels were run using the Hoefer SE400 electrophoresis 
system (Hoefer instruments, San Francisco, Ca.). The gel plates were 
thoroughly cleaned with water and 70% ethanol prior to use and assembled using 
0.75 mm spacers as instructed by the manufacturer. 
Gels were made fresh on the day of the experiment and consisted of 7.5 to 15 % 
acrylamide resolving gel and 10 % ammonium persulphate (APS) and 
Tetramethylethylenediamine (TEMED) which catalyse the polymerisation of the 
gels. 
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The Mini-PROTEAN TGX precast gels system retains Laemmli-like separation 
characteristics, however have an increased gel matrix stability. Gels with gradient 
concentrations of 4-20% polyacrylamide concentration were typically used and 
were run using the Mini-PROTEAN Tetra Cell electrophoresis system (BioRad). 
2.2.3.5.1 Protein sample preparation 
Samples were prepared for SDS-PAGE analysis by adding the appropriate 
amount of 5X Laemmli sample buffer to a final concentration of 1X (250mM 
Tris pH 6.7, 50% glycerol, 0.5% bromophenol blue, 500mM DTT, 10% SDS). 
Proteins immobilized on sepharose beads (from immunoprecipitations) were 
denatured by addition of Laemmli buffer. All samples were boiled for 5 
minutes then briefly centrifuged prior to loading onto the polyacrylamide gel. 
2.2.3.5.2 Preparation of SDS-PAGE 
The resolving gel mixture (Table 2-1) was poured into the space between the 
glass plates by pipette. The mixture was then overlaid with 1ml of ddH2O to 
avoid a curved meniscus forming on the top of the gel which leads to distortion 
of protein bands. The polymerization of the resolving gel typically takes 
around 30 minutes and can be visualized by a clear rounding of the gel corners 
at the edges beneath the water layer. Once polymerization was complete, the 
water was removed and any un-polymerized acrylamide was washed from the 
top of the cassette with water. The stacking gel was then cast with a comb to 
form the desired number of wells. Following polymerisation of the stacking 
gel, the comb was removed and wells were washed with tris-glycine running 
buffer (0.25mM Tris, 250mM glycine, 0.1% SDS) to remove any 
unpolymerised acrylamide. Wells were refilled with running buffer and samples 
were loaded using a Hamilton syringe (Hamilton, Reno, Nevada) or disposable 
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tips. After loading the samples the upper and lower buffer chamber were filled 
with running buffer. In case of homemade system, Gels were run at 25mA until 
samples pass the stacking gel then the current is raised to 40mA until the dye 
front reached the end of the gel. Pre-cast gel where run according to the 
manufacturer’s recommendations. 
  20 ml (one gel) Mini gels, 5 ml 
(one gel) 
Stacking Gel 
 
Concentration  7.5% 10% 15% 10% 15% 3ml 5ml 
ddH2O 9.63 7.9 4.6 1.9 1.1 2.1 3.4 
30% Acrylamide mix 4.97 6.7 10.0 1.7 2.5 0.5 0.83 
1.5M Tris HCl pH 8.8 5.0 5.0 5.0 1.3 1.3 0.38 0.63 
10 SDS 
 
0.2 0.2 0.2 0.05 0.05 0.03 0.05 
10 % APS 0.2 0.2 0.2 0.05 0.05 0.03 0.05 
TEMED 0.012 0.008 0.008 0.002 0.002 0.003 0.005 
Table 2-1: preparation of poly acrylamide gel 
2.2.3.6  Protein Visualisation  
Following electrophoresis proteins were visualised by staining or western blotting. 
Gels were stained by Coomassie or silver staining systems.  
2.2.3.6.1 Coomassie Staining 
For Coomassie staining gels were immersed in Coomassie Blue. Two Coomassie 
stain systems have been used. The InstantBlue is a ready-to-use Coomassie stain 
that is specially formulated for fast (15 – 60 minutes) and sensitive detection of 
proteins. Protein gels can be stained in minutes without the need to wash, fix or 
de-stain. 
The second system was the home made Coomassie Blue stain [0.5% (w/v) 
Coomassie brilliant blue R-250, 50% (v/v) methanol and 10% (v/v) acetic acid]. 
Gels staind by immersion in Coomassie Blue stain with gentle agitation for 20 
minutes, followed by de-staining in 20% (v/v) methanol, 10% (v/v) acetic acid 
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for several hours. The gel was then dried under vacuum at 80ºC for 1 hour. 
Coomassie brilliant blue binds to proteins stoichiometrically. The relative amounts of 
protein can be measured by densitometry. 
2.2.3.6.2 Silver Staining  
When more sensitive staining was required, gels were silver stained using a silver 
staining kit from Fermentas (PageSilver). The gel was first fixed in a fixative 
solution (50% ethanol, 10% acetic acid) for 10 minutes. The fixed gel was washed 
two times in 30% ethanol for 10 minutes, followed by two washing cycles with 
ddH2O for 20 seconds. The gel was agitated with sensitizing solution (0.4% 
sensitizer concentrate) for 1 minute, and after the sensitizing solution was 
removed, it was washed twice with ddH2O for 20 seconds. The gel was stained 
with staining solution (4% stainer, 0.054% formaldehyde) for 20 minutes. After 
two wash cycles with ddH2O, developing solution (10% sensitizer concentrate, 
10% developing reagent, 0.027% formaldehyde) was added. The gel was left to 
develop for 4 minutes, or until the required intensity of bands was reached. 
Staining was stopped by the addition of stopping solution (8% stop reagent), with 
gentle agitation for 5 minutes. After the stopping solution was discarded, the gel 
was stored in ddH2O. 
2.2.3.6.3 Western Blotting 
2.2.3.6.3.1 Proteins transfer to membrane  
After SDS-PAGE, the proteins were transferred from gels using the wet and semi-
wet protein transfer methods. The Trans-BlotTM (Biorad) and The Trans-Blot 
Turbo transfer systems were utilised to perform the semi-dry transfer. Once the 
gel cassettes were opened, superfluous parts of the gel were cut off and the gel 
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was placed on a sheet of PVDF membrane. The membrane and gel were 
sandwiched between four sheets of pre-soaked 3MM filter paper and air bubbles 
were removed. Transfer was then conducted at constant currents.  
2.2.3.6.3.2 Immunoblotting 
Following transfer, membranes were washed with TBST (10mM Tris-HCl pH7.5, 
150mM NaCl, 0.1% Tween 20) before they were blocked for 1 hour in TBST 
containing 5% (w/v) non-fat dried milk powder or 2% BSA. Blocking seeks to 
minimise non-specific binding of the antibodies to the membrane. Primary 
antibodies were diluted according to the manufacturer’s guidelines in TBST 
containing 2% BSA and 0.02% sodium azide. The membranes were then 
incubated with the primary antibody solutions overnight at 4°C. The following 
morning, the membranes were washed 3 times for 10 minutes per wash in fresh 
TBST buffer. The membranes were then incubated for 1 hour at room temperature 
with the relevant HRP-linked secondary antibody, which was diluted in TBST 
with 5% milk powder. TBST was then used to wash the membranes 3 times, 10 
minutes per wash prior to development by enhanced chemiluminescence (ECL).  
2.2.3.6.3.3 Developing Immunoblots 
An equal volumes of ECL solution 1 (coumaric acid, luminol, 50mM Tris-HCl) 
and ECL solution 2 (0.02% H2O2, 50mM Tris-HCl) were mixed and incubated 
with the membrane for 1 and a half minutes at room temperature. The membrane 
was then encased in Saran wrap and excess ECL solution was removed by 
blotting. The bands were then detected either by exposing the membrane to an X-
ray film in a dark room for different durations, or using the Fujifilm LAS-1000 
imaging system. Densitometry analysis was performed using either the Quantity 
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OneTM image processing software (BioRad) or Image J, a public domain Java 
image processing program. 
2.2.3.6.3.4 Stripping and re-probing  
In some cases, membranes were required for re-probing with a different antibody. 
Antibodies were first stripped from the membrane by incubating in stripping 
buffer. Two stripping buffer were used, the commercially available Restore 
Western Blot Stripping Buffer (Thermo Scientific) and a freshly prepared 
Stripping buffer (62.5mM Tris-HCl, pH 6.7; 2% SDS; 100mM 2-
mercaptoethanol). The membrane was incubated for 5 to 15 minutes at room 
temperature, and 50°C for 30 minutes respectively. Extensive washes in TBST 
buffer were required before blocking and then re-blotting with another primary 
antibody. 
2.2.3.7 Bacteria Cell Lysis and Purification GST-fusion Proteins 
BL21 (DE3) cells were pelleted by centrifugation at 5000 rpm for 20 minutes at 4°C, 
washed with ice cold PBS and lysed in 10 volumes of lysis buffer (20mM Tris-
HCl pH 7.5, 150mM NaCl, 50mM NaF, 5mM EDTA pH 8.0, 1% Triton, and 1X 
protease inhibitor cocktail from Roche) and left on ice for 30 minutes. Lysates were 
subjected to mild sonication by three 45-s pulses (25% duty; 80s on/off) on ice 
and cleared by centrifugation at 18000 rpm for 30 minutes at 4°C. Small aliquots 
were collected prior to and following centrifugation and boiled with Laemmli 
sample buffer to assess the solubility of the recombinant protein by SDS PAGE 
and coomassie staining. The GST fusion proteins were then purified from the 
supernatant by binding to Glutathione–Sepharose 4B beads (Amersham 
Pharmacia Biotech) for 2 hours at 4°C. Beads are washed in ice cold lysis buffer 
(4 times) and finally with 50mM Tris pH 7.5 (2 times) at 4°C. 
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GST fusion proteins were either retained on beads in the storage buffer (20mM 
Tris pH 7.5, 150mM NaCl, protease inhibitor cocktail (Roche), and 50% 
glycerol) or eluted by competition with elution buffer (20mM glutathione in 100 
mM Tris-HCl pH 8.0, 150 mM NaCl). Elution was repeated three times, 5 minutes 
each, at 4°C on a rotating wheel and the eluted fractions were subjected to dialysis 
against dialysis buffer 1 (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1mM DTT) 
overnight 4°C, and then against dialysis buffer 2 (buffer 1 containing 50 % 
glycerol) for three hours at 4°C to remove free glutathione and to concentrate the 
protein. Dialysis into 50 % glycerol allows long term storage at -20°C while 
avoiding damage to the protein caused by repetitive freeze-thaw cycles. The quality 
of the purified proteins was analysed by SDS-PAGE and coomassie staining. 
2.2.4 Bioinformatics methods 
The mTOR gene (156973 nucleotides) and the cDNA (7554 nucleotides) were 
analysed for exon-intron structure, for alternative starting codons and potential 
alternative splicing isoforms. The protein domains where analysed using Pfam. The 
initial alignment produced by the basic local alignment searching tool (BLAST). The 
BLAST alignment was then manually amended to test for the presence of any cDNA 
for potential mTOR isoforms. The EST alignment was extended to include different 
exon deletion or potential start or end codons along the C-terminal and N-terminal 
regions of mTOR.  
Extensive bioinformatics analysis allowed me to identify several potential alternative 
starting codons and potentially novel spicing isoforms. One was revealed by 
searching the protein databases. This clone (EAW71681.1) was reported by Celera 
Genomics WGS human genome sequencing project which was generated by the 
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whole-genome shotgun sequencing method. Another extensive bioinformatics search 
of EST and RNA analysis resulted in the identification of two cDNA clones coding 
two potential mTOR splicing isoforms (AK302863.1).  
2.2.5 Functional analysis  
Investigation of the identified mTOR isoforms in vivo and in vitro  
2.2.5.1 In Vitro Kinase Assay 
in vitro kinase assay was performed to assess the mTOR kinase activity. HEK 293 
cells were transfected with pcDNA3–Flag–mTORα, pcDNA3–Flag–mTORδ, 
pcDNA3–Flag–mTORγ or pcDNA3–Flag–mTOR S2215Y. Cells were lysed using 
lysis buffer (0.3% v/v CHAPS, 10 mM Tris-Base pH7.5, 150 mM NaCl, 5 mM 
EDTA, 50 mM NaF, 10 mM Na4P2O7, 1 mM NaVO3, EDTA-free protease inhibitor 
cocktail (Roche)). Protein from transiently transfected cells or stable cell line was 
immuno–precipitated with protein–G beads coated with anti–Flag antibody. IP was 
washed twice with Lysis Buffer, once with Wash Buffer (lysis buffer, 300 mM KCl) 
and once with Kinase Buffer (25 mM HEPES-KOH (pH7.4), 50 mM KCl, 10 mM 
MgCl2, 4 mM MnCl2, 5% v/v Glycerol). 
The kinase assays with 4EBP1 was performed in kinase buffer containing about 1 µg 
of a 4EBP1 (Calbiochem), 25 mM HEPES-KOH (pH 7.4), 50 mM KCl, 5% glycerol, 
10 mM MgCl2, 4 mM MnCl2, and 100 mM ATP. Kinase reactions were resolved by 
SDS-PAGE and analyzed by Western blot analysis. The reaction was carried out at 
37oC for 60 min and terminated by addition of SDS-PAGE sample buffer and boiling 
for 10 min. Proteins were resolved by SDS-PAGE either on 10% gels or on 4-12% 
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precast gradient NuPAGE gels (Invitrogen). The levels of immune–precipitated 
Flag–mTOR isoforms were measured by Western blotting with anti – Flag antibody. 
2.2.5.2 MTT proliferation assay 
The MTT assay is a colorimetric assay for measuring the activity of live cells. In 
viable cells, cellular enzymes reduce the tetrazolium dye, MTT, to produce a strongly 
pigmented formazan product (Promega). The amount of formazan is directly 
proportional to cell number. The absorbance of the pigmented product was measured 
using a micro–plate absorbance plate reader (Tecan). 
HEK 293 cells expressing mTORα, mTORδ, mTORγ or mTOR S2215Y were seeded 
into 96-well plate (5000 cells/well) and grown under standard conditions. After two 
days, medium was changed with serum free DMEM and time-lapse analyzed for 7 
days. MTT dye (Sigma) was added to wells and incubated for 3 hours, and optical 
density determined at 490 nm (as per manufacturers recommendation).  
2.2.5.3 Colony Forming Assay 
A clonogenic assay is a technique to study the effectiveness of specific agents on the 
survival and proliferation of cells. Any anchorage–independent growth of tumour 
cells is estimated by a soft–agar colony formation assay. To monitor the capacity of 
mTOR stable cell lines to grow in semisolid medium in vitro. Soft agar assays were 
performed in 6cm tissue culture plates in triplicate. For each dish, 3 ml of 0.8% 
agarose containing 1X DMEM and 10 % FBS was used as the bottom layer. This 
Mixture was maintained at 60 degree Celsius until immediately prior to pouring. 
After the bottom layer was poured it was allowed to solidify at room temperature. 
Following stabilization of the bottom agarose layer, the desired number of cells 
(2000 or 4000) of the cell lines included in the research model were diluted into 3 
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millilitre of 0.4% agarose containing 1X DMEM and 10%FBS. This model contains 
parental HEK 293 and HEK 293 over–expressing mTORδ, mTOR, mTOR and 
mTOR S2215Y. This mixture was then poured on top of the solid bottom 0.8% 
agarose layer. Cultures were maintained for 2 weeks at 37 degrees Celsius in a tissue 
culture incubator in 5% CO2 humidified atmosphere. Every three days cells were 
feed by the additions of 0.5 millilitre culture medium. This will also prevent agarose 
gel dehydration. All soft agar cultures were examined on one day for the number of 
colonies to eliminate possibility for interfering factors. Colonies were stained 3 
weeks later with 0.005% crystal violet-2% ethanol in PBS and counted manually. 
2.2.6  Statistical analysis  
The data were analyzed using SPSS (SPSS Inc., Chicago, USA) software, version 
18.0 for Windows. For the colony formation assay, the number of colonies was 
expressed as mean ± S.E.M and the statistical test used was one–way ANOVA, 
followed by Bonferroni post-hoc test. Whereas for MTT data points were presented 
as mean ± S.E.M and the statistical test used was two-way repeated measures 
ANOVA, followed by Bonferroni post-hoc test. The statistical significance was fixed 
at P <0.05. 
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Chapter 3: Chapter Three: Identification of novel mTOR 
isoforms 
 
3.1 Evidence of the existence of a novel mTOR isoforms 
Like other PIKK family members, there is increasing evidence for the presence of 
mTOR splicing isoforms. Data from our laboratory suggest the existence of several 
potential splicing isoforms of mTOR. Panasyuk et al. 2009, provided evidence for 
the existence of the mTOR splicing isoform, mTORβ, which lacks most of the 
HEAT and FAT domains. In addition, Northern blotting of human tissues indicated 
the presence of several potential mTOR splicing forms (Figure 3.1). Moreover, 
Western blot analysis of gel filtration fractions from MCF7 cells with anti-mTOR 
COOH–term antibody revealed the presence of several potential mTOR splicing 
forms (Figure 3.2). 
There are numerous commercially available mTOR specific antibodies, which 
recognise different regions in mTOR. When the manufacturers tested these 
antibodies using the Western blot analysis, they recognised the full–length mTOR 
(280 kDa) and a number of immuno–reactive bands with lower molecular weights in 
total cell lysates from different cell lines and tissues. These bands may represent the 
product of mTOR degradation, non-specific binding or potential splicing isoforms of 
mTOR (Figure 3.3). The initial aim of this study was to identify novel mTOR 
isoforms. This was attempted using protein, molecular and bioinformatics analysis.  
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Figure 3.1: Northern blotting of human tissues indicates the presence of several 
potential mTOR splicing forms (Performed by Dr. Alexander Zhyvoloup) 
 
Figure 3.2: Western blot of Gel filtration analysis of mTOR splicing forms in MCF7 
cells indicates the presence of several potential mTOR splicing forms (Performed by 
Dr. Alexander Zhyvoloup) 
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Figure 3.3: Western blotting examples of commercially available antibodies targeting 
mTOR (280 kDa). 
There are immuno–reactive bands with lower molecular weight in total cell lysates 
from different cell lines and tissues. These bands may represent the product of 
mTOR degradation, non-specific binding or potential splicing isoforms of mTOR  
(these results were performed by manufacturers and posted in their websites as a real 
results for their antibodies targeting mTOR). 
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3.2 Different approaches to identify novel isoforms 
Different approaches to identify novel isoforms of mTOR were used, including 
protein, molecular and bioinformatics analysis.  
3.2.1 Protein analysis 
Purification of the protein of interest followed by mass-spectrometry analysis is the 
most reliable approach to identify a novel binding/regulatory partner or isoform. 
Therefore, in this study, the identification process was initiated using the protein 
analysis approach. mTOR protein binds with high specificity to the FKBP12-
Rapamycin complex, thus mTOR has been identified as a target of Rapamycin. This 
complex was used in this study to purify mTOR from different cell lines and tissues. 
An affinity matrix was generated which consisted of GST-FKBP12-Rapamycin on 
Glutathione Sepharose beads. The GST-FKBP12 coupled to glutathione sepharose 
without rapamycin was used as a negative control. It is known that the GST-FKBP12 
alone does not bind mTOR, but interacts specifically with FKBP12-Rapamycin 
complex. The work for the protein approach was carried out using the following 
steps: 
Stage 1, Purification of GST-FKBP12 from bacteria and testing the quality of 
the purified protein. 
Stage 2, Preparation of the affinity matrix, by coupling GST-FKBP12 in 
complex with Rapamycin to Glutathione Sepharose Beads. 
Stage 3, Testing of the affinity matrix using lysates of cells over-expressing 
Flag-mTORα and Flag-mTORβ. Flag-mTORα and Flag-mTORβ were 
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expected to bind specifically to GST-FKBP12-Rapamycin, but not to GST-
FKBP12-without Rapamycin. 
Stage 4, Analysis of the pattern of mTOR splicing forms from cell lines or rat 
tissues (liver and heart), which specifically associate with GST-FKBP12- 
Rapamycin, but not to GST-FKBP12 without Rapamycin. Followed by 
analyse of the binding partners by silver or Coomassie stain. 
Stage 5, Examination of specifically associated proteins with mass-
spectrometry analysis. 
3.2.1.1 Results of the protein purification approach 
3.2.1.1.1 GST-FKBP12 Purification 
GST-FKBP12 protein was used in the preparation of the affinity matrixes. These 
affinity matrixes were used for the isolation of mTOR splicing isoform from cell 
extracts of different tissues and cell lines. The recombinant GST-FKBP12 protein 
was expressed in bacteria and purified using the Glutathione-S Transferase (GST) 
gene fusion system. Aliquots were taken from each purification step for gel 
electrophoresis and Coomassie staining, including, before and after sonication, 
soluble fractions, washes and elutes after affinity purification on Glutathione-
Sepharose 4B (Amersham Pharmacia Biotech). The GST-FKBP12 fusion protein 
was highly expressed and acceptable yields of the fusion proteins was obtained in a 
soluble form (Figure 3.4).  
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Figure 3.4: Coomassie stain of affinity purification of GST-FKBP12. 
Coomassie stain of affinity purified GST-FKBP12, expressed in E.coli. Recombinant 
GST fusion proteins were over-expressed in Rosetta cells with IPTG induction, 
lysed, sonicated, centrifuged, and purified by Glutathione-Sepharose beads, and 
dialyse by desalting column 
 
3.2.1.1.2 Preparation of the affinity Matrix 
The purified recombinant GST-FKBP12 protein was used to prepare the affinity 
matrix by coupling GST-FKBP12/rapamycin complex with Glutathione Sepharose 
Beads (Figure 3.5). 
The affinity matrix was tested for its ability to bind specifically to mTOR using 
lysates of cells over-expressing Flag-mTORα and Flag-mTORβ. The Flag-mTORα/β 
binds specifically to GST-FKBP12- Rapamycin, but not to GST-FKBP12-without 
Rapamycin (negative control). The Western blot analysis using antibody targeting 
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mTOR (anti FRAP C-terminal generated by Millipore) from cell lysates, indicating 
that the affinity matrix binds specifically to mTOR (Figure 3.6). The mTOR band 
intensity was not enough to indicate a good amount of mTOR, indicating that 
optimisation was needed. 
 
 
3.2.1.1.3 The affinity matrix sensitivity (optimisation) 
To improve the efficiency of the affinity matrix and to minimise the interfering 
factor and to achieve the maximum affinity of the matrix for mTOR binding, 
different conditions were analysed. These factors included rapamycin 
concentration, buffering conditions, beads from different sources, different 
GST-FKBP12 concentrations and purification methods and different 
approaches of coupling GST-FKBP12 to Glutathione beads.    
Figure 3.5: Schematic diagram of the affinity matrix for mTOR 
protein to identify a new mTOR splicing isoform. 
The affinity matrix consists of Glutathione beads in complex with 
GST-FKBP12 and rapamycin. The FRB domain of mTOR binds 
specifically to FKBP12-rapamycin complex. 
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3.2.1.1.3.1  The effect of rapamycin concentration  
Different concentrations of rapamycin resulted in a range of immune–reactivity 
bands with various intensity. Western blot analysis indicated that mTOR binds 
to the affinity matrix with rapamycin concentrations of 0.1 μM and 1 μM better 
than 10 μM (Figure 3.6). 
The presence of an additional hazy band of about 60 kDa with 1 μM rapamycin 
from cells over-expressing mTOR β suggested that this is a potential splicing 
isoform of mTOR, which was able to bind to the affinity matrix in these 
conditions. 
 
Figure 3.6: Affinity purification of mTORα and mTORβ from HEK 293 cells over-
expressing mTORα and mTORβ.  
Cells were lysed, centrifuged and purified using GST-FKBP12-Rapamycin affinity complex. 
The affinity matrix can bind specifically to mTOR from total cell lysate. The reaction 
showed better sensitivity with Rapamycin concentration of 0.1 μM. 
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3.2.1.1.3.2 The effect of buffer 
The environment surrounding the affinity matrix might affect the efficiency of 
the affinity purification. To test whether the buffer would affect the binding of 
the GST–FKBP12 to beads, a PBS buffer, pH 7.4 (no additives) was tested 
against the lysis buffer. There was no significant difference between the lysis 
buffer used and PBS buffer on binding GST-FKBP12 to Glutathione Sepharose 
beads (Figure 3.7).  
 
Figure 3.7: Western blotting to study the effect of buffer on GST-FKBP12 
binding efficiency to Glutathione Sepharose beads.  
There was no significant difference between the lysis buffer used in the study 
and PBS buffer on the binding of GST-FKBP12 to Glutathione Sepharose 
beads. 
 
3.2.1.1.3.3 The effect of beads on protein binding 
The quality and purity of Glutathione Sepharose beads, used to prepare the 
affinity matrix, might affect the efficiency of affinity purification. To elucidate 
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whether beads from different source would improve the binding efficiency, 
beads from different manufactures and different company, were tested. There 
was no significant difference between the amounts of GST-FKBP12 coupled to 
the new (Amersham Pharmacia Biotech) beads and those used previously 
(Thermo scientific) (Figure 3.8). 
When the amount of beads was doubled, a higher amount of mTOR was 
purified. However, when the same amount of beads was used and the protein 
concentration was doubled there was no significant improvement on the 
amount of mTOR purified (Figure 3.9). These results demonstrated that the 
amount of beads is limiting the quantity of the protein purified and not the 
protein concentration or the source of beads.   
 
Figure 3.8: Western blotting to study the effect of Beads on FKBP12 binding 
efficiency.  
GST–FKBP12 was incubated with beads from different manufacturers and there is 
no significant different between the amounts of GST–FKBP12 coupled to beads 
from different company. 
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Figure 3.9: Western blotting to study the effect of 
bead volume and protein concentration on the 
amount of mTOR purified using the affinity matrix.  
There was no effect on the amount of mTOR 
purified when the protein concentration doubled. In 
contrast, a higher amount of mTOR was purified 
with more beads. 
 
3.2.1.1.3.4 The effect of GST-FKBP12 
3.2.1.1.3.5 Different purification isolates of the protein 
GST-FKBP12 is part of the affinity matrix and its purity would be expected to 
affect the binding affinity to mTOR. During the expression and purification, 
the GST-FKBP12 was eluted from the beads using 30 mM glutathione. The 
eluted protein was dialysed two times against PBS and once against 50% 
glycerol in PBS to remove the excess glutathione. To prepare the affinity 
matrix, the GST-FKBP12 was re-coupled again to new beads. This process of 
elution and re-coupling might affect the efficiency of the affinity purification.  
WB:  
anti-mTOR 
uM 
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In addition, the presence of glutathione would possibly affect the binding of 
GST-FKBP12 to the beads.  
Elution of the GST-FKBP12 from the purification beads and re-coupling to the 
affinity matrix could affect the sensitivity of the affinity matrix. To overcome 
this problem, GST-FKBP12 was again purified but the protein was left on the 
beads (no elution step was performed).  Therefore, four independent expression 
and purifications conditions of the GST-FKBP12 were assessed to eliminate all 
factors expected to affect the affinity matrix. 
The resulting mTOR indicated that the expression and purification process is 
very reproducible and higher concentrations of GST-FKBP12 resulted in no 
significant improvement in the amount of mTOR purified (Figure 3.6 the old 
GST-FKBP12, and Figure 3.10 the new FKBP12). The same expression 
methods with different purification approaches (with or without elution) were 
performed at different stages of the research project, thus it was not possible to 
directly compare the differences between purifications.  
Chapter three  Zeyad Alharbi 
 
90 
 
 
 
Figure 3.10: Western blotting to study the effect of GST-FKBP12 concentration 
on the binding efficiency of mTOR to affinity matrix.  
There is no significant difference between the amounts of mTOR purified with 
different GST-FKBP12 concentrations. 
 
3.2.1.1.3.6 The effect of different GST-FKBP12 concentrations 
The concentration of GST – FKBP12 is believed to be crucial for the affinity of 
the matrix. Excess GST-FKBP12 concentration leads to the formation of free 
affinity matrix which will compete with the one bound to the beads for mTOR, 
consequently it will be washed out. Whereas using very few concentration 
might limit the amount of mTOR purified. Therefore, the concentration of 
GST-FKBP12 needs to be optimised and tested. A different concentration of 
GST-FKBP12 in the affinity matrix does not affect the yield of mTOR purified 
(Figure 3.10). These results suggest that there is another factor which limits the 
amount of mTOR purified. 
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After adjusting several factors affecting the efficiency of the affinity 
purification, the main goal was to examine the pattern of the immuno-reactive 
bands purified from different cell line and tissues by the use of the affinity 
matrix. 
3.2.1.1 Patterns of mTOR immuno–reactive bands from different tissues 
and cell lines 
Different tissues and cell line extracts were tested using the affinity matrix. 
When the extracts of these cell line and tissues were immuno–blotted they 
generated different patterns of immuno–reactive bands against an mTOR 
specific antibody. Affinity purification of mTOR from rat hearts, starved and 
starved stimulated HEK 293 cells show different immuno–reactive bands 
representing potential mTOR splicing isoforms (Figure 3.11 and Figure 3.12). 
The isolation process of a new isoform for mTOR consisted of five different 
stages. At this point of the protein analysis approach, stages one to four were 
successfully achieved; the first stage was purification of GST–FKBP12 from 
bacteria and testing the quality of purified protein; the second was preparing 
the affinity matrix; then the third was testing the affinity matrix and the 
fourth, examining the pattern of immuno–reactive mTOR splicing isoforms 
from cell lines and rats tissue.  
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Figure 3.11: Western blotting of affinity purified mTOR from Rats’ Heart.  
The arrow highlighted immune–reactive bands with anti mTOR C-terminal 
(Millipore), representing potential splicing isoform. 
 
Ideally, the next stage would have been to examine specifically associated 
potential mTOR proteins with mass–spectrometry analysis. Initially, two 
potential mTOR isoforms have been purified and analysed by silver stain. 
However, it was not possible to purify sufficient amounts of these potential 
mTOR proteins for mass-spectrometric analysis. mTORα was hardly visible 
by silver staining and increasing the stain intensity leads to a high 
background signals. Any potential alternative splicing isoforms were 
expected to be even less abundant and more difficult to observe. 
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Figure 3.12: Western blotting of affinity purified mTOR from Starved and 
starved stimulated HEK 293.  
The arrow highlighted immuno–reactive bands with anti mTOR C–terminal 
(Millipore), representing potential splicing isoform. 
 
Recently, a three–dimensional (3D) structure of human mTORC1 was 
determined by cryo-electron microscopy (Yip et al.2010). Yip et al revealed 
that extended incubation of mTORC1 with rapamycin may induce 
disassembly of mTORC1, and may lead to conformational changes. This 
could potentially explain why the binding efficiency of mTOR to the affinity 
matrix was weak and did not purify sufficient amount of mTOR protein for 
mass–spectrometry analysis. Subsequently, adjustments in the purification 
protocol have been made by minimising the incubation time of mTOR with 
the affinity matrix, which contains rapamycin to 15 minutes rather than 1 
hour as in all previous results demonstrated in this study. This modification 
resulted in two clear immuno–reactive bands with intensity similar to or 
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higher than mTOR. These intense bands represent potential mTOR 
isoforms. These bands migrated on SDS-PAGE to a relative molecular 
weights of approximately 130 kDa and 135 kDa (Figure 3.13).  
 
 
Figure 3.13: Western blotting of affinity purified mTOR from HEK 293 using the 
modified procedure, after the 3D structure has been revealed (15 min incubation 
with rapamycin).  
The arrows highlight immuno–reactive bands with anti mTOR C–terminal 
(Millipore), representing potential splicing isoform. 
 
To further examine the potential mTOR isoforms, the 130 and 135 kDa bands, the 
cell lysate were blotted with antibodies targeting different mTOR domains. Figure 
3.14 summarises numerous mTOR–specific antibodies that are commercially 
available. Five antibodies which recognise different mTOR domains were selected. 
These are listed below: 
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1. anti FRAP C-terminal (Millipore)  
Peptide (C-DTNAKGNKRSRTRTDSYS) corresponding to amino acids 
2433-2450 of mTOR 
2. anti mTOR C-19 (Santa Cruz) 
Epitope mapping at the C-terminus of mTOR, blocking peptide the last 19 
amino acids at the C-terminal  
3. anti mTOR Phospho-specific C-terminal (Millipore)  around 2448 
Recognizes mTOR when phosphorylated on Ser2448 
4. anti FRAP (N-19): (Santa Cruz) 
Epitope mapping at the N-terminus of FRAP of human origin. Blocking 
peptide, sc-1549 P 
5. anti mTOR F11: (Gnna Panasyuk) 
Epitope mapping corresponding at 1332-1504 amino acids of human origin 
 
The presence of the 130 and 135 kDa bands was confirmed by Western blotting 
analysis. The two potential isoforms were present in the Western blot with three 
antibodies, anti– mTOR targeting the kinase domain (anti FRAP COOH-terminal 
generated by Millipore), FATC domains (anti mTOR C-19 Santa Cruz) and the NH2-
terminus of the HEAT repeats domain (anti-mTOR N-19 target the first 19 amino 
acid at the NH2-terminus of the mTOR).  
Since the two bands were reactive with antibodies targeting the FATC, kinase and 
HEAT repeats domains, we can hypothesise that kinase, FATC and the NH2-
terminal of the HEAT repeats domains are present in both the 130 and 135 kDa 
proteins.  In addition, the 130 and 135 kDa bands were purified using the affinity 
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matrix, and while FRB domain bind to the affinity complex, this indicate the 
presence of FRB in both bands. 
Only one band was immune–reactive with each of anti–mTOR F11, and the 
phosphor–specific antibody. Anti–mTOR F11 target the C–terminus of the HEAT 
repeats domain and small part of the neighbouring FAT domain, which is missing in 
mTOR. The band which is non–reactive with anti–mTOR F11 is similar to mTORβ 
isoform which lacks most of the HEAT and FAT domains. Furthermore, one of these 
potential isoforms can be phosphorylated (Figure 3.15).  
  
Figure 3.14: Commercially available antibodies against different mTOR epitope. 
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3.2.1.2 Summary of protein analysis approach 
Although we have successfully identified potential splicing isoforms of mTOR, the 
quantity of endogenous proteins purified using the GST-FKBP12-Rapamycin affinity 
matrix was not sufficient for MS-MS analysis. Many optimisation steps to increase 
the sensitivity and specificity were applied, however, with limited success.  
The majority of mTOR protein from total cell lysates did not bind to the GST–
FKBP12–Rapamycin affinity matrix for unknown reason. It could be due to the low 
in vitro affinity of FKBP12–Rapamycin for endogenous mTOR complexes 1 and 2. 
This affinity was not good enough to pull–down a significant amount of the mTOR 
from the total cell lysate. This phenomenon is not uncommon since other groups 
used a much larger amount of total tissue or cell lysates to isolate mTORα, about 100 
times more than the number of cells we have used. Using this amount of cell lysate 
requires extended incubation and since the extended incubations of cells with 
Rapamycin leads to disassembly of mTORC1 (Yip et al. 2010b), it was impossible to 
use that amount in our protocol which requires a short exposure of mTOR to 
rapamycin. The success resulted from using less exposure time resulted in two 
intense new immune–reactive bands. However, no significant enrichment in the 
affinity purification of endogenous mTOR (enough for mass–spectrometry analysis) 
on the GST–FKBP12–Rapamycin matrix was observed. Since rapamycin is known 
to affect the integrity of mTORC1, therefore using rapamycin in this approach may 
lead to dissociation of mTOR from the affinity matrix. 
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Figure 3.15: Western blotting of affinity purified mTOR against different antibodies.  
The two bands were immuno–reactive with three antibodies, anti mTOR targeting 
the kinase domain, FATC domains and the NH2–terminous of the HEAT repeats 
domain. Only one band was immune–reactive with each of anti-mTOR F11, and the 
phosphor–specific antibody. 
 
3.2.2 Bioinformatics and molecular approaches 
The exon-intron structure of the mTOR gene (156,973 nucleotides) were analysed 
for alternative starting codons and potential alternative splicing isoforms. The full 
length mTOR mRNA (cDNA of 7,554 nucleotides) does not start with or contain a 
Kozak sequence; consequently it is very difficult to predict the alternative translation 
initiation start codon.  
Extensive bioinformatics analysis allowed us to identify several potential alternative 
start codons and potential novel spicing isoforms. One of these was revealed by 
searching the protein databases. This clone, EAW71681.1, was reported by Celera 
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Genomics (WGS) human genome sequencing project, which was generated by the 
whole–genome shotgun sequencing method.  This clone lacks exon 25 (amino acid 
1219-1267). This exon is located in between HEAT repeats and FATC domains. The 
HEAT repeats act as a binding site for substrate presenting proteins, while the FATC 
is involved in the activation of the mTOR kinase activity. It is interesting to study the 
effect of this deletion on the kinase activity of mTOR and the ability of mTOR to 
form complexes with substrate presenting proteins.  
Another extensive bioinformatics search of EST and RNA analysis resulted in the 
identification of two cDNA clones coding two potential mTOR splicing isoforms 
designated mTOR and mTORδ (AK302863.1). The mTORδ results from a frame 
shift in the middle of the FATN domain and leads to a premature translation stop 
codon, while mTOR possesses a 12 amino acid deletion which is located in the 
kinase domain (Figure 3.16). 
The COOH-terminal of mTOR results from a frame shift in the middle of FAT 
domains and leads to a premature translation stop codon. This frame shift resulted in 
a new amino acid sequence. To further investigate the existence of mTOR, an 
antibody targeting the COOH–terminal of the mTOR was generated by 
collaborators. Further details about anti–mTOR presented in chapter four. The 
expression of mTOR was confirmed by Western blotting in different cell lines, 
including HEK 293, Hep-2G, MC7 and Hela (Figure 3.17).   
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Figure 3.16: Schematic domain organization of mTOR splicing forms 
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(A) 
 
(B) 
 
 
Figure 3.17: Western blotting analysis testing the expression of mTORδ in different cell 
lines. 
(A) and (B) show clear immuno–reactive bands from different cell lines when blotted 
with an antibody targeting mTORδ. 
 
  
 
 
CHAPTER 4 
Molecular characterisation 
and functional analysis of 
mTOR 
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Chapter 4:  Molecular characterisation and functional 
analysis of mTORδ   
 
4.1 Molecular characteristics of the mTORδ isoform  
4.1.1 Introduction  
As mentioned in Chapter three extensive bioinformatics analyses revealed a novel 
mTOR splicing isoform denoted mTORδ. The identified alternatively spliced form, 
mTORδ, was found in the cell lysates of different cell lines via western blotting 
analysis. In contrast to the full–length wild–type mTOR, mTORδ lacks the kinase 
domain. Thus, it would be interesting to study the effect of this isoform on the 
mTOR mediated cellular functions. In this study, we generated mammalian 
expression constructs for the mTORδ and control proteins. Stable cell lines were 
created to study the relative importance of this isoform and its possible role in the 
regulation of mTOR activity. 
In addition, mTORδ is a novel spliced isoform of mTOR resulting from a frame–shift 
in the middle of the FAT domain leading to a premature stop codon. As a result of 
the frame shift, a novel amino acid sequence is generated at the COOH-terminus of 
this particular isoform. The predicted molecular weight of this spliced isoform is 
approximately 158 kDa. The isoform lacks the FRB, regulatory and kinase domains. 
Thus, it is thought that the mTORδ protein acts as a dominant negative regulator of 
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mTOR signalling by sequestering substrate–presenting proteins such as raptor and 
rictor.  
The main focus in studying the mTORδ isoform was to investigate its effect on the 
regulation of the mTOR pathway and on the mTOR–mediated cellular processes, 
including cell proliferation, cell cycle regulation and tumourigenesis.  
cDNA clones were constructed and sub–cloned into the pcDNA3 mammalian 
expression vector. The pcDNA3 plasmid is designed to provide high-level expression 
of recombinant proteins in a wide range of mammalian cells. In the pcDNA3 vector, 
the cDNA sequence is inserted at the COOH-terminus of the human cytomegalovirus 
(CMV) promoter. This permits high–level constitutive expression in mammalian 
hosts (Invitrogen guide). The bovine growth hormone (BGH) polyadenylation signal 
is located immediately after the multiple cloning site (MCS) at the COOH-terminus 
of the inserted cDNA. This BGH polyadenylation signal enhances the transcription 
termination and poly–adenylation of mRNA.  
A laboratory in Japan reported that a point mutation in the kinase domain of mTORα 
resulted in nutrient–independent activation of mTORC1 (Sato et al. 2010). This point 
mutant was denoted S2215Y. The wild–type form of mTOR (mTOR) and the 
activated mutant (mTOR S2215Y) were used as controls to assess the activity of 
mTORδ (Figure 4.1). The full–length mTOR cDNA consists of 7,647 nucleotides, 
whereas that of the mTORδ isoform consists of 4,212 nucleotides.  
An mTORβ isoform mutant was generated in our laboratory by Christopher Fu 
(Figure 4.2). The S2215Y point mutation was introduced into the DNA sequence of 
mTORβ using a set of primers for site–directed mutagenesis and was denoted 
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mTOR S2215Y. The mTOR plasmids were amplified and purified using the 
QIAGEN Miniprep Plasmid Purification kit. DNA sequence analysis was then 
performed to ensure that the correct mutation had been introduced into the cDNA 
sequence. 
All of the mTOR isoform plasmids used in this study were cloned from the 
previously created mTOR S2215Y mutant in addition to mTOR from Addgene 
and mTORδ from the National Institute of Technology and Evaluation (NITE).  
The mTOR, mTORδ and mTOR S2215Y cDNA sequences were cloned as Flag–
tagged fusion proteins in the pcDNA3 mammalian expression vector. As a result, the 
generated recombinant fusion proteins can be purified and detected using a Flag 
expression system. The Flag expression system is useful for western blotting, 
immuno–histochemistry, immuno–precipitation, flow–cytometry and protein 
purification and for studying protein–protein interactions and protein localisation. 
This small hydrophilic (8-amino acid peptide) tag significantly improves the 
detection and purification of recombinant fusion proteins when used together with 
highly specific and sensitive anti–Flag antibodies. The 8–amino acid peptide (Asp-
Tyr-Lys-Asp-Asp-Asp-Asp-Lys) is fused to the recombinant mTOR proteins when 
they are expressed. This Flag peptide sequence is likely to be positioned on the 
surface of the expressed protein due to its hydrophilic nature. As a result, it is likely 
to be detected by the anti-Flag antibody. In addition, due to the small size of the Flag 
tag, it is unlikely to obscure other epitopes, domains or alter the function or 
characteristics of the fusion protein. Another DNA sequence analysis was therefore 
performed to verify that the correct Flag–tagged DNA sequences had been 
introduced into the pcDNA3 expression vector. 
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Figure 4.1: Schematic representation of the domain organisation of the mTORδ splice 
isoform.  
mTOR is the full–length form of mTOR. mTORδ is a novel mTOR splicing 
isoform resulting from a frame–shift in the middle of the FAT domain that leads to a 
stop codon, resulting in premature termination. The S2215Y point mutation in the 
mTOR kinase domain was identified by searching the COSMIC database of somatic 
mutations. This mutation has been shown to confer constitutive mTOR activation, 
even under conditions of nutrient deprivation. 
 
 
Figure 4.2: Schematic representation of the domain organisation of the mTORβ 
mutant.  
mTORβ is a novel mTOR splicing isoform that lacks HEAT repeats and the majority 
of its FATN domains. In this study, the mTOR point mutant was denoted mTOR 
S2215Y. mTORα exhibits the same COOH–terminal sequence as mTORβ and the 
position of the S2215Y mutation will therefore be at the same place in mTORα. 
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4.1.2 Generation of Flag–tagged mTOR and mTOR S2215Y plasmids 
As mentioned previously, mTORα and mTORβ share the same COOH–terminus, 
which includes the kinase domain where the S2215Y mutation is located. In addition, 
mTOR lacks most of its HEAT repeats and FAT domains, which are located at the 
NH2-terminus of mTOR. Therefore, to generate mTOR and mTOR S2215Y, the 
NH2-termini of the wild–type mTOR and the mTOR mutant which harbouring the 
S2215Y mutation were replaced with the full–length NH2-terminus of the wild–type 
mTOR. The Flag tag sequence was introduced into the DNA at the NH2-terminus 
of the full–length mTOR. This process resulted in the generation of pcDNA3-Flag-
mTOR and pcDNA3-Flag-mTOR S2215Y (Figure 4.3). 
The pcDNA3-mTORβ and pcDNA3-mTORβ S2215Y plasmids were linearised with 
the HindIII restriction enzyme. The ends of the linearised plasmids were then blunted 
using T4 DNA ligase. The linearised and blunted plasmids were re-digested with the 
KpnI restriction enzyme. This resulted in a small fragment containing the NH2-
terminal region of mTORβ. This NH2-terminal fragment was then replaced with the 
full–length NH2-terminus of Flag–mTOR from pcDNA–Flag–mTOR (Figure 
4.4). To prepare the full–length NH2-terminal fragment, pcDNA-Flag-mTOR was 
linearised with the NotI restriction enzyme and blunted with T4 DNA ligase. The 
plasmid was then re-digested with the KpnI restriction enzyme. The resultant NH2-
terminus of full–length Flag–mTOR was blunted from its NH2-terminal side, and the 
COOH-terminus consisted of KpnI restriction sequence. The pcDNA3 containing the 
COOH-terminus of mTOR and codes for either full–length or the S2215Y point 
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mutation was blunted from its COOH–terminal and exhibit KpnI restriction sequence 
from its NH2-terminal. These two fragments, the pcDNA3 containing the COOH-
terminus of mTOR isoforms and the full–length NH2-terminus of mTOR, were then 
ligated together using T4 DNA ligase. 
 
 
Figure 4.3: Plan for the generation of the pcDNA3–Flag–mTORα and pcDNA3–Flag–
mTOR S2215Y isoforms. 
The pcDNA-mTOR isoforms (top) were linearised using the HindIII restriction 
enzyme, blunted using T4 DNA ligase and digested again with KpnI. This process 
resulted in two fragments: a large fragment containing the pcDNA3 plasmid and the 
COOH–terminus of mTOR and a small NH2-terminal fragment. pcDNA–Flag–
mTOR (bottom) was linearised using the NotI restriction enzyme, blunted using T4 
DNA ligase and digested again with KpnI and SalI. This process resulted in a full–
length NH2–terminal of mTOR with a blunt end at its NH2–terminus and a KpnI 
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sequence at its COOH–terminal. This fragment was then ligated to the pcDNA3 
containing the COOH-terminus of mTOR. 
 
 
 
Figure 4.4: Agarose gel image of the DNA fragments used for the construction 
of pcDNA3–Flag–mTORα and pcDNA3–Flag–mTOR S2215Y.  
The pcDNA3-mTORβ and pcDNA3-mTORβ S2215Y plasmids were 
digested with HindIII and KpnI. In addition, the pcDNA3-Flag-mTOR 
plasmids was digested with SalI, KpnI and NotI. These plasmids were 
electrophoresed in a 0.8% agarose gel. The NH2-terminus of the wild–type 
mTORβ and mutated mTORβ plasmids were digested and replaced with the 
Flag-tagged full–length NH2–terminus of mTOR. 
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The mutant DNA molecules were transformed into bacteria, and 8 colonies from 
each mutant were amplified and analysed on an agarose gels to confirm the size and 
the quality of the purified plasmids (Figure 4.5). Digestion analysis of the DNA was 
then performed to verify that the DNA was inserted into the plasmid. The restriction 
analysis was carried out using the Hin1I restriction enzyme, followed by analysis on 
0.8% agarose gel. The digestion of plasmids with inserts results in a band of 
approximately 1,280 bp. This band was absent in all of the selected colonies in the 
lanes indicated with blue number in Figure 4.5. However, all of the colonies in the 
lanes indicated with red numbers were positive for the fragment representing the 
insert from the digested plasmid (Figure 4.6 and Figure 4.7). Therefore, these 
colonies contained the cDNA insert within the plasmid. DNA sequence analysis was 
then performed to verify that the mutations were present. 
 
Figure 4.5: Agarose gel image of colonies selected for digestion and sequencing analysis.  
The constructed plasmids were transformed into bacteria and plated in selection 
media. Eight colonies from each mutant were selected for plasmid purification and 
tested on agarose gels to check the size and quality of the purified plasmids. The 
plasmids were then thoroughly tested through digestion and sequencing analysis. The 
results of the digestion analysis can be seen in Figure 4.6 and Figure 4.7. 
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Figure 4.6: Agarose gel image of the results of the digestion analysis of the pcDNA3–
Flag–mTORα and pcDNA3–Flag–mTOR S2215Y plasmids for the first selection which 
showed negative results.  
Digestion analysis was performed to verify that the DNA was inserted into the 
plasmid. The plasmids were digested using the Hin1I restriction enzyme and run on 
0.8% agarose gel. The digestion of plasmids with inserts should result in a band of 
approximately 1,280 bp. This band was absent in all selected colonies indicated with 
blue numbers. 
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Figure 4.7: Agarose gel image of the results of the digestion analysis of the pcDNA3–
Flag–mTORα and pcDNA3–Flag–mTOR S2215Y plasmids for the second selection 
which demonstrated positive results.  
Digestion analysis was performed to verify that the DNA was inserted into the 
plasmids. The plasmids were digested with the Hin1I restriction enzyme and run on 
0.8% agarose gel. The obtained band with a size of approximately 1,280 bp confirms 
that the insert is present in all of the selected colonies (indicated with red numbers). 
 
4.1.3 Generation of the pcDNA3–Flag–mTORδ plasmid 
mTORδ shares the same NH2–terminus as of the wild–type mTOR. Therefore, the 
pcDNA3–Flag–mTORδ plasmid was constructed by replacing the COOH–terminus 
of pcDNA3–Flag–mTOR with the COOH-terminus of mTORδ (Figure 4.8). The 
pcDNA3–Flag–mTOR and pME18S–FL3–mTORδ plasmids were digested with 
the EcoRI and XbaI restriction enzymes. The COOH–terminus of mTORδ and the 
pcDNA3 plasmid containing the NH2–terminal of Flag-mTOR were purified using a 
DNA gel extraction kit (QIAGEN) and ligated using T4 DNA ligase (Figure 4.9).  
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Figure 4.8: Plan to generate pcDNA3–Flag–mTORδ.  
The pcDNA3–Flag–mTOR isoform was digested with EcoRI and XbaI (top). As a 
result, the COOH–terminus of mTOR was removed from the plasmid, whereas the 
NH2–terminus remains attached to the plasmid. This NH2–terminus is shared with 
the NH2–terminus of mTORδ. pME18S–FL3–mTORδ was also digested with EcoRI 
and XbaI (bottom). This digestion resulted in the full–length COOH–terminus of 
mTORδ containing the EcoRI sequence at its NH2–terminus and the XbaI sequence 
at its COOH–terminal. This fragment was then ligated to pcDNA3 containing the 
NH2–terminus of mTOR. 
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Figure 4.9: Agarose gel image of the DNA fragments used for the construction of 
pcDNA3–Flag–mTORδ.  
The pcDNA3–Flag–mTOR and pME18S–FL3–mTORδ plasmids were digested 
with EcoRI and Xbal. These plasmids were then electrophoresed in a 0.8% agarose 
gel, and the resulting COOH–terminus of mTOR was replaced with the COOH–
terminus of mTORδ. 
 
4.1.4 DNA sequence analysis of the generated plasmids 
Sequence analysis of the generated plasmids was performed to verify the presence of 
the DNA sequences and the mutation. Samples of the pcDNA3-Flag-mTOR and 
pcDNA3-Flag-mTOR S2215Y plasmids were sent to GATC Biotech for DNA 
sequence analysis. The pcDNA3–Flag–mTORδ plasmids were sequenced at the 
Wolfson Institute for Biomedical Research, UCL. The presence of the full–length 
Flag–mTOR DNA inserts was confirmed by sequencing analysis and multiple 
sequence alignment.  
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The results indicate that the active mTOR S2215Y has a point mutation (TCT to 
TAT) in the kinase domain of mTORα. The sequencing results of mTOR S2215Y 
aligned against the mTOR sequence can be seen in Figure 4.10.  
 
 
 
 
Figure 4.10: Sequencing analysis of pcDNA3–Flag–mTOR S2215Y.  
The top of this figure presents the sequence alignment highlighting the point 
mutation. The lower part of the figure presents the sequence in the chromatogram, 
indicating that the mutation had been generated. Alignment of the resulting sequence 
against the mTORα sequence indicated that the mTOR S2215Y point mutation (TCT 
to TAT) had been successfully generated and that the DNA was inserted in the 
pcDNA3–Flag–mTOR plasmid. 
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These plasmids were then used to generate a recombinant protein and stable cell lines 
over-expressing a Flag-tagged recombinant form of mTOR. The obtained 
recombinant proteins and stable cell lines were then used to study the mTORδ 
isoform in vitro and in cells.  
In Figure 4.11 the mTORδ COOH-terminal sequence is highlighted in red, which is 
the sequence that was added to the pcDNA3 plasmid containing the Flag–tagged 
mTOR NH2–terminal. 
 
 
Figure 4.11: mTORδ COOH-terminal sequence highlighted in red.  
This sequence was added to the pcDNA3 plasmid containing the Flag-tagged mTOR 
NH2–terminus. The sequences highlighted in green demonstrate the primer 
sequences that were used for sequencing. The restriction/ligation sites for the EcoRI 
and XbaI restriction enzymes are highlighted between brackets. 
 
The alignment of the obtained sequence of mTORδ fragment against the predicted 
sequence of mTORδ can be seen in Figure 4.12. This novel and unique amino acids 
sequence which resulted from a splicing-mediated frame shift in the middle of FAT 
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domain was cloned into pET expression plasmid and exressed in bacteria as His-tag 
fusion protein. Recombinant His-mTORδC was purified nearly to homogeneity using 
NTA affinity chromatography and used to generate mTORδ specific polyclonal 
antibodies in mouse. We used recombinant His-mTORδC protein for affinity 
purification of mTORδ specific antibodies from the sera of immunized animals.  
 
 
4.1.5 Generation of stable cell lines expressing mTORδ 
To gain insight into the possible effects of the mTORδ isoform, HEK 293T cell lines 
stably expressing the mTORδ, mTOR or mTOR S2215Y isoforms were used as a 
research model. The parental HEK 293T cells and HEK 293T cells expressing wild–
 
 mTORδ COOH-terminal sequence (28 – 59 amino acids)  
CTCAGAAAACAGAAATACTGTCATGGAGGTGCTGAACACAGGGAAGGTCTGGTACATATTGGAAATT
ATGAGCAGAACAAATACTCAACTAAATGCACAAAGTATAAAGTGTAGCCATGT 
 
mTORδ ----------CTCAGAAAACAGAAATACTGTCATGGAGGTGCTGAACACAGGGAAGGTCT 
Sequencing-s-Tag GATCCGAATTCTCAGAAAACAGAAATACTGTCATGGAGGTGCTGAACACAGGGAAGGTCT 
           ************************************************** 
 
mTORδ GGTACATATTGGAAATTATGAGCAGAACAAATACTCAACTAAATGCACAAAGTATAAAGT 
Sequencing-s-Tag   GGTACATATTGGAAATTATGAGCAGAACAAATACTCAACTAAATGCACAAAGTATAAAGT 
 ************************************************************ 
 
 
mTORδ               GTAGCCATGT-------------------------------------------------- 
Sequencing-s-Tag GTAGCCATGTCTAGCTCGAGCACCACCACCACCACCACCACCACTAATTGATTAATACCT 
 *********** 
 
Figure 4.12: Nucleotide sequence alignment of the mTORδ fragment.  
The mTORδ fragment, which encodes a novel amino acid sequence that was used to 
generate a specific antibody targeting mTORδ, was aligned against the predicted 
sequence of mTORδ. 
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type mTOR or the activated form mTOR S2215Y were used as controls in the 
following functional analysis. Cells transfected with Flag- mTOR S2215Y were 
employed as a positive control. Cells transfected with the empty vector, referred to as 
parental cells, were used as a negative control.  
Mammalian expression vectors encoding the DNA sequence of Flag–mTOR were 
generated for all of the mTOR isoforms. The generated expression vectors were 
confirmed by restriction and sequencing analysis. These constructs contain the 
neomycin resistance gene, allowing the selection of transfected cells with Geneticin 
(G-418). Geneticin is an aminoglycoside analogue of Gentamicin sulphate. Geneticin 
is commonly used as a selective agent for eukaryotic cells. Geneticin interferes with 
the function of the 80S ribosomes and protein synthesis in eukaryotic cells. The 
Geneticin resistance gene (neomycin) is commonly used in mammalian expression 
vectors. Cells expressing these resistance markers can be selected when the culture is 
treated with a culture medium containing Geneticin. As a result, stable colonies of 
mammalian cells expressing these resistance markers can be generated in a period of 
10 to 20 days. 
HEK 293 cells were transfected with each vector separately, and transiently 
transfected cells exhibited adequate levels of expression for all of mTOR isoforms 
(Figure 4.13). This result demonstrated that the transfection was efficient and that the 
expression of the fusion protein in transiently transfected HEK 293 cells was 
abundant. To generate stable cell lines, prior to Geneticin treatment, HEK 293 cells 
were tested for Geneticin resistance, and the optimum concentration for selection 
was obtained.  
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Figure 4.13: Western blot confirming the expression of Flag–mTORδ, Flag–mTORα 
and Flag–mTOR S2215Y in transfected HEK 293T cells.  
HEK 293T cells transfected with the pcDNA3–Flag–mTOR, pcDNA3–Flag–
mTORδ or pcDNA3–Flag–mTOR S2215Y isoforms were lysed, 24 hours post 
transfection cells, then resolved via SDS–PAGE and immuno–blotted with an anti–
Flag antibody. 
 
HEK 293 cells over-expressing the mTOR isoforms were then selected by G-418 
treatment. The cell lines were treated with the optimum concentration (1,200 μg/ml) 
of G-418 for 2 weeks. Single colonies were visualised under microscopic 
examination. These cells were then collected and mixed together to generate 
polyclonal cell lines over–expressing each of the different mTOR isoforms 
separately. The cells were then maintained under a minimum G-418 concentration 
(200 μg/ml). Unfortunately, the selected cell lines lost the expression of the mTOR 
and mTOR isoforms within a week. The generation of stable cell lines was repeated 
with different selection conditions, including a wide range of Geneticin concentration 
and confluency, with no success. The concentration of G–418 used for the selection 
of HEK 293 cells generally does not exceed 800 μg/ml. During the analysis of the 
HEK293T 
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sensitivity of our HEK 293 cells to G-418, a concentration of 800 μg/ml was found 
to be insufficient to kill the cells. The HEK 293 cells may have became resistant to 
Geneticin. It is well known that Geneticin is a slow killer of eukaryotic cells. For 
Geneticin to be effective, the compound must be of a high purity so that a smaller 
amount can be used to achieve greater selection with minimal toxicity from either 
Geneticin itself or contaminants. In addition, Geneticin has been considered the gold 
standard antibiotic for the selection of cells transfected with the neomycin resistant 
gene for approximately two decades. Therefore, this widespread use might have 
promoted a wide ranging resistance against Geneticin. 
To overcome this problem, the HEK 293 cells where co-transfected with plasmids 
containing different mTOR isoforms and with the pcDNA 4/TO plasmid. pcDNA 
4/TO contains the Zeocin resistance gene, which allows the selection of stable lines 
using Zeocin. After co-transfection, the transiently transfected cells exhibited an 
adequate level of expression, and Zeocin treatment was initiated for 12 days. Five 
single colonies for each isoform were isolated and tested for Flag-mTOR expression. 
For each isoform, one colony of HEK 293 cells stably expressing the Flag–mTOR 
isoform was used for all subsequent experiments. Therefore, the results indicated that 
this co-transfection was successful, and HEK 293 cells were capable of expressing 
the mTOR fusion proteins.  
At a later stage in my PhD research, I found that the HEK 293 cell line used in this 
chapter and chapter 5 was actually HEK 293T cell line which already contains a 
neomycin resistance gene. This finding explains the poor selection achieved using G-
418, even under treatment with high G-418 concentrations. 
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These recombinant proteins were then used to study the mTORδ isoform in vitro and 
in vivo. The recombinant proteins were employed to perform an in vitro kinase assay 
using immuno–precipitated mTOR isoform complexes. In addition, these 
recombinant mTOR isoforms were also employed to analyse the effect of this 
isoform on cellular functions controlled by the mTOR signalling pathway. 
Finally, HEK 293T cells over-expressing these mTOR isoforms were employed to 
elucidate whether mTORδ over–expression is able to antagonise tumourigenesis 
mediated by the mTOR signalling pathway using colony formation assays and a 
xenograft model in nude mice (in progress). 
4.2 Functional Analysis   
Until present, the only recognised activity of mTOR is its kinase activity. mTOR 
phosphorylates S6K, 4EBP1 and PKB/Akt in vivo and in vitro (Harada et al. 2001; 
Ma & Blenis 2009; Vivanco & Sawyers 2002). The mTORδ isoform is the result of a 
frame–shift leading to the absence of the kinase domain. It is thought that mTORδ 
acts as a dominant negative regulator of mTOR signalling by sequestering the 
substrate–presenting proteins raptor and rictor.  
In addition to the novel amino acid sequence at the COOH-terminal of the mTORδ 
spliced isoform, mTORδ retains HEAT repeats domain at the NH2-terminus. The 
HEAT repeat is thought to mediate the mTOR localization on the cell membrane 
(Liu & Zheng 2007).  
The presence of mTOR isoforms is likely to affect the mTOR pathway and mTOR–
mediated cellular processes such as cell growth, survival and cell cycle regulation. 
Hence, we are prompted to study the cellular localisation of mTORδ and the effect of 
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mTORδ on the cell proliferation, cell cycle, cell size, overall tumourigenicity and 
tumour progression.  
To study the effect of mTORδ on cellular proliferation, MTT proliferation assays 
were performed. To elucidate whether mTORδ over–expression is able to antagonise 
tumorigenesis mediated by the mTOR signalling pathway, colony formation assays 
were performed, and a xenograft model in nude mice is in the process of 
development. To perform these experiments, mammalian expression vectors 
containing the coding sequences of the Flag-mTORδ, Flag-mTORα and Flag-mTOR 
S2215Y isoforms were generated, and stable HEK 293T cell lines were generated as 
discussed in section 4.1.24.1.3.  
The MTT proliferation assay has been used to study the effect of over-expression of 
the mTORδ isoform on cellular proliferation. A HEK 293T cell line over–expressing 
Flag–mTOR S2215Y was used as a positive control, and HEK 293T cells transfected 
with an empty vector were used as a negative control. In addition, a HEK 293T cell 
line over–expressing wild–type (mTOR) was included in the study to compare its 
cellular proliferation with that of mTORδ. 
4.2.1 mTORδ kinase activity  
The mTOR protein is defined as the functional subunit of two mTOR complexes. 
mTOR complex 1 phosphorylates S6K and 4E-BP1, whereas mTOR complex 2 
phosphorylates Akt. In contrast to mTORα and mTORβ, mTORδ lacks the kinase 
domain and possesses a new amino acid sequence at its COOH-terminus. Therefore, 
mTORδ will be unable to phosphorylate the mTOR substrates S6K, 4E-BP1 and Akt.   
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4.2.2 MTT assay – cell proliferation assay 
mTOR functions at the intersecting of various signalling pathways that control 
multiple cellular functions. mTOR integrates intracellular and extracellular signals to 
regulate cell growth, proliferation and survival (Corradetti & Guan 2006;Hay & 
Sonenberg 2004). mTOR protein regulates these various cellular processes via the 
activation of Akt, 4EBP1 and S6K. Akt inactivates several pro-apoptotic factors and 
mediates the stabilisation of cell surface amino acid transporters, promoting cellular 
growth and survival (Edinger & Thompson 2002;Guertin, Stevens et al. 
2006;Vivanco & Sawyers 2002). Together, 4E-BP1 and S6K1 promote mRNA 
translation, ribosome biogenesis and autophagy (Hara et al. 2002;Kim, Sarbassov et 
al. 2002;Kim, et al. 2003;Ruggero & Pandolfi 2003). In contrast, S6K1 generates a 
negative feedback loop to reduce survival signals and inhibit the pro-apoptotic 
protein BAD (Harada et al. 2001). Because wild-type mTOR plays a key role in the 
regulation of cell proliferation, mTORδ is expected to be involved in the regulation 
of mTOR activities.  
An MTT proliferation assay was performed to assess the differences in the levels of 
proliferation inhibition in response to the starvation of HEK 293T cells over–
expressing the mTORδ splicing isoform compared with parental HEK 293T cells. 
The MTT assay is a colorimetric assay for measuring the activity of live cells. In 
viable cells, cellular enzymes reduce the tetrazolium dye, MTT, to produce a strongly 
pigmented formazan product (Promega). The absorbance of the pigmented product 
was measured using a micro-plate absorbance plate reader (Tecan). 
 We used the created HEK 293T stable cell lines over-expressing mTORδ, mTOR 
and mTOR S2215Y isoforms and parental cells. About 5000 HEK 293T cells were 
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plated per well in 96 wells plate and nourished with DMEM containing 10% FBS. 
When the HEK 293T cell lines reached about 70% confluency, cells were starved of 
serum. Two days after starvation, MTT dye was added to wells and incubated for 3 
hours, followed by the absorbance measurement. From day 2 to days 6 after 
starvation, measurement was taken daily. The optical density determined at 490 nm 
using a plate reader. Results are normalized to the blank which contains media MTT 
but no cells.  
The HEK 293T cells over–expressing mTORδ exhibited decreased cellular 
proliferation compared with the parental cells. The significant difference in the cell 
proliferation was observed after 72 hours (P<0.05) (Figure 4.14).  
 
In conclusion, this demonstrated that the mTORδ protein is a negative regulator of 
the proliferative activity of HEK 293T cells.  
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Figure 4.14: Parental HEK 293T cells demonstrate a higher proliferation potential than 
HEK 293T cells over–expressing the mTORδ isoform.  
The MTT proliferation assay was performed using HEK 293T cells over-expressing 
mTOR, mTORδ, mTOR S2215Y or parental cells under condition of starvation. The same 
number of cells was seeded for all cell lines. Once the cells had reached optimum 
confluence, they were placed under starvation conditions. After 48 hours of starvation, the 
CellTiter 96 one solution reagent (MTT) was added, followed by three hours incubation and 
then the absorptions were measured at 490nm. From day 2 to day 6 after starvation, 
measurements were performed daily. Each data point represents the mean ± SEM from three 
independent experiments (P<0.05, n=3, independent experiments). 
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4.2.3 Colony formation assay  
The mTOR protein plays a critical role in the regulation of cellular processes, 
including cell growth, proliferation and survival and protein synthesis (Corradetti & 
Guan 2006;Hay & Sonenberg 2004). It is well known that extracellular signals and 
intracellular signals enhance the mTOR activity. The enhanced mTOR activity is 
implicated in tumourigenesis and promotes tumour progression. As noted previously, 
mTORδ lacks the kinase domain. Thus, mTORδ lacks catalytic activity and will not 
phosphorylate the mTOR targets, including S6K, 4EBP1 and Akt. Using an MTT 
proliferation assay, we demonstrated that mTORδ inhibits cellular proliferation. It 
would be interesting to elucidate whether over-expressed mTORδ is able to 
antagonise tumourigenesis mediated by mTOR signalling pathway.  
Colony formation assays, also known as clonogenic assays, are in vitro cell survival 
assays based on the ability of a single cell to grow into a colony in a compressed and 
unfavourable environment. The number of colonies derived from cells exhibiting 
oncogenic survival and proliferation properties will be significantly higher than the 
number of colonies derived from normal cells.  
Our previous results indicated that, in cancer, the mTORδ has the potential to 
promote reproductive cell death. To elucidate whether mTORδ has an oncogenic or 
anti–oncogenic effect, colony formation assays were performed. These assays 
basically measured the number of cells that were able to undergo continuous division 
in the HEK 293T cell line over-expressing mTORδ compared with the parental HEK 
293T cell line. 
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Parental HEK 293T cells and HEK 293T cells over-expressing mTORδ, mTOR or 
mTOR S2215Y were seeded at appropriate dilutions using soft agar to form colonies 
over a period of 1 to 3 weeks. The colonies were then stained with 0.005% crystal 
violet for 3 hours at 37 °C and photographed. The fold increase or decrease in the 
number of colonies that were able to survive was measured. Five independent 
experiments, each were performed in triplicate. 
 Figure 4.15 indicates  that  very  few  spontaneous  colonies  were  formed  from  
2,000 or 4,000  HEK 293T cells over-expressing mTORδ compared with parental 
HEK 293T cells. The parental cells exhibited a four–fold increase in the number of 
colonies. In addition, consistent with MTT results the colony formation assay 
indicated that the number of colonies generated from HEK 293T cells over-
expressing mTOR was significantly lower (p<0.05) than the number of colonies 
generated from parental HEK 293T cells (Figure 4.15). 
Therefore, the results suggest that when the mTORδ protein is stably expressed in 
HEK 293T cells, mTORδ causes either cell cycle arrest or cell death and, hence, a 
reduced number of colonies. This observation is in accord with the MTT data, which 
demonstrated that mTORδ over–expression inhibited cell proliferation. 
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Figure 4.15: The mTORδ protein stably enhances either cell cycle arrest or cell death. 
Anchorage-independent growth of parental HEK 293T cells and HEK 293T cells over–
expressing mTORδ, S2215Y or mTORα in soft agar. Cells were plated in a thin layer of 
agarose mixed with culture medium. Two weeks later, colonies were stained with 0.005% 
crystal violet, photographed and counted. The number of folds increase or decrease was 
plotted. Data are presented as the means ±SEM of five independent experiments. Parental 
cells exhibited a four–fold increase in the number of colonies compared with cells over-
expressing mTORδ.  
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4.2.4 Discussion and conclusions    
The initial aim of this study was to identify novel mTOR isoforms to better 
understand the regulation of the mTOR signalling pathway and its contribution to 
cancer. This goal was achieved through protein, molecular and bioinformatics 
analytical approaches, leading to the isolation of a cDNA clone encoding a novel 
homologous protein, mTORδ. The mTORδ protein lacks the FRB and kinase 
domains which are crucial for mTOR kinase activity. 
To study the molecular characteristics of the mTORδ protein and elucidate its 
potential role in tumourigenesis, a mammalian expression vector was constructed, 
and stable cell lines over–expressing mTORδ were generated. The full coding 
sequences of mTOR, mTORδ and mTOR S2215Y were successfully cloned into 
the pcDNA3 vector with a Flag–tag positioned at the NH2–terminus of the mTOR 
isoforms. The sequences of the constructs were verified by digestion and sequencing 
analysis. The expression of the fusion protein in HEK 293T cells that were either 
transiently transfected or stably expressing the mTOR isoforms was confirmed via 
Western blot analysis. Immuno–precipitation with Protein G beads coated with an 
anti–Flag antibody appeared to be efficient, based on the copious amounts of proteins 
that could be detected by Western blotting analysis. Subsequently, the recombinant 
proteins and stable cell lines were used to characterise mTORδ in vitro and in vivo. 
In contrast to mTORα, the mTORδ lacks the kinase domain. As a result, mTORδ 
lacks catalytic activity and is unable to phosphorylate mTORα targets. mTOR can 
only function in two distinct complexes, mTORC1 and mTORC2. The raptor, rictor 
and mLST8 proteins are critical for mTOR activity. Compared to the other partners 
in the complexes, they appear to make the most important contribution to the mTOR 
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activity (Guertin et al. 2006;Hara et al. 2002;Kim et al. 2002;Sancak et al. 
2008;Sarbassov et al. 2004).  
The component that binds to mTOR and also to the mTOR targets S6K and 4E-BP1 
is represented by raptor. Researchers have demonstrated that raptor binds to mTOR 
as well as S6k and 4E-BP1 and facilitate their phosphorylation by mTOR. Therefore 
raptor can be defined as the substrate presenting protein of mTOR complex 1 
(Nojima et al. 2003). 
A common partner of mTOR complexes is mLST8, a 36-kDa polypeptide that has 
seven “WD40” repeats (Nakashima et al. 2013). The binding site for mLST8 is 
represented by the catalytic domain of mTOR and an exaggerated expression and a 
sudden decrease of mLST8 have been demonstrated to increase the function of 
mTORC1. Some studies used mice that lacked mLST8 and revealed that this protein 
is necessary for binding of mTOR and rictor but not for the mTOR-raptor 
connection, therefore mLST8 is more important for mTORC2 in comparison to 
mTORC1 (Guertin et al. 2006). The specific role of mLST8 in relation with 
mTORC1 is still unclear and remains to be discovered. 
We hypothesised that mTORδ would act as a negative regulator of mTORα by 
sequestering mLST8 and the substrate–presenting proteins raptor and rector. Raptor 
has been reported to bind to mTOR via a strong NH2–terminal interaction and a 
weaker COOH–terminal interaction (Hara et al. 2002;Kim et al. 2002;Sancak et al. 
2008). Because the identified mTORδ splicing isoform lacks most of its COOH–
terminus, including FRB, kinase, FATC and part of the FAT, but retains domains 
responsible for the protein–protein interaction modules, including the HEAT repeats 
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at the NH2–terminal, it is assumed that the interaction of mTOR with raptor will not 
be affected. 
The mTORβ splicing isoform is missing many important protein domains required 
for interactions, such as the HEAT and FAT domains, but it retains the FRB, kinase, 
RD and FATC domains. Additionally, studies have demonstrated that mTORβ has 
the ability to form complexes in vivo with known complements of the full–length 
mTOR, raptor and rictor (Panasyuk et al. 2009).   
In addition, we have demonstrated that the proliferation of HEK 293T cells 
expressing mTORδ is significantly inhibited compared with parental HEK 293T cells 
in response to 72 hours of starvation. 
In a systematic review of the current and future directions of mTOR inhibitor 
development, expert opinion indicated that the preclinical results for mTOR 
inhibitors suggest a potent anti–proliferative activity against a broad panel of tumour 
cell lines (Fasolo and Sessa 2011). The mTORα and mTORβ proteins phosphorylate 
Akt, S6K1 and 4E-BP1, promoting cell survival and proliferation (Edinger & 
Thompson 2002;Guertin et al. 2006;Vivanco & Sawyers 2002). It is therefore 
hypothesised that, because mTORδ lacks a kinase domain, it may compete with 
mTORα and mTORβ for crucial binding partners such as the substrate–presenting 
proteins raptor and rictor, thereby inhibiting mTOR–mediated regulation of cell 
proliferation. 
Since our results demonstrating that mTORδ possesses anti-oncogenic potential, this 
result suggesting that the mTORδ protein expression causes either cell cycle arrest or 
cell death, consequently antagonise the oncogenic potentials. In clonogenic assays, 
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approximately four–fold more colonies were generated from parental HEK 293T 
cells compared with HEK 293T cells over-expressing mTORδ.  
Consistent with the previous study in which mTOR was identified and 
characterised, the number of colonies generated from HEK 293T cells over-
expressing mTOR was significantly lower than the number of colonies generated 
by parental HEK 293T cells. The study in which mTOR was isolated found that the 
HEK 293T cells over–expressing mTOR did not exhibit any significant features 
associated with oncogenic transformation. Cells over–expressing mTOR failed to 
generate a significant number of anchorage–independent colonies in soft agar culture 
and were incapable of forming tumours in immuno–suppressed mice in vivo 
(Panasyuk et al. 2009).  
The inhibited mTORα activity produce a strong feedback loop by S6K–IRS which 
may inhibit the whole process of cell growth and proliferation. mTORC1 can be 
reactivated by amino acids, energy and nutrient, however mTORC2 is insensitive to 
amino acids and nutrient. Therefore Akt will be inhibited and apoptosis will be 
activated.   
Taken together, our results support the hypothesis that mTORδ expression reduces 
cellular proliferation and inhibits tumour progression. However, the mechanism 
underling mTORδ–mediated responses remain to be found. One possible mechanism 
is that mTORδ may down–regulate mTOR function by sequestering the substrate–
presenting proteins of mTOR complexes. 
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Chapter 5: Molecular characterisation and functional 
analysis of mTOR 
 
5.1 Molecular characteristics of the mTORγ isoform 
5.1.1 Introduction  
Dysregulation of the mTOR signalling pathway is implicated in various disorders. 
The mTOR protein has attracted great interest as a target for cancer treatment. In 
chapter 3, we identified two mTOR isoforms, termed mTORδ and mTOR. the 
extensive analysis of mTORδ was discussed in chapter 4. Chapter 5 discusses the 
molecular characteristics and functional analysis of the mTORγ splicing isoform. 
The mTOR isoform was identified through extensive bioinformatics analysis of the 
EST database. mTOR consists of 2,537 amino acids, and its molecular weight is 287 
kDa. In comparison with the full–length wild-type mTOR, 12 amino acids are 
absent in the kinase domain of the mTOR splicing isoform. This deletion is located 
at the beginning of the kinase domain, which contains certain conserved residues that 
are critical for its kinase activity. This deletion removes the entire beta 5 strand from 
the catalytic domain, which includes the critical Lys2187 residue. The Lys2187 is 
thought to interact with the α–phosphate of adenosine tri-phosphate (ATP) (Sturgill 
and Hall 2009). Therefore, mTOR is an interesting protein with the potential to play 
a major role in the regulation of mTOR signalling and, thus, mTOR–mediated 
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cellular functions. We hypothesized that this 12–amino acid deletion in the kinase 
domain might disrupt the kinase activity of the mTOR splicing isoform, thus, the 
main focus of this study was to investigate the potential effect of this deletion on the 
kinase activity of mTORγ, on mTOR signalling pathway regulation and the cellular 
processes mediated by mTOR.  
To elucidate the possible role and function of this deletion, a mammalian expression 
construct expressing this splicing isoform was generated. Using the obtained 
construct, a stable HEK 293T cell line over-expressing mTOR was generated. The 
stable cell line was used to study the catalytic activity and the role of mTOR in the 
regulation of the mTOR pathway and cellular functions. 
In addition to mTORγ, mTORα, mTORδ and mTOR S2215Y were also employed in 
this study. The wild–type mTOR and the activated mutant mTOR S2215Y were 
used as positive controls to study the characteristics of mTOR. Because, mTORδ 
lacks the kinase domain, it was used as a negative control (Figure 5.1). 
For in vitro experiments, wild–type mTORα, the activated mTOR S2215Y mutant 
and mTORδ, which lacks the kinase domain, were used. For in vivo investigations, a 
parental HEK 293T cells which was transfected with an empty vector, and cells 
individually expressing mTORα, mTORδ, mTOR and mTOR S2215Y were used.  
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Figure 5.1: A schematic representation of the domain organisation of the mTOR 
splicing isoform.  
mTOR possesses 12–amino acid deletion in the kinase domain. This deletion 
involves conserved residues that are critical for kinase activity. The mTORβ isoform 
lacks most of the NH2-terminus and processes oncogenic potential. mTORδ is a 
novel mTOR splicing isoform that lacks the kinase domain. 
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5.1.2 Generation of a Flag-tagged mTOR plasmid 
The mammalian expression vector pcDNA3 was used to generate constructs 
containing the sequences of mTORα, mTORδ and mTOR S2215Y, and stable HEK 
293T cell lines were obtained as described in chapter 4. Thus, pcDNA3 and HEK 
293T cells were the vector and cell line of choice, respectively, for cloning mTORγ 
and generating a stable cell line. Similar to the other vectors in the research model, 
the cDNA sequence was cloned as a Flag–tagged fusion protein in the pcDNA3 
mammalian expression vector. Thus, the generated recombinant Flag–tagged fusion 
protein can be purified and detected using an anti–Flag antibody. Another DNA 
sequencing analysis was performed to verify that the correct DNA sequence was 
introduced into the pcDNA3 expression vector. 
The 12–amino acid deletion was introduced into the nucleotide sequence of 
pcDNA3-mTORβ in our laboratory by Christopher Fu (Figure 5.2). The generated 
protein was denoted mTOR 12. This deletion was introduced into the cDNA 
sequence of mTORβ using a set of primers for the 12–amino acid deletion. 
 
Figure 5.2: A schematic diagram demonstrating the location of the 12–amino acid 
deletion in mTORβ.  
mTORα exhibits the same COOH–terminal region as mTORβ. Thus, the position of 
the 12–amino acid deletion is at the same position in mTORα. The COOH–terminus 
of mTORβ 12 was used for the generation of mTOR S2215Y. 
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The pcDNA3-mTOR 12 plasmid was amplified and purified using the QIAGEN 
Miniprep Plasmid Purification kit. DNA sequence analysis was then performed to 
ensure that the correct mutations were introduced into the mTORβ DNA sequence. 
The mTORγ isoform was constructed from mTOR with a 12–amino acid deletion, 
in addition to pcDNA3-Flag-mTOR, which was discussed in chapter 4.  
The 12–amino acid deletion in mTOR lies in the kinase domain, which is located at 
the COOH–terminus of the DNA sequence of mTOR. mTOR shares the same 
COOH–terminal as mTOR and lacks most of the NH2–terminus of mTOR. 
Therefore, the NH2-terminus of mTOR, which was cloned as pcDNA3–mTORβ 
12, was replaced with the full–length NH2–terminal of the wild–type mTOR. The 
DNA sequence of the Flag-tag was inserted into the mTORγ DNA sequence at the 
NH2–terminal. This insertion resulted in pcDNA3-Flag-mTOR plasmid (Figure 
5.3).  
The pcDNA3-mTORβ 12 plasmid was linearised using the HindIII restriction 
enzyme. The ends of the linearised plasmid were then blunted using T4 DNA ligase. 
This linearised and blunted plasmid was subsequently re–digested with the KpnI 
restriction enzyme to produce two DNA fragments. The small fragment consists of 
the NH2-terminal DNA sequence of mTORβ 12. This fragment was then replaced 
with the full–length NH2-tirminus of mTOR (Figure 5.4). The large fragment 
consisted of the pcDNA3 nucleotide sequence attached to the nucleotide sequence of 
COOH–terminus of mTOR with the 12–amino acid deletion. The large fragment was 
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blunted from its COOH–terminal and possessed the KpnI restriction sequence at its 
NH2–terminal. 
 
 
Figure 5.3: The plan for the construction of the pcDNA3–Flag–mTORγ isoform.  
pcDNA3–mTOR 12 (top) was linearised using the HindIII restriction enzyme, 
blunted using T4 DNA ligase and re–digested with KpnI. These digestions resulted 
in two fragments, a large fragment containing the pcDNA3 plasmid and the COOH–
terminus of mTOR (including the 12–amino acid deletion) and a small NH2-terminal 
fragment. pcDNA–Flag–mTOR (bottom) was linearised using the NotI restriction 
enzyme, blunted using T4 DNA ligase and re–digested with KpnI and SalI, resulting 
in the full length NH2–terminal fragment of mTOR blunted from its NH2–terminal 
site and containing the KpnI restriction sequence at its COOH–terminal. This 
fragment was then ligated to the compatible ends of the pcDNA3 fragment 
containing the COOH–terminus of mTOR. 
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The pcDNA–Flag–mTOR plasmid was linearised with the NotI restriction enzyme 
and blunted with T4 DNA ligase. The plasmid was then re–digested with the KpnI 
restriction enzyme. The resultant NH2–terminus of the full–length Flag–mTOR was 
blunted at its NH2-terminus and possessed a KpnI restriction sequence at its COOH–
terminal. The pcDNA3 plasmid containing the COOH–terminus of mTORβ 12 was 
then ligated to the full–length NH2–terminus of mTORα using T4 DNA ligase to 
generate pcDNA3–Flag–mTORγ. 
 
Figure 5.4: Agarose gel image of the DNA fragments used for the construction of 
pcDNA3–Flag–mTORγ.  
The pcDNA3–mTORβ and pcDNA3–mTORβ 12 plasmids were digested with 
HindIII and KpnI, and the pcDNA3–Flag–mTOR plasmid was digested with SalI, 
KpnI and NotI. The digested plasmids were then electrophoresed on a 0.8% agarose 
gel, and the NH2–terminus of the mutated mTORβ plasmids were digested and 
replaced with the Flag–tagged full–length NH2–terminus of mTOR. 
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The generated plasmid was transformed into E.coli, and 8 colonies were amplified. 
The amplified colonies were subjected to agarose gel electrophoresis to confirm the 
size and the quality of the purified plasmids (Figure 5.5). 
 
 
Figure 5.5: Agarose gel image of the pcDNA3–Flag–mTOR colonies selected for 
digestion analysis.  
The generated plasmids were transformed into bacteria and plated in selection media. 
Eight colonies of each mutant were selected for plasmid purification and tested on 
0.8% agarose gel to confirm the size and quality of the purified plasmids. The 
plasmids were then thoroughly tested by digestion and sequencing analysis. 
 
To verify that the correct DNA sequence was inserted into the plasmid, the generated 
plasmid was analysed via restriction digestion analysis. The plasmid was digested 
using the Hin1I restriction enzyme and run on 0.8% agarose gel. Digestion of the 
plasmid containing the insert was expected to produce a band at approximately 1280 
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bp. The results clearly demonstrated that the colonies in the lanes labelled with blue 
numbers lacked the desired band (Figure 5.6), whereas all of the colonies in the lanes 
labelled with red numbers were positive for the desired fragment (Figure 5.7). 
Therefore, the colonies in the lanes labelled with red numbers were collected and the 
DNA sequence was verified by sequencing analysis. 
 
Figure 5.6: Agarose gel image of the results of the digestion analysis of the constructed 
pcDNA3–Flag–mTOR plasmid showing the absence of the insert band (negative 
result).  
Digestion analysis was performed to verify that the DNA was inserted into the 
plasmid. The pcDNA3–Flag–mTOR plasmid was digested using the Hin1I 
restriction enzyme and subjected to electrophoresis in 0.8% agarose gel. The absence 
of a band at approximately 1280 bp indicated that the DNA sequence was not 
inserted in colony numbers 1, 2 and 7 (labelled with blue numbers). 
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Figure 5.7: Agarose gel image of the resultant of the digestion analysis of the 
constructed pcDNA3–Flag–mTOR plasmid confirming the presence of the insert band.  
To verify that the DNA sequence was inserted into the plasmid, the plasmids were 
digested using the Hin1I restriction enzyme and subjected to electrophoresis on 0.8% 
agarose gel. The presence of a band approximately 1280 bp in size confirmed that the 
DNA sequence was inserted into the plasmid from the selected colony (indicated 
with red numbers). 
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5.1.3 DNA sequence analysis of the constructed pcDNA3 – Flag – mTOR 
plasmid 
Sequence analysis of the constructed plasmid was then performed to verify that the 
DNA sequence of the NH2–terminus had been inserted and that the 12–amino acid 
DNA sequence was deleted. A sample of the pcDNA3–Flag–mTOR plasmid was 
sent to GATC Biotech for DNA sequence analysis. The sequencing results revealed 
that the DNA sequence was indeed inserted and that the 12–amino acids were 
deleted. A sequence alignment was performed between the generated mTOR and 
mTOR, and the location of the 12–amino acid deletion is highlighted below (Figure 
5.8). This plasmid was then used to generate a stable cell line over–expressing Flag–
tagged recombinant mTOR to further study the mTOR isoform in vitro and in vivo. 
Chapter five  Zeyad Alharbi 
 
146 
 
 
Figure 5.8: Sequencing analysis of pcDNA3–Flag–mTOR.  
The obtained sequence is aligned against the mTORα sequence with the 12 amino 
acids highlighted (top). The chromatogram shows the sequence indicating the site of 
the 12–amino acid deletion (Bottom). 
 
5.1.4 Generation of HEK 293T cells stably expressing the mTOR isoform 
To investigate the potential of mTOR to play a major role in mTOR pathway 
regulation and mTOR–mediated cellular processes, HEK 293T cells stably 
expressing the mTOR isoform were generated. HEK 293T cell lines over–
expressing mTOR, mTORδ and mTOR S2215Y, generated in Chapter 4, were used 
as controls in this study. 
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As described in section 5.1.2, the mammalian expression vector pcDNA3 was used 
to generate a construct encoding the Flag–mTOR isoform. The pcDNA3 construct 
contains the neomycin resistance gene for the selection of transfected cells using G-
418. As noted in chapter four, G-418 was not the best antibiotic for selecting our 
stock of HEK 293 cells which found to be HEK 293T not HEK 293.  
 To address the issue of the poor selection achieved using G-418, a new strategy was 
followed that involved co-transfection with two plasmids with different selection 
markers: pcDNA3–Flag–mTOR (G-418) and pcDNA 4/TO (Zeocin). To generate a 
stable cell line similar to the control cell lines, HEK 293T cells were co-transfected 
with the pcDNA3–Flag–mTOR and pcDNA 4/TO plasmids. Due to the presence of 
the Zeocin resistance gene in pcDNA 4/TO, stable cell lines were selected using 
Zeocin. The optimum concentration of Zeocin for selection was predetermined (200 
μg/mL). Cells were treated with the optimum concentration of Zeocin to select co-
transfected cells and generate a stable cell line. Twelve days later, single colonies 
were visible. Five single colonies were isolated and tested for Flag-mTOR 
expression. Two colonies demonstrated a sufficient level of recombinant mTOR 
expression. One of the single colonies of HEK 293T cells stably expressing the 
mTOR isoform was used to study the potential role of mTOR in the mTOR 
pathway. Thus, HEK 293T cells stably expressing sufficient levels of mTOR were 
successfully generated. To precisely study the effects of the mTOR isoform, we 
employed several controls, including HEK 293T cell lines stably expressing Flag–
mTOR, Flag-mTORδ and Flag–mTOR S2215Y isoforms. The expression of the 
mTOR isoforms is shown in Figure 5.9. 
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Figure 5.9: Western blot confirming the high expression of Flag–mTORγ in parallel 
with the other mTOR isoforms in HEK 293T cell lines.  
HEK 293T cells were transfected with the pcDNA3–Flag–mTOR, δ,  or S2215Y 
isoform. These cells were then lysed, and the lysates were resolved by SDS–PAGE 
and subjected to immuno–blotting with an anti–Flag antibody. 
 
The HEK 293T cells over–expressing the mTOR isoform were then used to 
investigate the effect of the 12–amino acid deletion on kinase activity using an in 
vitro kinase assay, in addition to the effect of mTOR in the regulation of the mTOR 
pathway and the role of the mTOR splicing isoform in mTOR–mediated cellular 
processes. Finally, the stable cell lines were used to elucidate whether mTOR over–
expression induces oncogenic effects or antagonises the oncogenic characteristics of 
the mTOR signalling pathway. A tumorigenicity analysis was performed based on a 
colony formation assay and the results will be further validated using a xenograft 
model in nude mice (still in progress). 
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5.2 Functional Analysis   
It is well known that mTOR regulates cellular growth, proliferation and survival 
through its catalytic activity and the phosphorylation of Akt, S6K and 4EBP1 
(Edinger & Thompson 2002;Guertin et al. 2006;Vivanco & Sawyers 2002). As the 
12–amino acid deletion in the mTOR splice isoform is located within the kinase 
domain, this deletion may affect the kinase activity and, consequently, mTOR–
mediated cell growth, survival and proliferation.  
The main focus about mTOR was to determine whether this deletion affects the 
regulation of mTOR and to determine its ability to phosphorylate known 
physiological substrates of mTOR. In addition, we were interested in elucidating 
whether mTOR over-expression would affect tumorigenesis mediated by the mTOR 
signalling pathway. We  explored these questions by examining  in vitro mTOR 
kinase activity and by studying the the effect of the over–expression of mTOR on 
cellular proliferation using an MTT proliferation assay. The overall oncogenic 
potential was assessed via colony formation assays and xenograft model in nude 
mice (in progress).  
To perform the mentioned experiments and analyses, mammalian expression vectors 
containing Flag–mTOR sequences for different isoforms, including mTORα, 
mTORδ, mTOR and mTOR S2215Y were generated and confirmed through 
restriction and sequencing analysis. HEK 293T cells were transfected with each of 
the constructs individually. HEK 293T cells stably expressing mTORδ, mTOR, 
mTOR and mTOR S2215Y were generated. A sufficient level of expression of these 
mTOR isoforms was confirmed through Western blot analysis.  
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5.2.1 mTOR kinase assay 
The mTOR protein is a serine/threonine protein kinase that can only function in two 
intact complexes. mTORC1 is activated by growth factors and nutrients such as 
amino acids, glucose and energy. Activated mTORC1 phosphorylates S6K1 and 4E-
BP1 and thereby, modulates protein synthesis and cellular growth directly (Hay & 
Sonenberg 2004;Ma & Blenis 2009;Richter & Sonenberg 2005). In response to 
growth factors, mTORC2 phosphorylates and activates Akt/PKB, SGK1 and PKC, 
thereby regulating cellular survival and proliferation. Akt plays a critical role in 
multiple cellular processes, including glucose metabolism, apoptosis, cell 
proliferation, transcription and cell migration (Frias et al. 2006;Guertin & Sabatini 
2007;Hresko & Mueckler 2005;Lee et al. 2005;Yang et al. 2006). 
To investigate the kinase activity of mTOR, an in vitro kinase assay was performed. 
In this experiment, the main goal was to assess the catalytic activity of the immuno–
purified mTOR complex from HEK 293T cells over–expressing mTOR relative to 
the control group. As mentioned previously, for the in vitro experiments, the control 
group consisted of HEK 293T cells over–expressing Flag–mTOR S2215Y and HEK 
293T cells over–expressing Flag–mTOR as positive controls, whereas cells over–
expressing Flag–mTORδ were used as a negative control. HEK 293T cells were 
plated in two 100 mm plates. Once a suitable confluency was reached (approximately 
70-80%), the cells were lysed, and the Flag–mTOR complexes for each isoform were  
 
immuno–precipitated using anti–Flag antibodies. Each immuno–precipitation 
product was mixed with the mTORC1 substrate 4E–BP1, and the kinase reaction was 
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performed. The kinase activity in the reaction mixture was then assessed according to 
the phosphorylation of specific sites on 4E–BP1 via western blotting with a 
phospho–specific (Thr)37/p(Thr)46 antibody. A clear immuno–reactive band was 
observed for mTORα and mTOR S2215Y. In contrast, the mTOR reaction, similar 
to mTORδ, did not exhibit any band for phospho–4E–BP1. 
These results clearly indicate that in contrast to the full-length mTOR and mTOR 
S2215Y, the mTOR splicing isoform was unable to phosphorylate the mTOR target 
4E–BP1 (Figure 5.10). The phosphorylation level of Thr 37/Thr 46 in 4E–BP1 was 
increased in the activated mTOR S2215Y mutant compared with mTOR, whereas 
mTORδ and mTOR were unable to phosphorylate 4E–BP1. In conclusion, these 
results suggest that the mTOR isoform does not function through mTORC1.    
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Figure 5.10: In vitro kinase assay for mTOR. 
Western blot analysis of the in vitro kinase activity of immuno–precipitated Flag–
mTOR from the lysates of HEK 293T cells over–expressing different isoforms of 
Flag–mTOR. 4E–BP1, an mTOR complex 1 substrate, was added together with ATP 
to the IP mTOR complexes, followed by probing with anti–p–4E–BP1 (n=5, 
independent experiments).   
 
5.2.2 MTT assay – cell proliferation assay  
The catalytic activity of mTOR controls cellular proliferation via the phosphorylation 
of S6K1, 4E–BP1 and Akt. Akt plays a major role in cellular growth and survival 
(Edinger & Thompson 2002;Guertin et al. 2002). 4E–BP1 and S6K1 promote protein 
synthesis, ribosome biogenesis and autophagy (Hara et al. 2002;Kim et al. 2002;Kim 
et al. 2003;Ruggero & Pandolfi 2003). S6K1 generates a negative feedback loop to 
suppress PI3K activity, which leads to reduced survival signals and inhibits the pro-
apoptotic protein BAD (Harada et al. 2001). Thus, the mTOR signalling pathway is 
one of the main regulators of cellular growth, survival and proliferation. 
HEK293T 
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To assess the effect of mTOR on cell proliferation, the MTT cell proliferation assay 
was performed. The MTT cell proliferation assay can be used to detect and measure 
the cytostatic properties of various substances that could change the cellular status 
from proliferation to quiescence. Because mTOR is a central regulator of cell 
proliferation, this method provides remarkable results. The absorbance of a 
pigmented product resulting from the reduction of MTT upon incubation with viable 
cells is correlated with deceases in cell viability due to destructive processes such as 
necrosis or apoptosis. The MTT proliferation assay was used to assess the cell 
viability of HEK 293T cell lines stably expressing mTOR in comparison with the 
parental HEK 293T cell line (control) under starvation conditions. Starvation 
conditions were also utilised to minimise the effect of endogenous mTOR. 
For the MTT assay, 5000 HEK 293T cells stably expressing the mTOR, mTOR 
and mTOR S2215Y isoforms were seeded into each well in 96-well plates. Once the 
cells reached 70% confluence, they were subjected to starvation conditions. 
Proliferation was assessed 2 days after starvation and these assessments were 
repeated daily for the following 4 days. MTT dye was added to the wells and the 
plates were incubated at 37 °C for 3 hours in the dark. The optical density was then 
measured at 490 nm. The obtained absorbance was normalised to the blank, which 
contained medium and MTT, but no cells.  
The MTT assay produced a survival curve demonstrating the higher proliferation 
potential of parental cells compared with cells over–expressing mTOR. After 72 
hours, the proliferation of cells over–expressing the mTOR isoform was 
significantly inhibited relative to the parental HEK 293T cells (P<0.05) (Figure 
5.11). 
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As mentioned previously, the mTOR pathway plays an important role in cellular 
proliferation. The results presented here suggest that mTORγ is a negative regulator 
of cellular proliferation. 
 
 
Figure 5.11: mTORγ negatively regulates cellular proliferation.  
The parental HEK 293T cells and cells over-expressing mTOR, TOR, mTOR 
S2215Y were seeded into 96-well plates. The same number ofcells was seeded per 
well, and once the cells reached approximately 70% confluence, they were subjected 
to serum starvation. After 48 hours of starvation, the CellTiter 96 One Solution 
reagent was added, followed by incubation for 3 hours, and after which the 
absorption was measured. Measurements of cell activity were performed two days 
after starvation and repeated daily for the following 4 days (MTT proliferation 
assay). Each point represents the mean ± SEM from three individual experiments. 
The results are normalised to the blank which contained medium and MTT, but no 
cells. (n=3, independent experiments). 
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5.2.3 Colony formation assay 
Cancerous transformation is the result of various alterations of genetic and epigenetic 
mechanisms. These oncogenic processes lead to a cell population that has the 
capacity to grow and proliferate in an individualised manner. These new cell 
properties lead to the phenomenon of cell immortality. Cancerous cells are able to 
grow under harsh conditions. A common method used to detect, monitor and 
measure cell proliferation under the harsh conditions associated with cancer is the 
assay based on colony development in soft agar.  
The mTOR protein is implicated in tumour progression (Graff & Zimmer 2003). 
Previous results have demonstrated that the 12–amino acid deletion in mTOR 
removes the kinase activity of this particular isoform in vitro. The MTT proliferation 
assay also demonstrated mTOR in HEK 293T cells negative regulates cellular 
proliferation. These finding suggested that the mTOR would have a negative effect 
on tumour progression. In this study, we used colony formation assays to elucidate 
the overall effect of the mTOR protein expression on cellular tumourigenicity.  
In this study, an in vitro model was employed, including parental HEK 293T cells 
and HEK 293T cells over-expressing mTOR, mTOR or mTOR S2215Y. Using 6- 
well plates, 2,000 or 4,000 cells were seeded in 3 ml of 0.3% soft agar. To allow the 
agar to solidify, the plates were left in the hood for approximately 15 minutes, 
followed by incubation at 37 °C. After two weeks, colonies were stained with 
0.005% crystal violet for 3 hours at 37 °C and photographed. The number of colonies 
that were able to proliferate was counted. Here, we provide the results as the fold 
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increase or decrease in comparison with the colonies generated by parental HEK 
293T cells. Figure 5.12 shows that there was a four–fold increase in the number of 
colonies generated by parental HEK 293T cells compared with cells over-expressing 
mTOR. The number of colonies generated from HEK 293T cells over-expressing 
mTOR was significantly lower than the number of colonies generated by the 
parental HEK 293T cells (p<0.05). 
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Figure 5.12: mTORγ down–regulates the anchorage-independent growth of HEK 293T 
in soft agar.  
Parental HEK 293T cells or HEK 293T cells stably expressing mTORγ, mTORα or mTOR 
S2215Y were plated in a thin layer of agarose in culture medium. Two weeks later, colonies 
were stained with 0.005% crystal violet, photographed and counted. Data are presented as 
the means ±SEM of five experiments (n=5). The results were converted to the fold increase 
or decrease in relative to the number of colonies generated by the parental HEK 293T cells. 
The parental HEK 293T cells displayed a four–fold increase in the number of colonies 
produced relative to mTOR. 
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5.2.4 Discussion and conclusions    
The initial aim of this study was to identify novel mTOR splicing isoforms. Protein, 
molecular and bioinformatics approaches led to the isolation of cDNA clones 
encoding the novel mTOR isoforms, mTORδ and mTOR. mTORδ lacks the FRB 
and kinase domains, whereas mTOR exhibits a 12–amino acid deletion in the kinase 
domain. The results presented in this chapter demonstrate the molecular 
characteristics of mTOR and revealed some of its potential in cellular functions.  
The full coding sequence of mTOR was successfully cloned into the pcDNA3 
vector, with a Flag–tag positioned at the N-terminus of this isoform. The construct 
was confirmed by digestion and sequencing analysis. Using the generated constructs, 
HEK 293T stable cell lines were generated. The expression of the fusion proteins in 
HEK 293T cells was also confirmed by Western blotting analysis. Immuno–
precipitation with Protein G beads coated with the anti–Flag antibody resulted in 
copious amounts of protein that could be detected by western blotting.  
The 12–amino acid deletion in mTOR is located in the kinase domain. Therefore, 
the catalytic activity of this isoform was predicted to be affected by this deletion. 
This result prompted us to test whether mTOR is able to phosphorylate a known 
substrate of mTORα, 4E-BP1, in vitro. The in vitro kinase assay demonstrated that, 
in contrast to mTORα and mTORβ, mTOR is incapable of phosphorylating the 
mTORC1 target 4E-BP1.  
Many groups have reported that mTOR is a major player in the regulation of cellular 
growth, survival and proliferation (Corradetti & Guan 2006;Hay & Sonenberg 2004). 
Because mTOR lacks the catalytic activity, we hypothesised that the level of 
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mTOR protein expression could affect the proliferative activity of the HEK 293T 
cell line. The MTT assay indicated that, after 72 hours of starvation the proliferation 
of HEK 293T cells was significantly different between the cells over–expressing 
mTOR and the control group, consisting of parental HEK 293T cells. In contrast, 
Panasyuk et al. (2009) found that the proliferation of HEK 293T cells over–
expressing mTORβ was significantly higher compared with parental cells. 
The fact that the enhanced proliferative potential of HEK 293T cells over-expressing 
mTORβ was associated with an enhanced oncogenic potentials led us to ask whether 
the reduced proliferative potential of HEK 293T over–expressing mTOR will 
associate with less oncogenic potentials. A colony formation assay revealed about 4-
fold increase in the number of colonies generated from parental HEK 293T cells 
compared to HEK 293T cells over–expressing mTOR. These results suggested that 
over–expression of mTOR in HEK 293T cells leads to anti-oncogenic potential.  
A possible explanation for the effect of mTOR is that, the deletion present in this 
isoform inhibits its catalytic activity by either removing an essential part of the 
kinase domain or leading to conformational changes that affect the formation of both 
mTOR complexes. The future directions of studies on mTOR will be discussed in 
Chapter 6.  
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Chapter 6: Discussion  
 
6.1 mTOR protein 
The mammalian Target of Rapamycin, recently given an official name 
of mechanistic target of rapamycin is an evolutionarily conserved serine/threonine 
protein kinase. mTOR is a large protein consisting of 2,549 amino acids, composed 
of multiple highly conserved domains, including the HEAT repeats, FATN, FRB, 
RD, kinase and FATC domains. The mTOR protein localised on the mitochondria, 
nucleus, Golgi, endoplasmic reticulum and predominantly, the cytosol (Desai et al. 
2002;Drenan et al. 2004;Liu and Zheng 2007;Sabatini et al. 1999;Tirado et al. 
2003;Withers et al. 1997). 
The mTOR protein plays a critical role in the regulation of cellular processes, such as 
cellular growth, proliferation, cytoskeletal organisation, survival, RNA transcription 
and protein synthesis (Corradetti and Guan 2006;Hay and Sonenberg 2004). 
Dysregulation of the mTOR pathway is implicated in many disorders, including 
cancer, diabetes and cardiac hypertrophy (Beevers et al. 2006;Schaeffer and Abrass 
2010;Young and Nickerson-Nutter 2005). 
Extracellular and intracellular effectors including insulin, growth factors, and amino 
acids activate mTOR and enhance its activity (Hay & Sonenberg 2004). This 
enhanced mTOR activity is implicated in multiple disorders including, tumour 
progression. mTOR phosphorylates S6K1, Akt and 4E-BP1, thereby promoting cell 
growth, survival and proliferation (Edinger and Thompson 2002;Guertin et al. 
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2006;Hara et al. 2002;Kim et al. 2002;Kim et al. 2003;Ruggero and Pandolfi 
2003;Vivanco and Sawyers 2002). The enhanced mTOR activity significantly 
shortens the cell cycle and stimulates cellular growth (Corradetti & Guan 2006;Hay 
& Sonenberg 2004;Obaya et al. 1999). Activated mTOR also increases protein 
synthesis, which is required for tumour growth and development (Hay & Sonenberg 
2004). These features make mTOR an attractive target for cancer therapy. mTOR 
inhibitors exhibit a potent anti-proliferative activity against a broad panel of tumour 
cell lines (Fasolo and Sessa 2011). mTOR inhibitors are currently being evaluated in 
clinical trials for the treatment of various cancers (Barnett 2012). 
In cells, mTOR can only function in two distinct complexes known as mTORC1 and 
mTORC2 (Hay & Sonenberg 2004;Ma and Blenis 2009;Richter and Sonenberg 
2005). Some of the partners involved in the mTOR complexes, such as raptor and 
rictor, are essential for mTOR activity, whereas the absence of other partners has no 
effect on the mTOR function (Hara et al. 2002;Kim et al. 2002;Sancak et al. 2007). 
In humans, the mTOR gene encodes two mTOR isoforms, the full–length mTORα 
form and the short mTORβ form. mTORβ was identified in the Gouts’ laboratory. 
mTORβ lacks the majority of the HEAT repeat and FATN domains. In vivo, mTORβ 
forms complexes with the substrate–presenting proteins raptor and rictor. In vitro, 
mTORβ has been shown to phosphorylate the same substrates as originally reported 
for the full length mTORα, including S6K1, PKB/AKT and 4EBP1. Over–expression 
of mTORβ accelerates cell cycle progression and stimulates cellular proliferation. In 
addition, mTORβ over–expression transforms immortal cells and causes tumour 
formation in nude mice. It is thought that modulation of cell proliferation via the 
mTOR signalling pathway could be achieved through mTORβ. Because mTORβ is a 
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proto–oncogene, it can be considered a potential target for anti-cancer therapies 
(Panasyuk et al. 2009). 
Early studies in the field of cancer research focussed on genetic changes, including 
mutations, translocations, and over–expression etc. that are associated with 
malignancy and contribute to cancer development. Recent studies have revealed an 
increasing role of epigenetic changes in cancer development. These epigenetic 
changes include alterations that lead to the regulated production of different spliceing 
isoforms of RNA. These changes in gene activity that are not caused by changes in 
the DNA sequence result in a single gene encoding for multiple proteins. These 
discoveries have added a new direction for future researches in the field of cancer 
research and drug development.(Bonnal et al. 2012;Kim et al. 2008;Singh and 
Cooper 2012;Warzecha and Carstens 2012).  
Recent studies have revealed that alternative splicing and splicing regulators can 
regulate the tumourigenesis. Dysregulation of splicing regulators, including SF3B1 
and SRSF6 is implicated in several types of cancer (Cohen-Eliav et al. 2013a;Golan-
Gerstl et al. 2011a;Harbour et al. 2013;Kulis et al. 2012;Papaemmanuil et al. 
2011;Quesada et al. 2012). In addition, many studies have reported that a number of 
tumour suppressors and oncogenes are modulated by alternative splicing (Cohen-
Eliav et al. 2013b;Golan-Gerstl et al. 2011b;Jia et al. 2010;Venables 2006;Venables 
et al. 2009). 
Additionlly, it has recently been shown that splicing factors can play an oncogenic 
role in cells (Golan-Gerstl et al. 2011a;Lefave et al. 2011;Siegfried et al. 2013). The 
splicing factor SF2/ASF controls the alternative splicing of several onco–proteins 
including the oncogenic form of the mTOR target, S6K1. In addition, cells 
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transfected with the splicing factor SF2/ASF demonstrated high mTOR activity. 
Inhibition of mTOR activity blocks cellular transformation by SF2/ASF in vitro and 
in vivo. These results suggest that mTOR is a splicing target of SF2/ASF (Karni et al. 
2007;Karni et al. 2008).  
In a recent study, Huot et al. demonstrated that the splicing factor Sam68 regulates 
the alternative splicing of mTOR, and cells from Sam68−/− mice exhibit reduced 
levels of mTOR mRNA and reduced activity of the mTOR pathway. Within the 
mTOR gene, Sam68 binds specifically to intron splicing elements (ISEs) which is 
located at exon 5/intron 5 boundary leading to alternative termination. This binding 
results in the production of two mTOR isoforms of approximately 8 kb and 1 kb in 
various mouse tissues including white adipose tissue, the brain, and testis (Huot et al. 
2012).   
The most common barriers to the approval of an efficient drug by pharmaceutical 
companies and making it available in the market are poor response rate, poor 
sensitivity, high toxicity and side effects (Gomez-Martin et al. 2012). In the case of 
targeting a specific protein for the treatment of a disease, alternative splicing 
isoforms can contribute to the sensitivity, resistance and toxicity. In a splicing 
isoform, skipping exons or frame–shifts in a nucleotide sequence may lead to 
deletion of the drug–binding site which may give rise to the development of drug 
resistance. Moreover, a better understanding of the regulation of signalling pathways 
involved in tumour progression through the alternative splicing of components of 
these pathways may enhance the therapeutic potential and aid in the selection of 
drugs or combinations of drugs for cancer treatment in the clinic. 
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Within the mTOR pathway, the identification of alternative splicing isoforms of 
mTOR or mTOR substrates improves our understanding of mTOR pathway 
regulation and the sensitivity to mTOR inhibitors and further directs the selection of 
drugs for the treatment of cancer in the clinical setting. Selecting a common target 
sequence to inhibit all of the active isoforms enhances the sensitivity of an inhibitor, 
consequently permitting the usage of lower concentration with better efficacy and 
eventually less toxicity and fewer side effects. 
In this study, we provide evidence of the existence of two novel mTOR splicing 
isoforms termed mTORδ and mTOR and their potential role in the regulation of the 
mTOR pathway.  
6.2 Discussion 
mTORα consists of 2,549 amino acids, whereas mTOR and mTORδ isoforms, 
consists of 2,537 and 1,404 amino acids. The predicted molecular weights of the 
mTOR isoforms are 289, 287 and 158 kDa respectively. In contrast to wild-type 
mTOR, mTOR exhibits 12–amino acid deletion that removes the entire beta 5 
strand from the catalytic domain. The beta 5 strand contains the Lys2187 residue 
which is critical for the catalytic activity of mTOR (Sturgill and Hall 2009).  
mTORδ is a novel mTOR splicing isoform generated by a frame–shift in the middle 
of the FAT domain, resulting in a novel amino acid sequence at its COOH–terminus 
and termination at a premature stop codon. The mTORδ protein lacks a part of the 
FAT, FRB, kinase and FAT at the COOH–terminal domains, but retains the HEAT 
repeats. Therefore the mTORδ isoform lacks the catalytic activity and cannot bind to 
the inhibitory FKBP12/Rapamycin complex. An antibody targeting the new sequence 
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at the COOH–terminus of mTORδ was generated and the existence of the mTORδ 
isoform in vivo was confirmed in the cell lysates of several cell lines by Western blot 
analysis.  
The cDNA sequences of mTORδ and mTORγ were cloned into the pcDNA3 
mammalian expression vector. These constructs were used to produce Flag–tagged 
recombinant proteins and for the generation of HEK 293T cell lines stably expressing 
either the mTORδ or mTORγ. The stable cell lines were then used to characterise the 
role of mTORδ and mTORγ in vitro and in vivo.  
The mTOR protein is the catalytic member of two mTOR complexes and this 
catalytic activity is the only activity of mTOR identified to date (Hay & Sonenberg 
2004;Ma & Blenis 2009). mTOR phosphorylates several substrate proteins and 
among the best characterised mTOR substrates is the 4E-BP1, which regulates the 
protein synthesis by controlling the translation initiation process (Hay & Sonenberg 
2004). This prompted us to investigate the catalytic activity of the mTORγ. In vitro 
kinase assay was performed to assess the phosphorylation status of 4E-BP1 protein 
when exposed to the mTORγ in the presence of ATP. The results indicated that, in 
contrast to mTORα and mTORβ, the mTORγ does not phosphorylate the 4E-BP1. 
The defective catalytic activity of mTORγ caused by the 12–amino acid deletion can 
be explained by two hypothesises. First, it is possible that the 12 amino acid deletion 
removes an essential part for the kinase domain. This hypothesis is consistent with 
the finding of (Sturgill & Hall 2009) which indicates that the Lys2187 residue 
located within the deleted fragment is critical for the kinase activity of mTOR.  
The second hypothesis is that the 12 amino acid deletion leads to significant 
conformational changes, resulting in an isoform that is incapable of forming intact 
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complexes with the essential mTOR regulators, raptor and rictor. The first hypothesis 
appears to be more realistic and is supported by the finding of Sturgill and Hall. The 
second hypothesis is weaker since the mTORδ splicing isoform lack the majority of 
its COOH-terminal and retains the NH2–terminal and mTOR shares the same NH2–
terminal as mTORα. Therefore the second hypothesis is contradicts the fact that 
raptor protein binds preferentially to the NH2-terminal region of mTOR and with a 
weaker affinity to the COOH-terminal of mTOR (Hara et al. 2002;Kim et al. 
2002;Sancak et al. 2008). However, mTORβ lacks the majority of its NH2-terminal 
sequence and still can form intact complexes with raptor, rictor and mLST8 in vitro 
and in vivo (Panasyuk et al. 2009).  
mTOR integrates multiple intracellular and extracellular signals to regulate cell 
growth, survival, proliferation and the cell cycle via the phosphorylation of S6K1, 
Akt and 4E-BP1 (Harada et al. 2001;Hay & Sonenberg 2004;Ma & Blenis 2009). 
Over–activation of mTOR significantly shortens the cell cycle and stimulates cellular 
growth (Corradetti & Guan 2006;Obaya et al. 1999). mTOR inhibitors have shown a 
potent anti-proliferative activity against a broad panel of tumour cell lines (Fasolo & 
Sessa 2011). Because both the mTORδ and mTORγ isoforms lack the catalytic 
activity, we hypothesise that the mTORδ and mTORγ act as negative regulators of 
mTOR by sequestering the mTOR–associated proteins of mTORC1 and mTORC2. 
This prompted us to assess the effect of the over–expression of mTORδ and the 
mTORγ on the proliferation of HEK 293T cell lines in comparison with parental 
HEK 293T cells. The parental HEK 293T cells exhibited a higher proliferative 
potential compared with HEK 293T cells over–expressing mTORδ or mTOR. Thus, 
these results suggest that the mTORδ and mTORγ function as dominant negative 
regulators of cell proliferation. In contrast, Panasyuk et al. (2009) reported that the 
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mTORβ is an active protein kinase and the proliferation of cells over-expressing the 
mTORβ was found to be significantly higher compared with parental cells. 
The ability of over–expressed mTORδ and mTORγ to significantly inhibit cell 
proliferation led us to assess the oncogenic potential of these isoforms. Colony 
formation assays revealed a significant increase in the number of colonies generated 
from parental HEK 293T cells in comparison with HEK 293T cells over–expressing 
mTORδ or mTOR. These results strongly suggested that the mTORδ and mTOR 
inhibit the oncogenic potential of transformed cells.  
In contrast to mTORβ, which is an active protein kinase that triggers downstream 
signalling and is associated with the enhanced proliferation and proto–oncogenic 
transformation, mTORδ and mTOR lack the catalytic activity and act as dominant 
negative regulators of proliferation and possess anti-oncogenic characteristics 
(Panasyuk et al. 2009). Consistent with the finding of Panasyuk et.al, the number of 
colonies generated by parental HEK 293T cells was significantly greater compared to 
thenumber generated by HEK 293T cells over–expressing mTOR. 
Panasyuk et.al also reported that HEK 293T cells over–expressing mTOR did not 
display any significant characteristics associated with oncogenic transformation. 
Cells over–expressing mTOR failed to generate either significant anchorage–
independent colonies in soft agar culture and were incapable of forming tumours in 
immuno–suppressed mice in vivo (Panasyuk et al. 2009). 
Our results support the hypothesis which says that the identification of epigenetic 
changes and in particular the identification of new alternative splicing isoforms is 
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essential to better understand the regulation of the mTOR pathway and to make better 
choices of drugs which exhibit a greater activity and the best therapeutic window. 
Furthermore, the diagnostic and therapeutic potentials by the regulation of signaling 
pathways using alternative splicing of components of the pathway is immense. 
6.3 Conclusion  
The aim of this study was to identify new mTOR splicing isoforms, the molecular 
characterization of the identified isoform and to study the role of their in the mTOR–
mediated cellular processes, such as cell proliferation, cell survival and oncogenic 
transformation. 
In this study we provide evidence for the existence of two novel mTOR splicing 
isoforms, termed mTORδ and mTORγ. Bioinformatics and sequencing analysis 
revealed that mTORδ retains only the N-terminal HEAT repeats and a unique protein 
sequence, originated from a splicing-mediated frame shift. On the other hand, 
mTORγ possesses a 12–amino acids deletion, located at the beginning of the kinase 
domain, which contains conserved residues that are critical for ATP binding and the 
kinase activity. The existence of both mTORδ and mTORγ splicing variants was 
verified at the mRNA level through the identification of EST clones with 
corresponding exon-exon junctions. In addition, a specific immune–reactive band of 
approximately 150kDa was readily detected in a panel of cell lines when examined 
by Western blotting with specific anti-mTORδ antibodies. Using transient and stable 
overexpression systems, we demonstrated that mTORδ and mTOR lack the kinase 
activity in vitro. We also found that stable overexpression of mTORδ and mTORγ 
splicing forms in HEK293 cells results in the inhibition of cell proliferation and 
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colony formation in soft agar. Taken together, these novel findings suggest that 
identified mTORδ and mTORγ have the potential to regulate the mTOR signalling 
pathway in a dominant-negative manner. However, the underling mechanisms of 
uncovered regulation remain to be identified. 
6.4 Future directions for mTORδ and mTORγ 
A major effort is needed to exploit the full potential of these isoforms. It is important 
to elucidate the molecular mechanism by which mTORδ and mTORγ regulate 
signalling pathways and cellular functions. It would be interesting to investigate the 
role of mTORδ and mTORγ isoforms in the regulation of mTOR–mediated cellular 
functions such as cell growth, survival, and cell cycle regulation. Since the mTORβ 
protein significantly shortens the G1 phase of the cell cycle and stimulate cellular 
proliferation, therefore it is important to test whether the mTORδ and the mTORγ 
isoforms affect cell cycle regulation and cell size (Panasyuk et al. 2009). 
The future work has been prioritised according to the relevance and importance of 
the information to better understand the role and regulation of mTORδ and mTORγ. I 
have initiated the work on examining cellular localization of mTORδ and mTORγ 
splicing variants,  as well as the effect of the mTORδ on cell cycle control, cell size 
and the progression of cancer in nude mice. 
6.4.1 The effect of the mTORδ and the mTORγ on the cell cycle and cell size 
The treatment of cells with the mTOR inhibitor, rapamycin, leads to delayed cell 
cycle, reduced cell growth and cell size (Fingar et al. 2002). In addition it is proven 
that the mTOR protein significantly shortens the G1 phase of the cell cycle and 
stimulates the cellular proliferation (Panasyuk et al 2009).  
Chapter six  Zeyad Alharbi 
 
171 
 
In addition, in this study, the MTT proliferation assay and the colony formation assay 
have revealed that the mTORδ and the mTORγ are dominant negative regulators of 
the cellular proliferation. It is important to elucidate whether the mTORδ isoform 
arrest the cell cycle or take the cells into a programmed cell death.  
This study can be performed using HEK 293T cells over–expressing the mTORδ and 
cells over–expressing the mTORγ isoforms. The cellular DNA will be labelled with 
propidium iodide and scanned by FACScan flow-cytometer and forward scatter 
analysis.  
6.4.2 Cellular localization of the mTORδ and the mTORγ 
In cells, mTOR is localized predominantly in endoplasmic reticulum, Golgi, and 
mitochondria membranes, as well as the nucleus (Desai et al. 2002;Liu & Zheng 
2007;Zhang et al. 2002). Liu and Zheng reported that a sequences located within the 
HEAT domains is implicated in mediating mTOR membrane localization (Liu & 
Zheng 2007). To create a better understanding about the regulation and the role of the 
mTORδ and the mTORγ in cellular functions, it would be interesting to study the 
nuclear localization of these isoforms.  
This can be performed by subcellular fractionation followed by immune–blotting and 
immune–florescence analysis to identify the subcellular localization of the mTORδ 
and the mTORγ. 
6.4.3 The effect of the mTORδ and the mTORγ on the progression of tumour 
in a xenograft model in nude mice 
It is hypothesized that the expression of the mTORδ and the mTORγ would 
negatively affect the tumour progression. There is compelling evidence supporting 
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this hypothesis. The first evidence relies on the ability of mTOR protein to regulate 
multiple cellular processes including cellular growth, survival, development, 
metabolism, and angiogenic pathways. Dysregulation of these processes represent 
characteristic hallmarks of cancer (Hanahan and Weinberg 2011). Secondly, since 
the dysregulation of mTOR activities and mTOR signalling pathway is implicated in 
a wide variety of malignancies, the identified proteins are mTOR isoforms which 
may affect the mTOR pathway regulation. The third relies on the fact that the 
alternative splicing significantly regulates many oncogenes and tumour–suppressors.  
In addition, the MTT proliferation assay has shown that the mTORδ and the mTORγ 
are dominant negative regulators of the cellular proliferation. Moreover, series of 
colony formation assays have shown that the expression of the mTORδ and the 
mTORγ in HEK 293T cells resulted in significantly less number of colonies 
compared to parental HEK 293T cells. 
It would be interesting to elucidate whether the over–expression of the mTORδ and 
the mTORγ splicing isoforms in a tumour can provide a significant anti-proliferative 
activity and obtain disease stabilization or even tumour regression, or enhance the 
efficacy of other anticancer drugs. This can be achieved by injecting nude mice with 
the HEK 293T cells over–expressing the mTORδ and the mTORγ isoforms 
independently, and then the appearance and growth of tumours generated will be 
assessed over a period of 2 to 3 months. The tissue from the xenograft of nude mice 
will then be removed for microscopic and molecular studies.  
6.4.4 Binding partners of the mTORδ and the mTORγ 
In human cells, mTOR protein comes in two distinct multi-protein complexes, 
mTORC1 and mTORC2. In addition to mTOR protein, the mTORC1 is composed of 
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raptor, mLST8/GβL, PRAS40 and the recently reported IPMK (Hara et al. 2002;Kim 
et al. 2002;Kim et al. 2003;Kim et al. 2011;Vander et al. 2007). The second complex 
is mTORC2 which contains mTOR and mLST8/GβL, rictor, mSin1 and protor (Frias 
et al. 2006;Jacinto et al. 2004;Pearce et al. 2007;Sarbassov et al. 2004;Yang et al. 
2006). As described in chapter 1, phosphorylation of different substrates depends on 
the association of mTOR with different partners, and some of these partners are 
critical, while lacking the others does not show any effect on the mTOR activities. 
In yeast, TOR participates in a variety of cellular processes and some of these roles 
have not yet been identified in mammals (Crespo and Hall 2002;Rohde et al. 2001). 
It is important to identify the binding partners for the mTORδ and mTORγ which 
will help to better understand which pathway and feedback loops and cross-talks they 
could participate in and its potential role on cellular functions. The novel amino acids 
sequence at the COOH-terminus of mTORδ increase the chances of identifying new 
binding partners. 
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Appendices 
Appendix A: Buffers and solutions 
Solution/buffer Ingredients 
EB Buffer 
(Extraction buffer) (Lysis buffer) 
20 mM Tris HCl pH 7.5, 1 % Triton X-100, 150 mM 
NaCl, 5 mM EDTA, 50 mM NaF, EDTAfree 
protease inhibitor cocktail (Roche) 
ECL reagent 1 
50 mM Tris-HCl pH 8.5, luminol, ȡ-coumaric 
acid 
ECL reagent 2 50 mM Tris-HCl pH 8.5, 0.02 % H2O2 
Hypotonic Buffer 
20 mM HEPES pH 7.9, 0.5 mM dithiotreitol 
(DTT), EDTA-free protease inhibitor cocktail 
(Roche) 
Kinase assay buffer 
50 mM Hepes, pH 7.5, 10 mM MgCl2, 1 mM DTT, 
10 mM 3-glycerophosphate, 1 ȝM PKA inhibitor 
Laemmli sample buffer (5X) 
250 mM Tris pH 6.8, 5 0% glycerol, 0.5 % 
bromophenol blue, 500 mM DTT, 10 % SDS 
LB Agar 
1 % (w/v) bactotryptone, 0.5 % (w/v) yeast 
extract, 0.5 % NaCl, 1.5 % (w/v) bacto-agar 
LB Broth 
1 % (w/v) tryptone, 0.5 % yeast extract, 0.5 % 
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Solution/buffer Ingredients 
NaCl 
Loading Buffer (6X) 
(Laemmli sample buffer) 
0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF, 30% (w/v) glycerol in water 
Phosphate-buffered saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.4 mM KH2PO4, pH 7.4 
Primary antibody buffer 
TBS, 2 % BSA, 0.1% TWEEN-20, 0.02 % 
Sodium azide 
Stripping buffer 
62.5 mM Tris-HCl, pH 6.7; 2 % SDS; 100 mM 2- 
mercaptoethanol 
TAE Buffer 40 mM Tris-Acetate, 1 mM EDTA 
TBST buffer 10 mM Tris, 150 mM NaCl, 0.1 % TWEEN-20 
Transfer Buffer 
25 mM Tris, 200 mM Glycine, 20% methanol 
(v/v)) 
Tris-Glycine Running Buffer 0.25 mM Tris, 250 mM glycine, 0.1 % SDS 
Tris-HEPEs Running Buffer 100 mM Tris, 100 mM HEPES, 1 % SDS, pH 8.0 
Western Blocking Buffer 
1. TBS, 5 % non-fat dry milk, 0.1 % TWEEN-20 
2. TBS, 2% BSA, 0.1%TWEEN-20 
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